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Abstract 
With the high incidence of heart failure in the developing world and the inherent risks 
and limited availability of donor hearts, cell-based solutions have become an attractive 
solution. However, current methods to deliver cells to the heart have resulted in limited 
long term cell retention and consequently minimal therapeutic efficacy. In this work, we 
aim to use engineered tissues as a means to deliver cells to the injured myocardium 
post- infarction with increased cell retention. The results detailed in this dissertation 
indicate that engineered tissues can be constructed from both primary rodent 
cardiomyocytes and human pluripotent stem cell derived cardiomyocytes, and that these 
tissues not only engraft post-infarction with high cell retention , but in some instances 
also result in improved cardiac function and limitation of left ventricular remodeling post-
infarction.  
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Chapter 1: Introduction 
 
1.1 Introduction 
Heart failure has many causes, but the most prevalent initiator is a 
myocardial infarction, in which myocardial tissue is deprived of oxygen for an 
extended period of time, usually through a blockage of one of the coronary 
arteries. In the ischemia induced by an infarction, up to  one-quarter of the 4 
billion cells in the left ventricle can be lost1.  With this level of cell death, heart 
failure can develop as a result of the limited capacity of the injured myocardial 
tissue to recover or regenerate, leading to fibrosis and scar formation of the 
damaged myocardium, left ventricular dilation and thinning due to a resulting 
pressure and volume overload, and the inhibition of proper action potential 
propagation. Current treatments, whether they are pharmaceutical or medical 
device-based, act merely as palliative measures and the only effective long term 
treatment to date is to replace the damaged myocardium via total heart 
transplantation2.   
With the limited number of donors and the inherent risks of surgery and 
immunogenicity, cellular therapy has become an attractive solution to the high 
incidence of heart failure post-infarction. However, direct injection of cells into the 
myocardium has shown limited efficacy due to poor grafting efficiency3. Low rates 
of retention may be a product of cell loss due to inability to create focal 
adhesions with neighboring cells, the inflammatory response to myocardial injury, 
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or the hypoxic environment of the infarct zone. Thus, the use of engineered 
cardiac tissues has been a topic of increasing interest. Tissue engineering is not 
only provides a platform for the delivery of a large number of cells to the injured 
myocardium, it provides a means to replace damaged myocardium. Tissue 
engineering allows for in vitro development of cellular organization, intracellular 
communication and ECM deposition while also isolating the cells from the 
inflammatory infarct environment when implanted in vivo.  
In this chapter, we will review the currently used methods used to create 
engineered cardiac tissues, or “cardiac patches”, and their efficacy when 
delivered in vivo. We will begin by surveying the cells, scaffold and in vitro 
conditioning used to create these patches, and then move on to how they are 
characterized, and finally their efficacy to limit left ventricular remodeling post-
infarction.   
1.2 Cells for Cardiac Tissue Engineering 
 
1.2.1 Neonatal Rat Cardiomyocytes 
Until functional cardiomyocytes were able to be differentiated from human 
pluripotent stem cell sources, primary isolates of neonatal rat cardiomyocytes 
were the standard cell source for the development of cardiac patches4-6. These 
cells have been well characterized in vitro and can be obtained in large numbers, 
making them a useful tool for developing cardiac patches and interrogating the 
effects of in vitro conditioning on these tissues.  
  3 
1.2.2 Pluripotent Stem Cell Derived Cardiomyocytes 
Stem cells, whether taken from an embryo or reprogrammed from an adult 
cell, have enormous therapeutic potential due to their ability to be expanded in an 
undifferentiated state, and differentiated into cells of any lineage found in the 
body. In their undifferentiated state, pluripotent stem cells cannot be transplanted 
into patients as they can form teratomas. However, as the ability to not only 
differentiate pluripotent stem cells into functional cardiomyocytes but also in 
numbers large enough to be used therapeutically has become available, these 
cells have become the new standard cell source for creating cardiac patches.  
1.2.2.1 Embryonic Stem Cell Derived Cardiomyocytes 
Spontaneous differentiation of embryonic stem cells (ESCs) to cardiogenic 
cells was first observed in mouse ESCs in 1981 when these cells were cultured 
in 3D aggregates, called embryoid bodies7. Human ESCs were first obtained 
from a blastocyst in 1998,8 but it wasn’t shown until 2001 that they could 
successfully be differentiated into functional cardiomyocytes that exhibited 
contractile force generation and recordable action potentials9. Human ESC-CMs 
are now commonly used as a cell source for cardiac tissue engineering 10, 11. 
1.2.2.2  Induced Pluripotent Stem Cell Derived Cardiomyocytes 
In 2006 it was discovered that the introduction of four transcription factors 
(Oct3/4, Sox2, c-Myc, and Klf4) into adult murine fibroblasts reprogrammed these 
cells into an embryonic state, called induced pluripotent stem cells (iPSCs).12 
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This was a landmark discovery, as the reprogramming of adult cells into an 
embryonic state not only alleviates the ethical concerns of using embryonic 
cardiomyocytes but also allows for potentially autologous cell transplantation, 
eliminating the immunogenicity obstacle of allogeneic transplantation. Human 
iPSCs were reported in 2007 using the same factors or a new combination of 
Oct4, NANOG, LIN28, and SOX2,13, 14 and differentiated into functional 
cardiomyocytes in 2009. 15 They have been used in parallel with hESC-CMs for 
tissue engineering applications, and will likely become the preferred cell source 
for cardiac patches for the foreseeable future. 10  
 1.2.2.3  Differentiation Methods 
Initially, pluripotent stem cell derived cardiomyocytes were differentiated 
via the embryoid body method, where undifferentiated pluripotent stem cells are 
cultured in 3D aggregates on top of irradiated mouse embryonic fibroblast feeder 
cells and allowed to spontaneously differentiate into cells from all three 
embryonic germ layers, among them being cardiomyocytes. However, as can be 
expected, this method results in low percentages and yields of cardiomyocytes 
and requires purification steps in order to obtain high percentages of 
cardiomyocytes. In efforts to efficiently obtain high yields of cardiomyocytes from 
stem cell differentiation, Zhang et al developed a new method in which cells are 
cultured between two layers of matrigel,16 resulting in a significant increase in 
differentiation efficiency to cardiomyocytes. Recently, small molecule methods of 
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reprogramming and differentiation under defined conditions have been 
developed to eliminate the need for viral vectors and to increase reprogramming 
efficiency. 17 
1.2.3  Cardiac Progenitor Cells 
The heart has a limited capacity to regenerate via the presence of 
sparsely distributed resident cardiac progenitor cells (CPCs) and cardiac side 
population (SP) cells within the myocardium, approximately one CPC for every 
30,000-40,000 cells in the myocardium.18 These cells have been isolated based 
on their expression of a number of cell surface markers and gene expression, 
including c-kit,19 Sca-1, 20 and islet-1 21 as well as from their migration of 
progenitor cells out of excised cardiac tissue when cultured in vitro.22 Cells 
selected through these methods display the capacity to self-renew and 
differentiate into cardiomyocyte as well as endothelial phenotypes and can be 
used to create cardiac patches. 11, 23 
1.2.4  Non-Cardiomyocyte Cells and Co-Culture of Cells for Cardiac 
Patches     
Cardiomyocytes are not the only cell type used to create engineered 
tissues for cardiac repair. Non-cardiomyocyte cells are required for the creation 
of cardiac patches that utilize compacting biopolymer hydrogels, as 
cardiomyocytes do not contract collagen and fibrin hydrogels. Despite 
improvements in differentiation techniques, pluripotent stem cell-derived CM 
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populations are only 60-90% pure CMs, with the remaining 10-40% of cells 
primarily being fibroblast-like cells, though those cells remain poorly 
characterized. Neonatal rat cell isolates also contain between 50-60% of a 
heterogeneous population of non-CM cells, consisting primarily of fibroblasts, but 
also containing smooth muscle cells and endothelial cells from the vasculature 
and other interstitial cells from the myocardium24. The addition or inclusion of 
non-CM cells into cardiac patches has proven beneficial. Co-culture of hESC and 
hiPSc-derived cardiomyocytes with endothelial cells with or without 
mesenchymal stromal cells has resulted in an increase in contractile force 
generation by the resulting cardiac patches,10 and the force generated per 
cardiomyocyte has shown to be higher with less pure populations of hESC-CMs. 
25 Other non-CM cells used in cardiac tissue engineering include blood outgrowth 
endothelial cells (BOECs)26, human umbilical endothelial cells (HUVECs),27 
pericytes (PCs)28, and human dermal fibroblasts (HDFs).29 These cells are used 
either in combination with cardiomyocytes or by themselves in engineered 
tissues, all with the goal of rescuing the injured myocardium post-infarction.  
1.3  Scaffolds for Cardiac Tissue Engineering 
Cardiac patches are typically formed by the in vitro seeding and culturing 
cells in 3-dimensional scaffolds. The choice of scaffold influences cell survival, 
phenotype, and function through its physical and chemical properties, including 
stiffness, microstructure, and surface chemistry. Two general classes of scaffolds 
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are utilized to create cardiac patches: prefabricated scaffolds, in which cells are 
seeded onto a pre-existing scaffold structure; and biopolymer scaffolds, in which 
cells are present during scaffold polymerization and become entrapped in a 
fibrous network.  
1.3.1   Prefabricated Scaffolds 
Synthetic biodegradable, elastomeric polymers including polycaprolactone 
(PCL),30 poly(glycerol-sebacate) (PGS)31, and poly(lactide-co-glycolide) (PLGA)32 
copolymers and natural materials such as collagen I,33 alginate,34 and gelatin35 
are materials that have been used to create prefabricated foam or nanofiber 
scaffolds. Foam scaffolds allow for control of pore size and structure through the 
use of different material processing techniques. Highly porous scaffolds have 
proven successful in creating cardiac patches with high cell viability, but they are 
often isotropic and do not result in cellular alignment. Nanofiber scaffolds can be 
created through electrospinning 36, in which fiber diameter and orientation can be 
controlled, mimicking organization of collagen fibers in the native myocardium. 
These scaffolds can be fabricated in advance and can incorporate surface 
modifications to enhance cell adhesion and activity, such as the conjugation of 
RGD peptides.23 
1.3.2   Biopolymer Scaffolds 
Biopolymers are another class of scaffolds used in cardiac tissue 
engineering. These are native protein fibril networks in hydrogel form made from 
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either collagen I or fibrin 5, 37, 38. Rather than being seeded onto pre-formed 
scaffolds, cells are suspended in a gel-forming solution and fibrillogenesis occurs 
around the cells, entrapping them in a hydrated, fibrillar network. Initially, 
collagen and fibrin gels are extremely soft andisotropic. Over time, entrapped 
non-CM cells compact the gel, resulting in a denser fibril network. Eventually, the 
entrapped cells not only compact the gel, but begin to degrade the fibrils (in the 
case of fibrin gels) and replace them with cell-produced matrix. By constraining 
the compaction of the gel, fibrillar and cellular alignment can be induced in these 
gels. Induction of alignment allows the native architecture of the myocardium to 
be mimicked and has been shown to result in an increase in both contractile 
force generation by entrapped cardiomyocytes and the presence of gap junctions 
between cardiomyocytes.5 Collagen and fibrin biopolymer scaffolds can be 
altered by the addition of Matrigel. 10, 25, 39  Other biopolymer scaffold materials 
include alginate, which can be 3D printed into various geometries 23.  
1.3.3   Tissue-Based Scaffolds 
Decellularized heart tissue has been used as a scaffold to culture cardiac 
cells. Heart tissues are decellularized by perfusion with SDS followed by Triton-X 
to remove cells while leaving most of the heart ECM content and structure 
intact.40 Cells can then be reperfused into the heart,40 or entrapped in an ECM-
hydrogel matrix to create cardiac patches. 41  
1.3.4   Scaffold-Free Tissues 
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Scaffold-free approaches have been used to create cardiac patches in the 
form of cell sheets 42 and cell aggregate patches 43. Cell sheets are created by 
seeding cells onto temperature-responsive membranes, allowing them to deposit 
cell-produced ECM and form cellular connections, and releasing them from the 
culture surfaces through temperature reduction. Cell sheets can then be stacked 
to create thin 3D tissues or layered with cell sheets of endothelial cells to 
facilitate rapid vascularization upon implantation 42. Cell aggregate patches are 
prepared by culturing cells on a low-attachment plate placed on an orbital shaker, 
allowing for large numbers of cells to aggregate in solution and form tissues.  
1.4  In vitro Cellular Conditioning 
In addition to seeding cells onto or into scaffolds, external stimulation of 
the cells is often required to induce them to convert the scaffold into a functional 
cardiac tissue. This may be achieved through mechanical, electrical, or 
pharmacological stimulation.  
1.4.1  Mechanical Stimulation 
Cardiomyocytes in the native myocardium experience cyclic mechanical 
stretch as part of the cardiac cycle. Taking inspiration from this, in vitro 
mechanical stimulation has been widely used to stimulate alignment, 
hypertrophy, and maturation of cardiomyocytes in engineered tissues. 
Stimulation through cyclic stretching has been achieved for ring-shaped cardiac 
patches using two methods: looping the patch around one fixed post and another 
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coupled to a motorized stretching device,44 or through pneumatically-controlled 
distension of a latex mandrel on which the patch is mounted37. In both instances, 
cyclic stretching resulted in over a two-fold increase in contractile force 
generation. 
1.4.2  Electrical Stimulation 
Ventricular cardiomyocytes in the heart beat under the continuous 
regulation of their electrical activity through the cardiac conduction system 
originating at the sinoatrial node. In vitro, cardiomyocytes in cardiac patches beat 
spontaneously, but often at an irregular and variable rate, and not in synchrony 
with cardiomyocytes in other regions of the patch. Electrical stimulation of cardiac 
patches throughout culture has resulted in increases in the maximum frequency 
at which these patches can be stimulated and elicit a contractile response 
synchronous with pacing, a reduction in the voltage threshold at which 
cardiomyocytes contract, increased contractile force and also stimulated 
cardiomyocyte hypertrophy.45  
1.4.3  In vitro Perfusion  
Due to the high metabolic demand of cardiomyocytes, diffusion limitations 
hamper the ability to make the large thickness cardiac patches that are 
necessary to achieve clinical relevance. To increase oxygen and nutrient 
availability to cells, different methods of in vitro perfusion have been utilized in 
cardiac patches. Pulsatile perfusion of cell culture medium through porous pre-
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formed scaffolds has proven effective in increasing cell viability and myofibril 
assembly through media flow6 and activates the ERK 1/2  signaling pathway46. In 
biopolymer hydrogels, microchannels have been included in the gel,47 and 
perfusable microvessels have been created within the gel to allow for medium 
flow through the gel during culture48-50. Though promising, this latter approach 
has yet to be combined with cardiomyocyte culture in vitro.  
1.4.4  Medium Supplementation 
Supplementation of culture medium with pharmacological agents can also 
be used to stimulate development of cardiac patches. The addition of platelet-
derived growth factor BB (PDGF-BB) to cultures of collagen/matrigel scaffolds 
containing neonatal rat cardiomyocytes protected cells from apoptotic death, thus 
increasing the final contractile performance of the patch.51 Insulin and  ascorbic 
acid have been used to promote matrix deposition by entrapped non-CM cells.37 
1.4.5:  Combination Treatments 
In addition to exposing cardiac patches to one form of in vitro conditioning, 
combinations of the above mentioned techniques have been used in combination 
to further condition tissues. Electrical stimulation has been used in concert with 
perfusion and resulted in an increase in cell elongation, enhanced expression of 
gap junction protein connexin-43, increase in cell number, and an increase in 
contractile performance.52, 53 However, the combination of stretch and β-
adrenergic stimulation resulted in no additional benefit.53 
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1.5:  Characterization of Cardiac Patch Function 
One additional benefit of using engineered tissues to treat heart failure 
post-infarction is that these engineered tissues and the cells entrapped in them 
can be functionally characterized in vitro, allowing for quality control and a more 
thorough understanding of the benefits of cell transplantation. Functional 
performance of patches is primarily assessed through contractile force 
measurements and optical mapping of electrical conductivity.  
1.5.1:  Contractile Force Measurements 
Cardiac patches should, once developed, function as a piece of cardiac 
muscle tissue and generate contractile stresses close to physiological values. 
Quantification of this contractile activity is widely used to assess the quality of a 
cardiac patch. Contractile activity can be assessed through the magnitude of 
patch contraction both spontaneously and in response to pacing, the maximum 
frequency by which a patch can be paced and still elicit a contractile response in 
phase with the electrical stimulus, the force-frequency relationship of contractile 
amplitude with increasing pacing frequency, and the contractile response of the 
patch to exposure to pharmacological agents. Such agents include β-adgrenergic 
agonists, gap junction blocker 1-Heptanol,54 or cholinergic agonist carbacol,39  
1.5.2  Optical Mapping  
Electrical activity of cardiac patches can be assessed through optical 
mapping. To do this, tissues are submerged in medium containing a voltage 
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sensitive dye, such as Di-4ANEPPS or ANNINE-6. The tissues are then point-
stimulated and the action potential propagation is recorded by a high speed 
camera. This data can be analyzed to assess both conduction velocity (the rate 
at which action potentials propagate across the tissue), and action potential 
duration (the time it takes for a cell to re polarize to either 50 or 90% of its resting 
potential). This data can be used to obtain the conduction velocities of action 
potentials across the patch, as well as the action potential duration.. These 
values can then be compared to physiological values to assess the functional 
quality of the cardiac patch 55. Additionally, calcium transients can be similarly 
imaged with a calcium sensitive dye. 56 
1.6  In vivo Assessments of Cardiac Patches 
Although cardiac can be fully characterized in vitro and can be conditioned 
in vitro to obtain functional values close to that of the native myocardium, cardiac 
patches can only truly be effective if their implantation results in the restoration of 
cardiac function post-infarction. Some studies have made progress towards 
achieving this goal, utilizing both small and large animal models, and acute or 
delayed implantation. The timing of patch implantation is a crucial aspect of in 
vivo assessments as a way to help determine the mechanisms by which any 
benefits provided by the patch occur.  Acute transplantation is transplantation of 
the patch immediately after infarction, delivering it during the initial inflammatory 
phase before fibrosis begins to occur. Chronic, or delayed transplantation, 
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requires a second surgery and applies the patch after the inflammatory phase 
has passed and either before or after mature scar formation, depending on the 
time of implantation.  
1.6.1  Rodent Models 
Rodent models of myocardial infarction treatments are commonly used as 
the first initial model due to the smaller size of patch required for treatment. Acute 
placement of a cardiac patch using fibrin as the scaffold and syngeneic neonatal 
rat cardiac cells, within vitro stretch conditioning of the patch prior to implantation, 
resulted in minimal scar formation and restoration of cardiac function 4 weeks 
post-infarct, with 36% cardiomyocyte retention. 37 A similar patch made with a 
collagen/Matrigel scaffold rather than fibrin and implanted two weeks post-
infarction limited further scar formation and preserved cardiac function from the 
time of implantation. 4 Transplantation of a layered neonatal rat cell sheet patch 
into a nude rat infarct model 14 days post-infarction resulted in significant 
improvements in cardiac function, though cell retention was minimal after 4 
weeks.57 Few studies to date have been published assessing the functional 
consequences of a human stem cell derived cardiac patch in an infarcted rat 
model. Acute transplantation into non-infarcted rats of scaffold-free tissue 
patches utilizing hESC-CMs and HUVECs resulted in rapid vascularization of the 
patches in vivo. Patches containing only an enriched CM population resulted in 
poor CM retention. 58 
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1.6.2:  Large Animal Models 
The use of large animal models of myocardial infarction is a necessary 
step towards bringing cardiac patches to clinical relevance Few studies to date 
have been able to generate the large numbers of human stem cell derived 
cardiomyocytes required to create cardiac patches large enough to be 
implemented in large animal models. Human ESC-CMs in cell sheet form were 
transplanted into a porcine ischemia-reperfusion model 4 weeks after ligation in a 
feasibility and safety study, and it was found that the cell sheet treatment resulted 
in a reduction in LV dilation and an improvement in cardiac function both 4 and 8 
weeks post-transplantation.59  
1.7  Current Deficiencies and Obstacles 
Despite the many advances in cardiac tissue engineering, there remain 
deficiencies in the field and many obstacles still to be overcome. Contractile force 
generation and cellularity of cardiac patches average far below physiological 
values of 44 mN/mm2 and 20-40M cells/gram for human ventricular myocardium 
and 56.4 N/mm2 rat ventricular myocardium.60 Diffusional limitations may 
contribute to this, and may be overcome by the development of a microvascular 
network- withing the patch during its fabrication. As mentioned earlier, progress 
has been made, but microvascular network have yet to be created and perfused 
in the presence of a cardiomyocyte-containing patch of size relevant to even a rat 
infarct. Other issues that will be addressed in the coming years are maturation 
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mismatch of donor cells to recipient hearts. Currently used stem cell-derived 
cardiomyocytes are a mixture of atrial, ventricular, and pacemaker phenotypes, 
and all exhibit a fetal or neonatal phenotype. Immature phenotypes also have 
different electrophysiological, metabolic, and contractile properties than adult 
CMs. It has yet to be determined if transplantation of immature cells will elicit 
arrhythmic events, or if cells need to be differentiated to maturity prior to 
transplantation. However, more mature cells may not survive transplantation with 
the same efficiency as less mature cells.  
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Chapter 2: Creation and Optimization of a Tissue-Engineered Cardiac Patch 
Utilizing Neonatal Rat Cardiac Cells 
2.1  Introduction 
The creation of a tissue-engineered cardiac patch to replace damaged 
tissue or deliver cells to the injured myocardium has become an attractive 
solution to the shortcomings of direct cell injections to the heart. An ideal cardiac 
patch would contain high densities of elongated cardiomyocytes that are 
electrically coupled, generate contractile stresses near physiological values (44 
mN/mm2 for rat, 56.4 mN/mm2 for human)60, and remain viable after 
transplantation, coupling to the host myocardium and supplementing left 
ventricular contractility. To determine the ideal material and culture conditions for 
the creation of a cardiac patch, neonatal rat cardiomyocytes were used in the 
following initial studies, as they have been well characterized in the literature4-6 
and can be isolated from hearts with high viability and little to no loss of resultant 
CM function, something which is not feasible with cardiomyocytes isolated from 
adult hearts61. The following studies outline the creation and optimization of a 
neonatal rat cell-based cardiac patch using fibrin as a biomaterial scaffold.  
2.2  Methods 
2.2.1  Primary Cell Isolation of Neonatal Rat Cardiac Cells 
Neonatal rat cardiac cells were isolated from 48-72h neonatal Sprague-
Dawley rats (HSD, Harlan Sprague Dawley) as previously described5 by a serial 
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collagenase digestion. Briefly, pups were anesthetized via hypothermia and 
euthanized via decapitation. The chest was swabbed with iodine, the sternum 
was opened with a scalpel and the heart was removed and rinsed in a solution of 
cold 3.96 g/L D-glucose (PBS-glucose) in phosphate-buffered saline (PBS) and 
1% penicillin/streptomycin. The ventricles were then excised from the hearts and 
minced into < 1 mm2 pieces. Minced ventricles were placed into tubes containing 
a solution of 37°C PBS-glucose containing 300U/ mL collagenase and incubated 
for 7 minutes on a shaker at 37°C. The tissue-collagenase mixture was agitated 
to knock free loose cells, and the supernatant was removed and the collagenase 
was quenched with a solution containing 10% serum. The sedimented tissue 
pieces were re-incubated in collagenase solution and this process was repeated 
7 times, until most all tissue had been digested. Quenched supernatant was 
strained through 70 μm cell sieves, centrifuged, and washed twice in basal media 
before being prepared for creation of cardiac patches.     
2.2.2  Fibrin Patches With Cell –Induced Alignment 
Aligned patches were constructed by combining a mixed population of 
neonatal rat cardiac cells at a concentration of 4x106 cells/mL with a fibrin-
forming solution consisting of bovine fibrinogen (5 mg/mL, Sigma), bovine 
thrombin (2 U/mL, Sigma), and 2 µM CaCl2  in a 4:1:1 ratio to create a final fibrin 
concentration of 3.3 mg/mL. The fibrin forming solution containing cells was 
injected into 13 mm long, 1.25 mL tubular molds consisting of an 8mm outer 
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diameter Teflon mandrel coated in 2% agarose to allow for cell-induced gel 
compaction and alignment in the circumferential direction or on solid Teflon 
mandrels to prevent lateral compaction and result in planar isotropic patches as 
previously described5 and depicted in Figure 2.1. The cell-containing solutions 
were incubated for 15min at 37°C to allow the fibrin gel to form. Once formed, the 
molds were ejected from their casings and placed into culture medium 
(Dubecco’s modified eagle medium, 10% heat-inactivated horse serum (to limit 
fibroblast proliferation), 1% fetal bovine serum,  1% penicillin-streptomycin, 
2mg/mL aminocaproic acid (to limit fibrinolysis), with 2 μg/mL insulin and 50 
μg/mL ascorbic acid (to promote extracellular matrix (ECM) production).  
2.2.3  Modulation of Cell Preparation and Gel Formulation to Maximize 
Contractile Force Generation 
 To optimize the cell content of patches to maximize contractile force 
generation,  
two different parameters were investigated: the ratio of cardiomyocytes to non-
cardiomyocytes and the fibrin concentration in the initial gel.  
2.2.2.1  Fibrinogen Concentration 
To assess the influence of matrix structure on cardiomyocyte survival and 
force generation, subsets of patches were constructed with fibrin concentrations 
of 2 mg/mL, 3.3 mg/mL and 4 mg/mL. The ratio of fibrinogen/thrombin in the 
initial solutions was kept the same in all conditions and patches were constructed 
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with the same cell number and cultured statically for 14 days before being 
harvested for contraction force testing and histology.  
2.2.2.2  Cardiomyocyte Purity 
 Studies previously initiated in the Tranquillo lab utilized Percoll, colloidal 
silica particles coated in polyvinylpyrrolidone (PVP), to enrich cell populations for 
cardiomyocytes62. Isolated cardiac cells were placed on top of a single layer 
gradient consisting of 40% Percoll diluted in Hank’s Buffered Saline Solution 
(HBSS) and spun at 2200 rpm for 20 minutes. The cells that transited the 
gradient and formed a pellet at the bottom was collected and used to fabricate 
patches at a cell concentration of 5x106 cells/gel, similar to that of non-enriched 
cell populations. Patches were cultured statically for 14 days prior to being 
harvested for contraction force testing and histology. Cardiomyocyte percentages 
were determined after casting histologically through immunostaining of freshly 
constructed fibrin gels.  
2.2.4  Uniaxial mechanical Testing 
To assess the overall mechanical properties of the patches, tissue strips 
consisting of one-half the length of a patch were tested for tensile properties in 
the circumferential direction. Tissue thickness was measured using a 50g force 
probe coupled to a displacement transducer and then strips were placed in grips 
attached to the actuator arm and load cell of a uniaxial tensile testing system 
(MTS systems), straightened, and preconditioned by 6 cycles of 0–10% strain at 
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2 mm/min. The tissues were then stretched to failure at the same rate. Young’s 
modulus (E) was determined by linear regression of the linear region of the 
stress-strain curve, and ultimate tensile strength (UTS) was determined by the 
stress at failure. 
2.2.5  Contraction Force Testing 
To assess the macroscopic contractile activity of patches at the end of 
culture, patches a custom built force transducer setup was used. Ring-shaped 
patches were placed in a 37ºC media bath consisting of basal media, 2 mM Ca++, 
and 50 μg/mL ascorbic acid, and looped between two posts, one adjustable and 
coupled to a force transducer (Figure 2.2a). Patches were pre-tensioned to 1 
gram force and exposed to field stimulation of 1-8 Hz square wave pulses, 10ms 
duration, 8V amplitude from two carbon electrodes located on either side of the 
posts. Data was acquired using a LabView data acquisition program and 
analyzed offline in using a custom Matlab script. Contraction force was measured 
as peak force obtained during pacing or spontaneous activity minus baseline 
tension before stimulus (Figure 2.2b). Patches were allowed to reach steady 
state for 5 seconds at each frequency before recording data for analysis. 
2.2.6  Stretch Conditioning of Patches 
To investigate the effect of cyclic stretching on patch contractile force 
generation, a pre-existing cyclic distension system was utilized63 (Figure 2.3a). 
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Patches were statically cultured 7 days and then transferred to 8 mm outer 
diameter distensible thin latex tubes, with 2-3 patches per tube (Figure 2.3b). 
Tubes were capped at one end with polycarbonate plugs, and attached to a 
pressurized air source on the other end. Airflow was controlled externally via a 
pressure regulator and downstream solenoid valve. Mounted patches were 
placed inside sealed, vented jars containing 50 mL of cardiomyocyte (DMEM, 
10% heat-inactivated horse serum, 1% fetal bovine serum, 2 mg/mL ε-
aminocaproic acid, 2 μg/mL insulin, 50 μg/mL ascorbic acid, 100 U/mL penicillin 
and 100 μg/mL streptomycin) medium. Distension of the tubes (and consequently 
the patches) was regulated by a control set located outside the incubator, 
consisting of a pressure regulator, timing circuit, and a three-way solenoid valve, 
allowing for independent control of the frequency, duty cycle, and amplitude of 
pressurization of the latex mandrels..After being transferred to the cyclic 
distension system, patches were cultured while exposed to cyclic stretching at a 
frequency of 1Hz and duty cycle of 66.7%, for a total of 14 days culture, the 
same as for statically-cultured samples. Three stretch ratios of 5%, 7.5%, and 
10% were investigated for the optimal stretch conditions. Stretch ratios were 
established via a pressure-diameter correlation of the latex tubing.  Non-
stretched constructs on latex tubing were cultured side by side with stretched 
constructs and those statically cultured on agarose and Teflon mandrels. To 
further investigate the influence of stretch parameters on contractility of patches, 
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patches were stretched at 5% stretch ratio for varying duration, 5, 7, or 9 days. 
Total culture time remained 14 days.  
2.2.7  Histology 
For histological analysis, patches were cut into pieces and fixed in 4% 
paraformaldehyde for 1 hour on ice, frozen in embedding medium (Tissue-Tek 
OCT), cut with a cryostat into 5 µm-9 µm sections at -18°C and placed onto 
Superfrost Plus Microscope slides (ThermoFisher Scientific) for histological 
analysis. Cyrosections were labeled with fluorescent antibodies and 
subsequently imaged to assess the cellularity, cell composition, and cell 
morphology. A subset of patch pieces were not frozen after fixation and used for 
whole-mount tissue staining. 
For immunofluorescence staining of sections on slides, sections were 
permeabilized with 0.01% Triton-X-100 (Sigma), blocked in 5% Normal Donkey 
Serum (Jackson Immunoresearch), incubated overnight at 4°C in primary 
antibody followed by a 60 minute incubation in secondary antibody at room 
temperature and a 10 minute incubation in Hoescht 3332 (LifeTech). Slides were 
mounted in fluorescent mounting medium (Dako) and imaged within 24 hours. 
For immunofluorescence staining of whole tissue pieces, a similar process was 
followed, but with extended incubation times to allow for antibody and reagent 
diffusion into the tissue thickness. Additional histology methods and information 
can be found in the protocols contained in appendices 3 and 4. 
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2.2.8  Protein Extraction and Western Blotting 
 To assess the effect of stretch on gap junction formation between adjacent 
CMs, portions of both statically cultured and stretch-conditioned patches were 
frozen after contraction force testing and stored at -80ºC for protein analysis. For 
analysis, patches were thawed and lysed using a sonicator (QSonica Q125) at 
4°C in a NP-40 lysis buffer consisting of 0.5% Nonidet P-40, 5% glycerol, 25 mM 
Tris (pH 7.4), 25 mM NaF, 225 mM NaCl, 0.025% sodium deoxycholate, 1 mM 
EDTA, 2 mM NaVO4, and 1 mg/mL each of aprotinin, pepstatin, and leupeptin 
(Sigma-Aldrich). Total protein was assessed using a BCA protein assay (Pierce 
Biotechnology). 10μg of protein was loaded into the lanes of a 4-20% Mini-
Protean TGX 10-well gel (BioRad) for protein separation and transfer. Western 
blot was conducted by assessing using primary antibodies for the proteins 
connexin-43 and β-actin, blocked in 5% blocking grade buffer (BioRad) with 0.1% 
Tween (Sigma-Aldrich), horseradish-peroxidase conjugated secondary 
antibodies (GE Healthcare Life Science) and chemiluminescence agent 
(Millipore). Expression intensity was analyzed using ImageJ software. 
2.2.9  Statistics 
All data are presented as mean +/- standard deviation. When applicable, 
results were compared using student’s t-test or a one-way analysis of variance 
(ANOVA) in conjunction with a Tukey HSD post-hoc testing. p-values <0.05 were 
considered significant.  
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2.3  Results 
2.3.1  Maximal Force Generation with Non-Enriched Cell Populations and 
3.3 mg/mL Fibrin Gels 
After it was established that aligned patches could be constructed, the 
optimal ratio of cardiomyocytes to non-cardiomyocytes was ascertained. Patches 
created with enriched CM populations exhibited an increase in axial length 
(width) compared their non-enriched counterparts, but were otherwise similar in 
appearance (Figure 2.4a). More importantly, enriched cardiomyocyte population 
patches had reduced measured contraction forces than those created with the 
native cell population (Figure 2.4 b). Thus, it was determined that the native ratio 
of fibroblasts to cardiomyocytes was optimal for patch creation, concurrent with 
other published results that show that high purities of cardiomyocytes result in 
decreased contractile force generation when using neonatal rat cardiomyocytes.6, 
64 
To further validate the use of a native cell isolate, cardiomyocyte 
preparations gathered using Percoll gradients gave highly variable CM purities, 
ranging from 42-67% CMs, with an average CM fraction of 53.5% based on 
histological staining of fibrin gels immediately after casting, no different than the 
average 45% CM fraction of the native cell isolate. The use of percoll was 
additionally associated with decreased cell yields, indicating a negative effect of 
Percoll on cell viability.  
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2.3.2  Increased Contractile Force Generation with Cyclic Stretching 
 2.3.2.1  Dependence upon Stretch Amplitude 
It was found that 5% stretch ratio amplitude was optimal based on 
measurements of twitch force generation, with a 2.12±0.51 fold increase over 
statically cultured samples (Figure 2.5a). Neither a 7.5% or 10% stretch ratio led 
to an increase in twitch force generation of patches (0.99±0.40 and 1.35±0.55 
fold change compared to static, respectively). Although there was an increase in 
contractile force generation with 5% stretch, the exact mechanism by which this 
improvement is achieved is unknown. Previous work has shown an increase in 
the contractile force generation was associated with an increase in the presence 
of gap junction protein connexin 43 (CX43) in patches that featured aligned 
matrix fibers and cells rather versus isotropic5, but no further increase was seen 
when aligned patches were cyclically stretched (Figure 2.6 ). Upon histological 
interrogation, no increase in cell density or cardiomyocyte size was observed 
(Figure 2.7), indicating minimal or negligible effects of cell survival, proliferation, 
or significant hypertrophy.  
 2.3.2.2  Independence from Stretch Duration 
At 5% stretch ratio, there was found to be no dependence upon the 
duration of stretching (Figure 2.5b) in terms of force generation by patches. This 
would imply that the increase in contractile force generation is more likely a 
stimulus response than a sustained response.  
  27 
2.4 Discussion 
 This work was a continuation of the work completed by Black and Myers, 
et al5, which created aligned patches containing neonatal rat cardiac cells in a 
fibrin scaffold, and found that aligned patches generated more contractile force 
than isotropic patches through an increase in the presence of CX43. Here we 
further optimized these patches to maximize contractile force generation. We 
found that neither modulation of the initial matrix density nor enrichment for CMs 
resulted in increased force generation. However, patches that were bioreactor 
conditioned with exposure to cyclic mechanical stretch displayed over a 2-fold 
increase in contractile force generation, although the exact mechanisms of this 
increase remain unknown. Other reports have shown evidence of physiological 
CM hypertrophy when engineered cardiac tissues have been exposed to cyclic 
stretching10, 44, but CM hypertrophy was not clear in this study with the methods 
used to characterize these patches. Future work to elucidate the mechanism of 
this increase in contractile force generation would protein analysis to evaluate the 
presence and relative presence of contractile proteins, and DNA synthesis 
markers to assess hypertrophy. Rather than fully investigate the effect of cyclic 
stretching on neonatal rat cardiomyocytes in these patches, we elected to assess 
the functional benefits these patches have when transplanted into an acute rat 
infarct model and pursue the cyclic stretching studies in a more clinically 
relevant, human iPSC-CM model.  
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2.5 Figures 
 
Figure 2.1: Aligned patch immediately after gel formation (A) and after 14 days 
static culture (B). Fiber alignment is in the circumferential direction around the 
agarose-coated mandrel.  
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Figure 2.2: Contraction force measurement setup (A) and representative images 
of force generation recordings at varying frequencies (B).   
 
Figure 2.3: Setup of cyclic distension bioreactor (A) and schematic of bioreactor 
jar37 (B). 
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Figure 2.4: Size (A) and contractile force generation (B) of patched created using 
an enriched (Percoll) and non-enriched (Native) CM preparation. Percoll-
enriched CM cell population patches generated lower average contractile force 
than patches made with the native cell population.  
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Figure 2.5: Contractile force generation of stretch conditioned patches. A 2-fold 
increase over statically cultured sampled was observed with a 5% stretch 
amplitude. The duration of stretch had no effect on force generation. 37 
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Figure 2.6: Western Blot for gap junction protein connexin-43 (CX43) of stretched 
and statically cultured samples. Stretched samples were stretched at 5% strain 
for 7 days at 1 Hz  
 
Figure 2.7: Histological comparison of statically cultured (A, C) and stretch 
conditioned (B, D) patches. No qualitative increase in cell number or cell size 
was observed with stretch conditioning  
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Chapter 3: Functional Consequences of a Tissue-Engineered Myocardial 
Patch for Cardiac Repair in a Rat Infarct Model  
The material discussed in this Chapter is adapted from the following: 
 Wendel et al, Functional Consequences of a Tissue-Engineered Myocardial 
Patch for Cardiac Repair in a Rat Infarct Model. Tissue Engineering Part A. 
201437 
3.1  Introduction 
Though cell-based therapies hold much promise to limit left ventricular 
remodeling post-infarction, the mechanisms responsible for the improvements 
observed largely unknown. The transplanted cells may limit LV remodeling and 
infarct expansion by fusing directly with native tissues, stimulating the growth of 
new blood vessels that subsequently increase perfusion to the infarcted area65, 
releasing cytokines that reduce cardiomyocyte apoptosis3, to improve the 
passive mechanical properties of the ventricle.66 However, in most studies 
utilizing directly injected cells as a method of delivery, very few transplanted cells 
are retained in the infarcted region, perhaps because they fail to create focal 
adhesions with neighboring cells, or because the inflammatory response to 
myocardial injury and the hypoxic environment of the infarct zone reduce cell 
survival.67  Thus, the use of engineered tissues has become an attractive solution 
to deliver cells to the injured myocardium high retention.  
 In Chapter 2, we observed that cyclic stretching causes a 2-fold increase 
in contractile force generation of our cardiac patches. However, the end-goal of 
these patches is to limit left ventricular remodeling post-infarction, and the ability 
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of these optimized patches to improve cardiac function post-infarction had yet to 
be investigated.  
 While some studies have assessed the benefits of a cardiac patch in the acute 
phase using non-cardiac cells68 or when administered 14 days post-infarction4,  
of an engineered cardiac patch using a fibrin scaffold in the acute phase, post-
infarction has yet to be investigated. Thus, for the experiments described in this 
report, we created engineered heart-tissue patches by seeding a fibrin gel with 
either the complete native population or a cardiomyocyte-depleted population of 
neonatal rat cardiac cells, and then stimulated cellular alignment and maturation 
by cyclically stretching the patches for seven days. A cardiomyocyte-depleted 
population was used to evaluate whether or not any benefits obtained from the 
patch originated from cardiomyocytes or from non-cardiomyocyte paracrine 
effects. The patches were evaluated in a rat acute myocardial injury model to 
determine whether fibrin-based engineered tissues could improve cardiac 
function and limit adverse cardiac remodeling one and four weeks after 
experimentally induced MI. 
3.2  Methods 
 3.2.1  CM + and CM- Patch Construction  
 Two kinds of patches were made for this study. The first, further noted as 
CM+ patches, were constructed similar to the patches constructed in Chapter 2 
using cardiac cells from syngeneic Fisher F344 (Harlan Sprague Dawley) rats 
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and cultured statically for 7 days before being stretch-conditioned at 5% stretch 
at 1Hz frequency for 7 days, as optimized in Section 2.3.2.  
Secondly, to determine if any benefits seen from patch transplantation are 
attributed to active coupling of donor cardiomyocytes to the host or paracrine 
factors from the co-entrapped non-cardiac cardiac cells, patches containing only 
non-cardiomyocytes were constructed, further noted at CM- patches. Non-
cardiomyocytes were selected through pre-plating of the cardiac cell isolates for 
45 minutes on tissue culture plastic in complete medium (DMEM high glucose 
with 10% FBS and 1% penicillin/streptomycin) to remove slow-adhering 
cardiomyocytes. Adherent cells were cultured in 15% serum complete medium 
until confluent before harvesting for patch construction. Immunostaining for cTnT 
revealed the initial cell population had been reduced to 6.0 ± 2% CMs at the time 
of harvest. Non-cardiomyocyte (CM-) patches were fabricated at a cell 
concentration of 2.4x106 cells/mL in order to match the approximate number of 
non-cardiomyocytes contained in CM+ patches made from the entire isolate, as 
the freshly isolated cardiac cell population was found to contain approximately 
40-45% cardiomyocytes and 55-60% non-cardiomyocytes. The CM- patches 
were cultured otherwise identical to CM+ patches. 
3.2.2  Quantitative Image Analysis to Assess Cell Distribution 
To assess the cellularity and cell distribution of patches, a custom matlab 
algorithm was developed. Cross-sectional images of patch sections co-labeled 
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with DAPI (cell nuclei), f-actin, and either cardiomyocyte (cTnT), myofibroblast 
(smooth muscle actin), or endothelial (CD31) markers. Gray-scale images of 
each component stain were imported into matlab, normalized ofr intensity, 
thresholded, converted to binary, and overlaid on top of each other.  
F-actin/DAPI co-labeling (Alexa Fluor 488 Phalloidin, Invotrogen) was 
used to quantify live cell % within cross-sections of the patches prior to 
implantation. This method was chosen due to the relatively large thickness (657-
694 μm) and the non-uniform cell distribution through the thickness of the 
patches. F-actin was assumed to be present in all live cells, as after cell death F-
actin dissociates into G-actin monomers, which is not labeled by Phalloidin. To 
verify this approach, a subset of patches were first subjected to live/dead staining 
via a 5 minute incubation in 10 μg/mL Hoescht 33342 (Invitrogen) and 10 μM 
Sytox Green nucleic acid stain (Molecular Probes)in Hank’s Buffered Saline 
Solution (HBSS). Samples were next fixed in 4% PFA, frozen in OCT, and cut 
into 9 μm sections before imaging. Live cell% was quantified as the percentage 
of total cells DAPI+/Sytox-. This data was then compared to the percentage of 
cells co-labeling for F-actin and DAPI in sections from the same sample.  
Cell types and locations were identified by the intersection of a cell 
nucleus (DAPI+ object) with f-actin and the desired cell label staining. Both global 
and local cell numbers and densities could be determined using this method. 
More detail can be found in Appendix 2 
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 3.2.3  Implantation of a Cardiac Patch into an Acute Infarct Model 
Procedures used in this study were reviewed and approved by the 
University of Minnesota Institutional Animal Care and Use Committee (IACUC) 
and the Research Animal Resources (RAR) Committee.  
  Female Fisher F344 syngeneic immune competent rats, weighing 175-199 
g (Harlan Sprague Dawley), were used in these studies. Rats were anesthetized 
with 50 mg/kg Ketamine and 2 mg/kg Xylazine delivered intramuscularly, 
intubated, and the heart was exposed through a limited left lateral thoracotomy. 
To induce a myocardial infarction (MI), the pericardium was opened and the left 
anterior descending (LAD) coronary artery was permanently ligated with a 6-0 
polypropylene suture. After a MI had been established, approximately 5-10 min 
post-ligation, a single patch was applied across the epicardial surface of the 
infarcted area of the left ventricle, approximately parallel with surface myocardial 
alignment. Patches, some of which were incubated with 1μg/mL DAPI overnight 
prior to implantation to label donor cells, were removed from their mandrels, cut 
into 3 individual 8 mm strips and sutured parallel to each other on the epicardial 
surface of the LV over the infarct area immediately below the ligation using 8-0 
vicryl sutures. The epicardium was scratched in this process to allow for the 
patch to bond with the host myocardium. After patch placement, the chest was 
closed and the animal was allowed to recover. 5 mg/kg Ketoprofen 
supplemented with 0.05 mg/kg Buprenorphine, delivered subcutaneously, were 
used as analgesia for 72 hours post-operatively. 15 mg/kg enrofloxacin, delivered 
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subcutaneously, was administered for 5 days post-operatively to prevent 
infection. Animals were euthanized by an intracardiac injection of Potassium 
Chloride 3, 7, or 28 days post-operatively.  
 3.2.4 Functional Analysis 
Cardiac function was evaluated via echocardiograph assessments of left 
ventricular fractional shortening (LVFS) and left-ventricular ejection fraction 
(LVEF), as previously described, 69 both 1 week and 4 weeks post-implant. 
Hearts were harvested at either the 1 week or 4 week time point for histological 
assessment.  
 3.2.5  Histology and Immunohistochemistry 
Non-implanted  patches were fixed in 4% paraformaldehyde on ice for 1 
hour, frozen in embedding medium (Tissue-Tek OCT), cut with a cryostat into 5 
µm- 9 µm sections at -18°C and placed onto Superfrost Plus Microscope slides 
(ThermoFisher Scientific) for histological analysis.  
After harvest, the left ventricles of explanted hearts were sliced 
circumferentially into 2-4 mm slices and slices were either fresh frozen in 
embedding medium, cut into 5 μm slices at -18°C and fixed in 4% PFA, or fixed 
overnight in a 10% formalin solution, paraffin embedded, and cut into 4 µm slices 
and placed onto slides for histological analysis.  
Cyrosections were labeled with fluorescent antibodies and subsequently 
imaged to assess the cellularity and cell composition of the patch prior to 
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implantation, and the patch-grafted area on the heart. Cell density and cellular 
composition of the patches were determined using a custom MATLAB program 
detailed in chapter 2.2.8.  Live cell percentage was determined as the 
percentage of cells staining positive for both DAPI and f-actin.  
Infarct size and wall thicknesses are reported as the average of 
measurements performed on Masson’s trichrome-stained sections from each of 
three locations of the left ventricle: immediately below the ligation suture, mid-
way between the ligation suture and the apex, and near the apex. Infarct sizes 
were calculated as the percentage of LV anterior wall surface area that was 
occupied by scar tissue, and wall thicknesses were measured across the 
infarcted portion of the wall.  
 3.2.5  Experimental Design 
Four groups were investigated for this study: 1) Sham (n=5): No ligation, 
the chest and pericardium were opened and then closed. 2.) MI only (n=6): 
ligation of the LAD coronary artery and no treatment. 3.) CM- patches (n=5): 
patches made with a cardiomyocyte-depleted cell population, and 4.) CM+ 
patches (1 week, n=3, 4 weeks, n=7): patches made with cardiomyocytes + non-
myocyte cardiac cells.  
 3.2.6  Statistical Analysis  
Data are presented as means ± standard deviations. All results were 
compared using MiniTab statistical software. One-way analysis of variance 
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(ANOVA) in conjunction with Tukey HSD post-hoc testing was used to compare 
all groups. P-values <0.05 were considered significant. 
3.3  Results 
 3.3.1  In vitro Characterization of Patches  
As shown in Figure 3.1, the average cell viability for F-actin/DAPI staining 
was 87±10.0% and for live/dead staining was 83.4±7.7% (p=0.31).Thus F-
actin/DAPI staining is sufficient in the patches used in this study to quantify live 
cell%.  
Figure 3.2a shows stretch-conditioned patches prior to implantation. Both 
CM+ and CM- patches had compacted into short tubes, or rings, and were 
dimensionally similar with thicknesses of 657 ±41.3 µm and 694 ±70.9 µm, and 
axial lengths of 3.15±0.29 mm and 2.72 ±0.3 mm, respectively. Both samples 
had a circumferential length of 25.1mm, based on the mandrel outer diameter.  
Both patches had similar moduli (CM+: 86.0±3.8 kPa CM-: 135.5±46.7) and UTS 
(CM+: 75.7±11.5 kPa, CM-: 47.2±12.1 kPa) in the aligned (circumferential) 
direction in the rings, values near to what has been reported for myocardium (50-
100kPa for both modulus and UTS).31, 70, 71   
In order to assess the quality and consistency of implanted patches, a 
subset of samples intended for implantation were histologically and functionally 
evaluated after stretch conditioning to quantify their cellular composition and 
contractile response. These patches had approximate cell densities of 1540 ±631 
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cells/mm2 for CM+ patches and 1030±219 cells/mm2 for CM- patches based on 
immunoflourescent staining of 5 µm sample cross-sections (Table 3.1). However, 
cellularity was not homogenous throughout the patches.SMA+ cells being located 
primarily on the abluminal surface of CM- patches (Figure 3.2 i) and higher 
densities of cardiomyocytes were located near the outer surface and edges of 
the ring-shaped patches (Figure 3.2 e, f). SMA+ cells within the CM+ patches 
were primarily found in areas containing cardiomyocytes (not shown). Cells 
throughout the patches exhibited elongated morphologies aligned in the 
circumferential direction (Figure 3.2 d, g) and adjacent cardiomyocytes within the 
CM+ patches exhibited gap junctions as well (Figure 3.2 d). CM+ patches were 
found to contain 90.1 ±7.1 % live cells (f-actin+/DAPI+), 39.1±16.5% of which 
were cardiomyocytes (f-actin+/DAPI+/cTnT+) and 15.2±3.7% were positive for α-
smooth muscle actin (f-actin+/DAPI+/SMA+), indicating they were either smooth 
muscle cells or myofibroblasts (Table 3.1). The final percentage of 
cardiomyocytes was similar to that of the initial cell population, which can be 
attributed to the use of horse serum, which limits fibroblast proliferation, in the 
culture medium. Only a few cells were found to be CD31+ endothelial cells in 
either group. Cells positive for neither cardiomyocyte markers, SMA or CD31 
were assumed to be quiescent cardiac fibroblasts, which constituted 45.7±20.2% 
of the final cell population. CM- patches were found to contain 92.7±3.8 %live 
cells, 1.8%±1.0% cardiomyocytes, 11.5±14.1% SMA+ cells, and 80.4±15.2% 
quiescent fibroblasts. 
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In addition to histological interrogation of the patches to assess cellularity, 
extracellular matrix production by the entrapped cells was also evaluated. 
Trichrome staining (Figure 3.3 b) revealed that after 14 days in vitro culture, the 
content of the patch ECM remained primarily fibrin. However, collagen I and the 
basement membrane proteins laminin and collagen IV were deposited in the 
extracellular space surrounding all cells within the CM+ patches, and significantly 
less of collagen I and IV were produced in the CM- patches (Figure 3.3 a, c). 
Small amounts of collagen III and fibronectin were also present in the ECM of 
both patches (not shown). 
 CM+ patches exhibited visible, measurable contractions both 
spontaneously and synchronously in response to electrical pacing from 1-4Hz 
frequency (Figure 3.2 b-c). The maximum pacing frequency in which a twitch 
force could be measured occurring synchronous with stimulation averaged 
between 5-7 Hz, comparable to the heart rates of the rats used in these studies.  
The twitch force ranged from 1.3-2.7 mN over 1-4 Hz, values that were over 
three-fold higher than samples cultured statically for 14 days. 
 3.3.2  Functional Consequences of Patch Transplantation 
  3.3.2.1  Echocardiography 
 
Echocardiography was conducted both 1 week and 4 weeks post 
operatively. One week post-implant, neither treatment group displayed a 
reduction in ejection fraction or fractional shortening of the LV wall compared to 
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the sham surgery, but there was a reduction in cardiac function in the animals 
receiving MI-only (data not shown). Four weeks post-implantation, both ejection 
fraction and fractional shortening were further reduced in animals receiving MI-
only as compared to values 1 week post-ligation (Figure 3.4 a, b). Animals 
receiving the CM- patches showed no improvement in either ejection fraction or 
fractional shortening over MI-only. Hearts receiving CM+ patches had ejection 
fractions and fractional shortenings substantially higher than both MI-only and 
CM- patch groups, values which were not different than the sham operated group 
(Figure 3.4 b). This indicates that a patch containing the full complement of 
cardiac cells, cardiomyocytes included, yielded the best functional outcome.  
  3.3.2.2  Left Ventricular Remodeling 
Animals receiving MI-only had large infarcts (Figure 3.5 a), comprising on 
average 61.3 ±7.9 % (range 53.7%-69.5%) of the LV anterior wall surface area, 
with significant wall thinning to 661.3 ± 37.4 μm, or ~25% of the thickness of the 
non-infarcted myocardium (Table 3.2). CM- patches resulted in significant 
reduction of infarct size (Figure 3.5 b) to 36.9 ±10.1% (range 30.9%-48.6%). 
Thinning of the LV anterior wall was also substantially reduced to 
1058.2±136.4μm, or ~40% of the thickness of the non-infarcted myocardium. 
Concurring with the functional data, animals receiving the CM+ patch had very 
small infarcts (Figure 3.5 c) of 13.9±10.8% (range 5.4%-29.1%) of the LV anterior 
wall. Wall thinning was also substantially reduced over both MI-only and CM- 
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patch groups, to 2274.6±111.5 μm, a value not significantly different than that of 
the sham-operated myocardium (Table 3.2).  
 3.3.3  Patch Engraftment  
At 1 week post-implant, CM+ patch recipients were found to have a large 
amount of adhesions and scar tissue surrounding the heart, rendering it difficult 
to remove the heart with the patch intact. After 4 weeks in vivo, the presence of 
adhesions was reduced, and hearts receiving either CM+ or CM- patches had a 
thin, pale film covering the epicardial surface of the LV anterior wall, consistent 
with a collagenous tissue film revealed with trichrome staining not seen on a 
sham-operated myocardium (Figure 3.6 b, c), extending across both the infarcted 
and non-infarcted area of the LV epicardial surface. This film was not seen in 
sham-operated hearts (Figure 3.6 a) or those receiving ligation only (not shown) 
and had an average thickness of 372.6 ±55.39 μm and 131.0 ±39.0 µm for CM+ 
patch and CM- patch recipients, respectively. Cyrosections of these hearts 
revealed that this film contained large numbers of DAPI+ cells (Figure 3.7), 
indicating that these cells were donor cells and that the film seen was the 
remodeled patch. DAPI+ cells were also found in the host myocardium in hearts 
that received CM+ patches, indicating that there was cell migration from the 
engrafted patch into the myocardium. Invading donor cells both 1 week and 4 
weeks post-implantation (Figure 3.7 a. b), and donor cells were found associated 
with vascular structures within the host myocardium interspersed with host cells 
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(Figure 3.7 b). Invading donor cells located outside of vascular structures, 
presumably cardiac fibroblasts (cells both SMA- and CD31-), were found inside 
the host myocardium and in neo-tissue identifiable as the zone devoid of 
cardiomyocytes between the host myocardium and patch. At 1 week post-
implant, bright DAPI+ cells were widely spread throughout the patch and the 
interface, and cells were seen in the myocardium as well. At 4 weeks post-
implant, DAPI+ cells were much dimmer. This dimming may be attributed to 
dilution of the DAPI label through cell division. 
The engrafted patches underwent near complete remodeling in vivo, with 
the ECM being converted from being primarily fibrin at implantation (Figure 3.3 b) 
to highly collagenous at explant (Figure 3.6 b, c). Elongated donor 
cardiomyocytes were found within the patches of animals that received CM+ 
patches (Figure 3.6 d, f), but not CM- patches (Figure 3.6 e). Both patches were 
vascularized in vivo, with ingrowth of host endothelial cells seen both 1 week and 
4 weeks post-implantation (Figure 3.8 c, d). Vascular structures containing red 
blood cells found throughout the entire engrafted areas of both CM+ (Figure 3.8 
a, b) and CM- (not shown) patches, with no difference in the vascular density 
within the patches between the two groups (not shown). The presence of red 
blood cells in these vessels indicates that the patches were perfused through 
angiogenesis from the host myocardium. In the engrafted CM+ patch, the 
percentage of cardiomyocytes present was reduced to 11.0 ± 10% after 4 weeks 
in vivo, with a very heterogeneous distribution. There was over an 18-fold 
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increase in the cell density in the engrafted patch compared to patches prior to 
implantation. This increase in cell density and reduction in cardiomyocyte 
percentage could be attributed to cell death due to ischemia post-implantation, 
proliferation of donor non-cardiomyocytes in vivo, and the infiltration of host cells 
into the patch. Factoring in the increase in cell density and the percentage of 
cardiomyocytes within the patches, it can be estimated that 36.5% of implanted 
cardiomyocytes survived transplantation. Gap junctions between donor 
cardiomyocytes were found within the patch (Figure 3.6 f); however, electrical 
coupling of donor cardiomyocytes to the host myocardium was not possible due 
to the presence of a 101± 40 µm non-cardiomyocyte neo-tissue zone between 
the CM+ patch and the host myocardium. This area consisted primarily of 
fibroblast-like cells of both donor (DAPI+) and host origin, but also contained 
numerous microvessels spanning the zone. Additionally, alignment of the patch 
with the host myocardium was not completely maintained. Regional alignment of 
donor cardiomyocytes within the CM+ patches was seen, but this alignment did 
not consistently match the alignment of the host cardiomyocytes along the 
epicardial surface of the heart. This misalignment may be attributed to movement 
or misplacement of the patch during or shortly after implantation, but before 
patch attachment to the host engraftment. 
3.4  Discussion 
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The main finding of this study is that engraftment of the CM+ patch 
occurred by 4 weeks after implantation, accompanied by a remarkable 
amelioration of left ventricular remodeling underneath the patch (Figures 3.5, 3.6)  
in the form of a reduction in both LV scar size and wall thinning  accompanied by 
a substantial improvement of LV contractile function (Figure 3.4). A surprise and 
novel finding of this study is that the administration of a CM- patch also resulted 
in a reduction of LV scar formation and thinning of the LV anterior wall, but to a 
lesser extent than the CM+ patch (Figure 3.5, Table 3.2) and without 
improvements in contractile function, suggesting the benefits observed with this 
treatment require cardiomyocytes.     
 3.4.1  Fibrin Patch Transplantation 
The creation of an in vitro myocardial patch is an area that has seen 
significant and increasing interest for many years, leading to a number of studies 
utilizing a variety of different cell sources and fabrication methods. The objective 
of restoring LV contraction by transplantation of a patch that generates 
physiological contractile stress to the injury site of the LV has been largely 
unsuccessful.66, 72-78  Rather than trying to replace the damaged myocardium, the 
present study evaluated the capacity of a patch, with or without donor 
cardiomyocytes present, to restore LV contraction. Fibrin was chosen as the 
scaffold due to its biocompatibility and capacity to be remodeled both in vitro79, 80 
and in vivo. 81 Fibrin possesses many of the properties of collagen that are 
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advantageous for tissue engineering82, such as being a native substrate for cell 
adhesion and the capacity for the protein fibrils to become aligned when cell 
induced gel compaction is mechanically constrained.83 This cell induced 
alignment has been shown to be associated with an increase in the contractile 
force generation of engineered myocardial tissues.5  Fibrin gels have also been 
seeded with human embryonic stem cell-derived cardiomyocytes84, murine 
cardiovascular progenitor cells or with both mESC-derived CM and non-myocyte 
supporting cells to generate engineered cardiac tissues. These tissues contained 
aligned, highly differentiated and electromechanically coupled CMs that exhibited 
rapid conduction velocities (22-25 cm/s) and contractile forces of up to 2 mN in 
static culture.11  
 3.4.2  Patch-Induced Myocardial Protection 
One of the major objectives of the present study was to evaluate the 
efficacy by which a fibrin-based, stretch conditioned myocardial patch can limit 
left ventricular remodeling and infarct expansion. It was a surprise finding that the 
patch implantation caused a dramatic reduction of infarct size (Figure 3.5).  In 
addition, the beneficial effects were remarkably more prominent in hearts 
receiving a CM+ patch compared to a CM- patch (51 % reduction in CM- and 77 
% reduction for CM, p<0.05, Figure 3.5, Table 3.2).  Although the transplantation 
of a non-cardiomyocyte patch was associated with reduction in infarct size and 
LV wall thinning, these beneficial effects were improved and cardiac function was 
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completely restored in hearts receiving a patch containing both cardiomyocytes 
and non-cardiomyocytes (Figures 3.4, 3.5).  Although a large fraction of the 
donor cardiomyoctes (36%) were estimated to survive 4 weeks implantation 
within the CM+ patches, these remarkable effects were not caused by their 
electrical coupling to the host myocardium as the presence of a physical barrier 
in the form of a non-cardiomyocyte neo-tissue zone separating donor 
cardiomyocytes from the host myocardium and preventing electrical coupling 
between them. This zone could be scar formation as a result of the patch 
implantation or the patch remodeling and engraftment process itself. Due to the 
thin size, low stiffness properties and modest twitch force generation of the CM+ 
patch when implanted, these effects were also not likely a result of passive or 
active force inhibition of LV scar formation and dilation, but rather through 
cytokine support provided by donor cardiomyocytes. The affixed patch on the 
surface of the infarcted region prevented host cardiomyocyte death immediately 
after infarction. Two physical effects occur as a consequence of this cytokine 
support. First, a reduction in host cardiomyocyte death in the infarct zone 
prevents overstretching of neighboring host ventricular cardiomyocytes, thus 
blocking the detrimental signaling pathways initiated by cardiomyocyte 
overstretch.85 Second, the regional left ventricular wall stress, and therefore the 
energy demand of the host myocardium is decreased which in turn prevents LV 
bulging.86, 87  Consequently, ischemic cardiomyocytes that would otherwise 
progress towards apoptosis are spared until perfusion can be re-established. The 
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end result of these two events is a significant reduction in LV scar size and a 
subsequent reduction in LV dilation.  
Since we employed a permanent LAD occlusion model, the level of 
reduction of coronary flow at initiation of occlusion was identical among the 
hearts with or without patch implantation.  Therefore, the reduction of infarct size 
that resulted from the patches was a result of either sparing the ischemia 
threatened cardiomyocytes that otherwise would go on to the apoptosis 
pathways, as noted above, or from the mobilization of the endogenous cardiac 
progenitors to the injury site to facilitate regeneration.  Survival of donor 
cardiomyocytes within the patch (Fig 3.7 c, e, f) was not surprising, as neonatal 
rat cardiomyocytes have been shown to be hypoxia-resistant due to their ability 
to rely on glycolysis until a vascular network has been established.   
 3.4.3  Cytokine Effects 
Invasion of donor cells from the CM+ patch into host myocardium was 
seen both 1 week and 4 weeks post-ligation (Figure 3.7), suggesting the 
important paracrine effect of the patch requires communication between 
cardiomyocyte and non-cardiomyocyte cardiac cells. Cytokine-driven cardiac 
repair has been hypothesized to be mediated primarily by non-cardiomyocytes, 
88, 89 and yet apparent cytokine benefits in this study were seen to a much higher 
degree in the CM+ patch compared to the CM- patch. Thus, cardiomyocytes 
played an indirect, yet crucial role in this system. While there are a wealth of 
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studies investigating the role non-cardiomyocytes have on cardiomyocytes in 
culture and during development,10, 11, 88-91 the influence cardiomyocytes exert on 
non-cardiomyocytes has been less thoroughly investigated. When exposed to 
stretch, cardiac fibroblasts have been shown to increase ECM production, but 
only in the presence of cardiomyocytes or cardiomyocyte-conditioned media 
through cardiomyocyte-produced TGF-β1.92, 93 This result is consistent with the 
CM+ patches used in this study, with an increase in both collagen I and collagen 
IV compared to CM- patches (Figure 3.3 c).   
 
Previous work has shown that cell-based therapies can improve cardiac 
function post-infarction through paracrine factors or neovascularization.86, 87  It 
was also shown that stretch-conditioned engineered patches constructed from 
neonatal rat cells entrapped in a collagen gel limit further LV remodeling and 
electrically couple to the host myocardium when implanted 14 days post-
infarction, with improvements in cardiac function in cases of severe infarctions.4 
However, these functional improvements were limited, and no invasion of donor 
cells into the host myocardium was reported.  The patch to heart size ratio was 
larger compared to this study, perhaps resulting in benefits through passive or 
active mechanical affects not seen in this study. Interestingly, no beneficial 
effects were reported with the administration of collagen-based non-
cardiomyocyte patch, whereas a decreased size of infarct and a reduction in LV 
anterior wall thinning occurred in this study for the fibrin-based CM- patches. 
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These differences may be attributed to either the patch itself or the timing of 
treatment.   
 
3.5  Figures and Tables 
 
All figures and tables are adapted from Wendel et al, Tissue Engineering Part A 
201437 
 
Table 3.1: Cell Composition in Patches Pre-Implantation 
Patch Cell density 
(cells/mm2) 
% Live % CMs SMA + CD31+  
CM+ 1540 ±631  90.1±7.1% 39.1±16.5%  15.2±3.7%  <0.5% 
CM-  1030±219 92.7±3.8%  1.8%±1.0%  11.5±14.1%  <0.5% 
 
 
Table 3.2: Infarct Size and LV Thickness of 4-week implants 
Group  Infarct Size  LV anterior wall thickness  
Sham (no ligation)  -  2618.9± 221.4μm * #  
MI only  61.3 ±7.9 %  661.3 ± 37.4μm  
MI + CM- patch  36.9 ±10.2% *  1058.2±135.4μm*  
MI + CM+ patch  13.9±10.8% * # 2274.6±37.4μm * #  
* p< 0.05 vs. MI only, # p< 0.05 vs CM- patch 
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Figure 3.1: Validation of the use of f-actin as a marker for live cells 
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Figure 3.2: In vitro characterization of cardiac patches: twitch force and 
cellularity. Ring-shaped patches prior to cutting into strips for implantation were 
characterized. Top  Panels: (A) Two patches on a distensible latex mandrel in the 
cyclic distension bioreactor. Scale= 5mm. (B-C) Twitch force generation of CM+ 
patches in response to electrical pacing of variable frequencies. Bottom Panels: 
Circumferential (D,G) and cross-sectional (EF), (H-I) views of CM+  and CM- 
patches, showing elongated, aligned cells in each patch (D,G) and cell 
distribution of both cTnT+ and SMA+ cells in each patch. Few cardiomyocytes 
were found in the CM- patch, and SMA+ cells were located close to the abluminal 
surface in both patches. 
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 Figure 3.3: In vitro characterization of cardiac patches: ECM deposition. Cellular 
deposition of collagen I, IV, and laminin was evident after 14 days in vitro culture 
(A), even though the patch ECM still consisted primarily of fibrin, as seen in 
Masson’s Trichrome images of CM+ and CM- patches (B). Increased deposition 
of collagen I and IV was found in CM+ patches compared to CM- patches (C), 
based on quantitative image analysis of staining intensity normalized to cell 
count.  This is evident by the presence of matrix proteins distributed throughout 
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CM+ patches while ECM deposition in CM- patches was largely limited to the 
exterior of the patch. *p<0.05. 
 
 
Figure 3.4: Echocardiography results 1 week and 4 weeks post-implantation. A 
significant reduction in both LVEF and LVFS from 1 week to 4 weeks post-
ligation was seen in animals receiving no treatment (A). *p<0.05 Week 4 vs. 
Week 1. However, substantial improvement over the MI only control and CM- 
graft in ejection fraction (EF) and fractional shortening (FS) resulted with the 
application of a CM+ patch by 4 weeks of implantation (B). * p<0.05 vs. MI only. 
# p<0.05 vs. CM- patch. 
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Figure 3.5: Infarct size and LV free wall thickness from coronal sections. 
Masson’s Trichrome image of a MI-only heart (A), and hearts that received a CM- 
patch (B) and CM+ patch (C). The engrafted patch can be seen as the thin blue 
layer on the outside of the heart in (C). CM- patches were not easily 
distinguishable using Trichrome due to large infarct scars. 
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Figure 3.6: Patch Engraftment 4 weeks post-implant. 
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 Massons’s Trichrome stained sections of a sham-operated (A), CM- patch (B), 
and CM+ patch (C) recipient heart, indicating the presence of a remodeled patch 
affixed to the epicardium (. (D)-(F): Immunohistochemistry of patches. 
Cardiomyocytes (cTnT+ cells) are present in the engrafted CM+ patch (E), and 
an absence of cTnT+ cells are visible in the CM- patch (D), along with substantial 
thinning of the LV free wall.  (F) Sarcomeric organization is visible in 
cardiomyocytes within the engrafted CM+ patch, along with evidence of gap 
junctions between adjacent CMs within the patch. 
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Figure 3.7: Invasion of DAPI pre-labeled cells into host myocardium  
Blue = DAPI prelabeled donor cells. Cell invasion occurred for CM+ patches at 1 
week (A) and 4 weeks (B) post-implantation.  Some of the invading cells were 
associated with vascular structures within the host myocardium (white arrows). 
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Figure 3.8: Vascularization of the CM+ patch.  
Top Panels: H&E of an engrafted CM+ patch after 4 weeks in vivo. Red blood 
cells, noted by black arrows and indicating perfusion, are visible in the patch-host 
interface (A) and in the patch itself far (C) from the host myocardium. Bottom 
Panels: SMA/CD31 staining of engrafted patches both 1 (C) and 4 (D) weeks 
after implantation, showing both host endothelial cell migration into the patch and 
the establishment of vessels in the patch. 
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Chapter 4: The Creation and Optimization of a Tissue-Engineered Cardiac 
Patch from Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes 
Portions of the following chapter along with chapter 5 were adapted from: 
Wendel, et al. Functional Effects of a Tissue-Engineered Cardiac Patch from 
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in a Rat Infarct 
Model. Stem Cells Translational Medicine. Accepted June 2015 
4.1 Introduction 
Cardiovascular diseases remain a leading cause of death in the 
developed world,94 and despite advances in interventional and pharmacological 
therapies, these treatments remain largely palliative. In light of these 
shortcomings, cell-based therapies have become an attractive approach to 
prevent heart failure post-infarction. Cardiac tissue engineering, which aims to 
generate functional myocardium in vitro, provides a method to deliver cells to the 
injured myocardium with enhanced cell survival and large graft sizes, enhancing 
the ability of cells to regenerate myocardium in vivo and limit left ventricular 
remodeling post-infarction. With the discovery of induced pluripotent stem cells 
(iPSCs)14 and the ability to differentiate human iPSCs into functional 
cardiomyocytes (hiPSC-CMs),15, 95 these cells have become a prime candidate 
for use in cardiac tissue engineering. First differentiated to cardiomyocytes using 
the embryoid body method15, hiPSCs are now differentiated by using a matrix 
sandwich method16 or by small molecule methods modulating the Wnt/β-catenin 
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signaling pathway17 to provide the high yields of hiPSC-CMs needed for use in 
engineered cardiac tissues (ECT). These methods have been able to achieve 
highly variable cardiomyocyte (CM) purities, but for enhanced therapeutic effect 
or to study the interactions of CMs with a defined population of non-CM cells, 
further purification may be necessary. Purification of CMs has been achieved 
through genetic methods utilizing puromycin resistance96 and non genetic 
methods such as the use of CM-specific cell surface markers for fluorescence97-
99 and magnetic-activated cell sorting100, microdissection101, and targeting 
metabolic pathways as used in lactate-based purification102.  
While there are numerous studies reported for ECTs constructed using 
neonatal rat cells4, 5, 37, there are far fewer made from human pluripotent stem 
cells. Human embryonic stem cell derived CMs (hESC-CMs) have been 
entrapped in fibrin-matrigel,25 collagen-matrigel10, and gelfoam scaffolds.58 These 
studies have shown that the addition of non-CM cell types not only facilitate the 
compaction of biopolymer hydrogels, but result in improved contractile force 
generation and survival of entrapped cardiomyocytes. 
4.2  Methods 
 4.2.1  Culture of Human iPSC-Derived Cardiomyocytes 
Human iPSC-derived cardiomyocytes were prepared in the lab of Dr. 
Timothy Kamp at the University of Wisconsin-Madison. The hiPSC line DF19-9-
11T103 was used in this study for cardiomyocyte differentiation. Cells were 
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differentiated via the small molecule Wnt/GSK3 inhibition (GiWi) protocol,17 and 
the purity of cardiomyocytes was measured by flow cytometry for cTnT+ cells at 
15 days differentiation. hiPSC-CMs with a purity of 70-95% cTnT+ cells were 
frozen into cryovials in 90%FBS, 10%DMSO at 10 x106 cells/vial before shipping. 
Cells were thawed into T75 flasks coated with 2.5 µg/cm2 fibronectin (Sigma-
Aldrich) at 10x106 cells/flask. Adherent iPSC-CMs were cultured in EB20 medium 
(20% FBS, 1% penicillin/streptomycin (Gibco), 0.1 mM nonessential amino acids 
(NEAA, Gibco), 0.1 mM β-mercaptoethanol (Gibco) in DMEM/F12 Basal Media 
(Corning)) for 48 hours, and reduced to 2% serum media (EB2) for an additional 
24 hours before harvesting for patch creation. Initial studies investigated the use 
of CMs for casting directly from thaw or cells that had been cultured as above 
prior to be used for gel creation.  
4.2.2  Harvest of hiPSC-CMs for Use in Patch Construction 
HiPSC-CMs were harvested for construct preparation by rinsing cells in 
the flask twice with phosphate-buffered saline (PBS) and then exposing cells to a 
solution of 0.25% Trypsin (Hyclone) with 2% Chicken Serum (Hyclone) at 37ºC  
for 5-10 minutes before quenching with EB20 medium. Cells were spun down at 
200 x g for 5 minutes at room temperature prior to being counted and 
resuspended in EB20 medium for patch creation.  
4.2.3  Hemispheres for Screening of hiPSC-CM Density and Matrix 
Formulations 
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As hiPSC-CMs are not available in the same quantities as neonatal rat 
cardiomyocytes, small hemispheres were created to screen multiple gel 
formulations and cell seeding densities while limiting the number of cells used. 
Hemispheres were created by melting a circular ring into a tissue culture plate 
using a heated tissue punch. Gel forming solution was dropped into the center of 
these circular stamps, and gels were allowed to polymerize for 6 minutes at room 
temperature before being transferred to a 37ºC, 5% CO2 incubator for 15 
minutes. After polymerization was complete, EB20 media was added to each well 
to cover the gel and the gels were returned to the incubator. EB20 media was 
changed the next day and after 48 hours switched to 2% serum media for the 
remainder of culture. Hemispheres were cultured and observed daily for a total of 
14 days before being fixed in 4% PFA for qualitative histological assessment. In 
these experiments, 4.5 mm and 6 mm diameter tissue punches were used to 
create 25 μL and 50 μL hemispheres, respectively, and the  gel and cell seeding 
densities were assessed as displayed in Table 4.1. Media to cell ratios were kept 
constant to ensure that relative nutrient availability did not affect the results.  
4.2.4  Construction and Culture of hiPSC-CM Patches 
To quantitatively assess the cellularity and contraction force generation 
aligned patches containing hiPSC-CMs and to compare them to the previously 
constructed neonatal rat cell patches, aligned hiPSC-CM patches were 
constructed nearly identical to the patches constructed in Chapter 2 by mixing 
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2.2x106 CMs with a fibrin-forming solution and injecting it into a 8mm-ID, 1.25 mL 
tubular mold as previously described37  to create a final fibrin concentration of 3.3 
mg/mL. The cell-containing, fibrin-forming solutions were incubated at 37°C for 
15 min to allow formation of a fibrin gel. Gels were then removed from their 
casings and placed in EB20 culture medium supplemented with 2 mg/mL ACA 
for the first 48 hours of culture, followed by culture in 2% serum medium for the 
remaining 12 days culture, 14 days total static culture, with media changes 3 
times weekly. 2.2x106 CMs were chosen to put into these patches in order to 
match the input number of cardiomyocytes to that of the rat patches constructed 
in chapter 2 and chapter 3.  
4.2.6  Purification of hiPSC-CMs 
hiPSC-CMs used in these studies were received with CM fractions ranging 
from 70-95% cTnT+ cells. The remaining 5-30% of cells in these preparations is 
comprised of primarily fibroblast-like cells that remain poorly characterized to 
date. Little has been reported on the non-CMs in CM preparations from 
pluripotent stem cells, these cells have been reported to express one or multiple 
of the following proteins: VE-Cadherin, PDGFRb, Vimentin, VonWillebrand 
Factor, SM22α, and TRA-1-160, a marker for undifferentiated cells25, 104.  Thus, 
for experimental consistency and quality control purposes, obtaining a cell 
population of cardiomyocytes with maximal purity is necessary.  
4.2.6.1  CM Purification through Pre-plating  
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The use of pre-plating has been widely used with neonatal rat cells to 
select for cardiomyocytes. Pre-plating functions based on differential adhesion- 
the fact that some cell types (in this instance cardiomyocytes) take longer to 
settle and adhere to substrates than others (in this instance fibroblasts and other 
interstitial cardiac cells). Thus, allowing a cell suspension to settle and begin 
adhering for a short period of time before removing the supernatant and re-
plating the cells into a new container will theoretically separate a large number of 
non-cardiomyocytes from the cardiomyocyte cell population. Two variables were 
assessed to optimize the pre-plating procedure for selection of hiPSC-CMs: 
length of time cells are allowed to adhere to the initial substrate prior to removing 
the supernatant, and the protein coating on the preplating substrate. Unlike 
neonatal rat cardiomyocytes, hiPSC-CMs require a protein coating to support cell 
adhesion to tissue culture plastic. The following combinations of variables were 
assessed: 
Pre-plating incubation time: 
- 20, 40, 60, 80, 120, 180, and 240 minutes 
Protein Coating on pre-plating surface: 
- Fibronectin, Gelatin Collagen I, and Tissue culture plastic 
Cells were plated from thaw into either 6 or 24 well plates in EB20 media. 
Fibronectin wells were coated with 2.5 μg/cm2 of fibronectin for 1 hour at room 
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temperature, and gelatin wells were coated with 1 mg/mL gelatin for 10 minutes 
at room temperature prior to seeding cells. Collagen-I coated wells were 
incubated overnight in 0.05mg/mL collagen I at 37ºC and then rinsed twice with 
Hank’s Buffered Saline Solution (HBSS) prior to seeding cells.  Cells were then 
allowed to adhere for the allotted amount of time before the supernatant was 
removed and placed into an adjacent well. Fresh EB20 was then added to the 
preplate wells and all cells were allowed to adhere and culture for 24 hours prior 
to being fixed in 4% paraformaldehyde (PFA) for histological assessment of CM 
purity.  
CM purity was assessed by staining cells in all wells for DAPI, f-actin (all 
cells) , and cTnT (cardiomyocytes). A custom matlab code was then used to 
import images and count he numbers of the designated cell types in each image. 
At least 9 images were acquired for each condition and averaged to obtain an 
overall CM%. Additional information on the cell-counting matlab code can be 
found in Appendix 2.  
4.2.6.2  CM Purification through the Targeting of Metabolic Pathways 
Utilizing Lactic Acid 
As an alternative method to pre-plating, cardiomyocytes were purified 
using a lactate-based selection media targeting the differing metabolic pathways 
of fibroblast-like cells, which rely on glycolysis, and cardiomyocytes, which can 
utilize both glycolysis and oxidative phosphorylation for energy metabolism. 
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Based on previous work102 and a protocol obtained from the Healy lab at the 
University of California-Berkley, the use of lactate-supplemented glucose-free 
media was investigated as a means to select for cardiomyocytes.  
Prior to exposing hiPSC-CMs to the lactate selection media, the optimal 
conditions for eliminating non-cardiomyocytes were assessed by treating human 
pericytes (PCs), ovine dermal fibroblasts (ODFs), and neonatal human dermal 
fibroblasts (NHDFs) to various media compositions to ascertain the formulation 
that will eliminate non-cardiomyocytes while minimize the stress upon remaining 
cardiomyocytes. An initial experiment was conducted with ODFs and PCs and a 
follow up study was run with NHDFs. The following conditions were investigated 
in a lactate media consisting of glucose-free DMEM (Invitrogen), 
penicillin/streptomycin, NEAA, β-mercaptoethanol, and the following: 
 ODFs and PCs: 
- 1mM or 4mM lactic acid (Sigma-Aldrich, stock diluted to 1M in HEPES) 
- 0% or 2% FBS. Serum contains an undetermined amount of glucose, 
which may or may not provide enough nutrients to sustain non-
cardiomyocytes in culture. 
NHDFs: 
- 1 mM or 4 mM lactic acid  
- 0 mM or 1 mM NEAA 
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Cells were plated to be confluent and allowed to culture in their respective 
culture 
medias 24h prior to exposure to the test medias. Cells were imaged daily with a 
phase contrast inverted microscope until significant cell death was observed or 7 
days passed.  
 Once the media conditions were assessed with non-cardiomyocyte cells, 
the candidate media formulations were used with hiPSC-CMs. The candidate 
media formulation used in this experiment consisted of DMEM no glucose, 0% 
serum, 1 penicillin/streptomycin, 0.1mM NEAA, 0.1mM β-mercaptoethanol, and 
4mM lactic acid. hiPSC-CMs were plated into 48 well plates coated in 2.5 
ug/cm2, per the standard thaw and culture protocol in EB20 media. Cells were 
maintained in EB20 until day 3 of culture, at which they were switched to a 2% 
serum media for 24 hours before being switched to the treatment lactate media. 
Lactate media was changed every 2 days, and at every change cells were rinsed 
with PBS twice before adding new media. Cells were cultured in lactate media for 
2, 4, 6, or 7 days before being fixed for immunofluorescent staining and imaging 
to assess CM% at each time point.  
After the optimal media formulation and exposure time were obtained for 
maximum hiPSC-CM purity, a comparison of purified and unpurified hiPSC-CMs 
was conducted to assess any potential changes to the cell phenotype as a result 
of lactate treatment. For comparison of unpurified and purified hiPSC-CMs, cells 
were seeded directly from thaw into 24 well plates coated with 2.5μg/cm2 
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fibronectin at a density of 1x105 cells/cm2. Adherent hiPSC-CMs were cultured in 
EB20 medium for 48 hours, and reduced to 2% serum media (EB2) for an 
additional 24 hours. On day 4 of culture, half of the cells were exposed to lactate 
media and the remaining wells were maintained in EB2 media. Cells were 
exposed to either lactate or EB2 media for 4 days, two total media changes, 
before being returned to EB2 media on day 8 of culture. Cells were cultured for 
an additional 3 days in EB2 media before being harvested for protein analysis.  
4.2.6  Co- entrapment of Purified hiPSC-CMs with PCs 
As cardiomyocytes have been shown to exhibit increased survival and 
contractile force generation when co-entrapped with non-cardiomyocyte support 
cells, and non-CMs are necessary to induce compaction of the fibrin gel, which is 
essential to concentrate and align CMs,37 we investigated the use of utilizing 
pericytes (PCs) as a support cell for cardiomyocytes. PCs were chosen with 
respect to future strategies to include preformed microvessels created with PCs 
and endothelial cells in gels along with hiPSC-CMs.  
GFP-labeled human brain pericytes were obtained from the lab of Dr. 
George Davis at the University of Missouri-Columbia, and were previously 
characterized to express nuclear GFP.28 Pericytes were cultured for 10 days on 
gelatin coated flasks in culture media consisting of DMEM low-glucose (Gibco), 
supplemented with 10% FBS, 1% penicillin/streptomycin and 0.01mg/mL 
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gentamycin (Gibco). Pericytes were harvested by exposing cells to a solution of 
0.05% Trypsin EDTA (Hyclone) for 5 minutes before quenching with FBS.  
 For initial experiments to validate whether or not hiPSC-CMs and PC can 
be co-entrapped together, 50 μL hemispheres similar to those constructed with 
hiPSC-CMs alone were created with 3.3mg/mL fibrinogen, the same seeding 
density of CMs (2.2x106 CMs/mL), and either 1.5, 1.0 or 0.5 x106 PCs/mL. 
Hemispheres were cultured in CM media (EB20, EB2) supplemented with ACA 
for 14 days static culture prior to harvest for histological assessment of cell 
morphology.  
4.2.7  Statistical Analysis 
 Data are presented as means ± standard deviations. All results were 
analyzed using Microsoft Excel or MiniTab statistical software. Student’s t-tests 
and one-way analysis of variance (ANOVA) in conjunction with Tukey HSD post 
hoc testing was used to compare all groups. p-values <0.05 were considered 
significant. 
4.3 Results 
4.3.1  Preferential CM morphology and Cell Distribution with Pre-Cultured 
CMs 
Two methods of hiPSC-CM culture were used in preliminary studies 
entrapping hiPSC-CMs in fibrin: entrapping CMs directly after thaw or pre-
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culturing CMs for 72-96 hours prior to harvesting for patch construction. At thaw, 
CMs had on average X% viability, but fewer than 20% of the cells remained 
viable in the long-term and successfully adhered to the fibronectin-coated T75 
flasks. Although there was significant cell loss with pre-culture, patches these 
cells largely remained viable after entrapment in fibrin, exhibiting spread 
morphologies and resulting in patches that generated visible contractions. 
However, when patches were created with cells directly from thaw, the vast 
majority of the cells that survived entrapment retained small, rounded 
morphologies and resultant patches contained a large amount of cellular debris 
with minimal to no visible contractions. Thus, for all successive experiments, 
hiPSC-CMs were pre-cultured in flasks prior to use for patch construction. 
4.3.2  hiPSC-CM Patches Exhibit Similar Cell Densities to Neonatal Rat 
Cell Patches But With Decreased Contractile Force Generation 
hiPSC-CMs remained viable and exhibited elongated morphologies in all 
gel formulations and cell seeding densities investigated (data not shown). 
However, gels cast at low fibrinogen concentrations (1.5, 2.0 mg/mL) resulted in 
gels that were qualitatively less dense and more fragile than those fabricated with 
higher fibrinogen concentrations, limiting these tissues ability to be feasibly 
handled and sutured for transplantation. Due to these results and to best 
facilitate a comparison between the characteristics of hiPSC-CM and neonatal rat 
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cell patches, all future hiPSC-CM patches were fabricated at a fibrinogen 
concentration of 3.3 mg/mL.  
Rings created using hiPSC-CMs compacted similarly to neonatal rat cell 
patches, resulting in a tissue approximately 3mm wide and 400 um thick, 
compared to the approximate dimensions of the neonatal rat cell patches of 3mm 
wide and 550 um thick. Cross-sectional CM densities after 14 days in vitro 
culture (cTnT+/DAPI+ cells) were not significantly different between hiPSC-CM 
and neonatal rat cell patches (Figure 4.1) and cells were elongated and aligned 
in the circumferential direction (Figure 4.2) in both cases. At higher magnification, 
it was observed that many hiPSC-CMs were either multi-nucleated and/or 
clumped together in long, elongated strands rather than existing as single 
elongated cardiomyocytes (Figure 4.3) As it was not easy to distinguish the 
boundaries between CMs, it cannot be determined to what degree these 
structures are multinucleated and multicellular. Interestingly, although there was 
a widely observed decrease in cell and CM density towards the center of patches 
and CM concentration in regions along the edges of patches made with neonatal 
rat cells (Figure 4.2, Figure 3.1 b, c), CM distribution was relatively uniform 
across all dimensions of hiPSC-CM patches, negating any further need for patch 
optimization to attain uniform cell density.  
hiPSC-CM patches generated measurable forces both spontaneously and 
in response to pacing frequencies between 0.5 and 1.5 Hz, with a maximum 
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average force generation of 0.46 mN/ ring (0.2nN/ input CM) at 0.5 Hz pacing 
frequency (Figure 4.4). Patches were not able to respond synchronously to 
pacing above 1.5 Hz. These values are significantly lower than those obtained for 
neonatal rat cell patches, and could be due to the differing species and 
maturation states of these cells, as hiPSC-CMs are widely considered to be more 
immature than neonatal cell phenotypes105. More on cell maturity can be found in 
Chapter 6. This decrease in overall force generation may likely also be due to 
non-optimal gel and culture conditions for hiPSC-CMs, as these studies are all 
preliminary.  
4.3.3  Efficient Purification of hiPSC-CMs is achieved With Lactate- Based 
Selection Media 
Two methods of CM purification were investigated with hiPSC-CMs, 
differential adhesion via pre-plating and a lactic acid supplemented selection 
media. Through preplating, the combinations of different pre-plating incubation 
times and substrate protein coatings were utilized to optimize this process for 
maximal CM capture. The percentages of adhered CMs in all conditions can be 
found in Table 4.2. In summary, it was found that there is no difference in 
adhesion time for CMs and non-CMs in hiPSC-CM cell populations, and short-
term adhesion was not altered by the presence of any protein coating. As 
expected, cells adhesion was substantially reduced after 24 hours in well that 
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had no protein coating (data not shown). Thus, pre-plating is not a reliable 
method to select for hiPSC-CMs.  
In the optimization process for a lactate-based selection media, it was 
found that the concentration of lactic acid (1 mM vs. 4mM) had no effect on the 
cell death timeline of the non-cardiomyocyte cells evaluated (Table 4.3), but the 
addition of 2% serum with daily media changes provided enough glucose to 
sustain cells indefinitely. In the absence of serum, ODFs began to die after 5-6 
days of glucose and serum deprivation; PCs began to die after 4 days and were 
completely eliminated by day 6 of exposure; and cell death was induced in 
NHDFs by day 2 of exposure and cells were completely eliminated by day 3-4. 
Additionally, the addition or withdrawal of NEAA had no effect on the results 
obtained with NHDFs.  
Based on these results, two candidate selection mediums were chosen to 
use with hiPSC-CMs: both contained DMEM no glucose, NEAA, β-
mercaptoethanol, and penicillin/streptomycin, and 4mM lactic acid. As the 
concentration of lactic acid had no effect on non-myocyte death, the higher 
concentration was used in hiPSC-CM studies. The only difference between 
treatment groups was the addition of supplemental L-glutamine and media 
changes every 2 days, based on an existing protocol form the lab of Kevin Healy 
at UC-Berkley, and a protocol based on the initial non-CM experiments without 
supplemental L-glutamine and daily media changes. After 2 days culture, Lactate 
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media with daily media changes has a significantly higher CM fraction than 
control cells (Figure 4.5, 4.6), and by day 4 both treatment groups contained 
~95% CMs while control cells remained ~80% cTnT+. CM purity reached 97-98% 
after day 6-7 in culture, but significant cell loss of both CMs and non-CMs alike 
began after 5 days in lactate media. Interestingly, although the purification 
process was begun on day 4 of culture when CMs had not yet resumed beating 
after thaw, CMs began beating on average at day 2 of lactate treatment, 
approximately the same time point in which cells cultured in control media began 
to beat. Additionally, in later studies in which hiPSC-CMs were returned to their 
normal culture media after 4 days of lactate media, there appeared to be no 
overall loss in confluency or expected cell yield (~20% of cells that were thawed), 
indicating that CMs enlarged in culture to occupy the space left by eliminated 
non-CMs and may potentially have expanded to some degree, though no 
evidence has been found to support the latter hypothesis to date.  
Thus, it was concluded that a lactic acid supplemented culture media was 
an effective and efficient method to purify hiPSC-CMs. Due to the similar results 
of both treatment groups, the lactate media with media changes every 2 days 
was chosen for use in future studies to maximize cell culture efficiency.  
4.3.4  hiPSC-CMs Can Be Successfully Co-Entrapped With PCs in Fibrin 
Gels   
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Pericytes were chosen to replace the poorly characterized non-CM 
population eliminated from the hiPSC-CM population through purification, acting 
as a support cell type to CMs and as a contractile cell type to compact and align 
the fibrin into a tissue. PCs added at 0.5, 1.0, or 1.5 x 105 cells/mL to 50 μl 
hemispheres led to gel compaction in all cases, and did not qualitatively affect 
CM survival or morphology (Figure 4.7 a-c). All hemispheres contained hiPSC-
CMs with spread morphologies and visible striations (Figure 4.7 d) and 
macroscopic beating was observed in all experimental groups (data not shown). 
These results indicate that not only can pericytes serve as a support cell type to 
contract the gel and facilitate CM beating, but that the hiPSC-CM purification 
process does not negatively affect the ability of hiPSC-CMs to survive and beat 
after entrapment.  
4.4 Discussion 
In this chapter, we established that pre-cultured hiPSC-CMs can be 
entrapped in a fibrin matrix and result in a compacted, aligned tissue that 
generates measurable contractile forces. Through this process, we found that 
when seeded at similar densities to the neonatal rat cell patches in Chapter 2, 
the final CM density in hiPSC-CM patches were similar to the CM densities in 
neonatal rat cell patches, but with reduced CM elongation and substantially 
reduced contractile force generation. This difference in CM morphology and force 
generation may likely due to the relatively immature phenotype of the hiPSC-
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CMs used in this work16, and further optimization of these patches is needed in 
the future to maximize force generation of these CM in their current maturation 
state, as the contractile forces generated in this work are not only lower than 
what has been achieved with our neonatal rat cell patches, but is also lower than 
similar patches made by other groups (Figure 4.8). Further optimization may be 
conducted to induce some degree of cell maturation in vitro, which may result in 
increased cell elongation and increased force generation, as physiological 
hypertrophy is an effect of cell maturation105. However, maturation of hiPSC-CMs 
in vitro has not proven to be an easy task, and is elaborated upon in Chapter 6.  
It was additionally found that hiPSC-CMs can be efficiently and 
consistently purified to 95% cTnT+ cells after 4 days of exposure to glucose-free, 
serum-free media supplemented with 4mM lactic acid. Purification of hiPSC-CMs 
is necessary for experimental consistency, as different preparation of hiPSC-CMs 
have purities ranging from 70%-90% cTnT+ cells, as well as to limit potential 
variability and contributing effects of the poorly characterized non-CMs in the 
hiPSC-CM preps. These purified hiPSC-CMs were subsequentially co-entrapped 
with PCs, a cell type that has been characterized in the literature28, 106-108, to 
enable patch compaction and act as a support cell to the hiPSC-CMs. Future 
work featured in Chapter 5 will assess the capacity of these purified hiPSC-CM + 
PC patches to engraft and survive in vivo, as well as their effect on left ventricular 
remodeling post-infarction.  
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4.5 Figures and Tables 
Table 4.1: Experimental Design of Preliminary Hemisphere Experiments 
  Fibrinogen  Concentration  (mg/mL)    
  1.5 2 3.3 4 
hiPSC-
CM 
4 2x105 cells, 
0.85 mL 
media  
2x105 cells, 
0.85 mL 
media  
2x105 cells, 
0.85mL 
media  
2x105 cells, 
0.85mL 
media  
Seeding 6 3x105 cells,   3x105 cells,   3x105 cells,  3x105 cells,   
Density 
1.25mL 
media  
1.25mL media  1.25mL 
media  
1.25mL 
media  
(M/mL) 8 4x105 cells,  4x105 cells,  4x105 cells,  4x105 cells,  
1.7 mL 
media  
1.7 mL media  1.7 mL 
media  
1.7 mL 
media  
 
Table 4.2: CM fractions, Pre-Plating Experiments 
Pre-Plate 
Wells 
  Fibronectin           
  20 min 
40 
min 
60 
min 
80 
min 
120 
min 
180 
min 
240 
min 
avg 0.66 0.73 0.68 0.76 0.66 0.69 0.69 
stdev 0.05 0.04 0.02 0.03 0.04 0.08 0.06 
  Gelatin             
  20 min 
40 
min 
60 
min 
80 
min 
120 
min 
180 
min 
240 
min 
avg 0.74 0.82 0.79 0.82  -  -  - 
stdev 0.11 0.01 0.03 0.01  -  -  - 
  Collagen I           
  20 min 
40 
min 
60 
min 
80 
min 
120 
min 
180 
min 
240 
min 
avg   0.76 0.73 0.77  -  -  - 
stdev 0.01 0.10 0.16 0.07  -  -  - 
  Tissue Culture Plastic         
  20 min 
40 
min 
60 
min 
80 
min 
120 
min 
180 
min 
240 
min 
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avg 0.67 0.65 0.70 0.71  -  -  - 
stdev 0.07 0.07 0.04 0.05  -  -  - 
Supernatant 
Wells 
  Fibronectin           
  20 min 
40 
min 
60 
min 
80 
min 
120 
min 
180 
min 
240 
min 
avg 0.65 0.34 0.42 0.45 0.20 0.45 0.39 
stdev 0.13 0.16 0.30 0.25 0.55 0.50 0.18 
  Gelatin             
  20 min 
40 
min 
60 
min 
80 
min 
120 
min 
180 
min 
240 
min 
avg 0.44 0.23 0.23 0.20  -  -  - 
stdev 0.17 0.15 0.10 0.19  -  -  - 
  Collagen I           
  20 min 
40 
min 
60 
min 
80 
min 
120 
min 
180 
min 
240 
min 
avg 0.53 0.24 0.43 0.36  -  -  - 
stdev 0.04 - 0.20 0.11  -  -  - 
  Tissue Culture Plastic         
  20 min 
40 
min 
60 
min 
80 
min 
120 
min 
180 
min 
240 
min 
avg 0.58 0.45 0.30 0.31  -  -  - 
stdev 0.07 0.10 0.15 0.08  -  -  - 
 
Table 4.3: Time to Cell Death for non-CM Cell Types in Lactate (LA) Selection 
Media 
Time to  Cell Death  (Days) 
  ODF   PC   NHDF   
  start complete start  complete start complete 
1mM LA, 
no serum 5 - 4 6 2 3 
1mM LA, 
2% Serum n/a n/a n/a n/a n/a n/a 
4mM LA, 
no serum 6 - 4 6 3 4 
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4mM LA, 
2% serum n/a n/a n/a n/a n/a n/a 
 
 
Figure 4.1: Cardiomyocyte (CM, cTnT+) cross-sectional density of patches 
created with hiPSC-CMs or neonatal rat cardiac cells. No significant difference in 
CM density was found 
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Figure 4.2: Histological comparison of ring patches constructed with 
hiPSC-CMs (left panels) and neonatal rat cardiac cells (right panels), showing 
circumferential alignment (bottom panels) of both cell types and uniform CM 
distribution of hiPSC-CMs in patch (top left).  
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Figure 4.3: High Magnification View of elongated CMs in hiPSC-CM ring 
patch showing clustering of nuclei in CMs. 
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Figure 4.4 (continued on p 88) 
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Figure 4.4: Contraction Force (Twitch Force) Generation of hiPSC-CM 
patches (A-B) and in comparison to similar patches constructed with neonatal rat 
cardiac cells (C-D). 
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Figure 4.5: CM Purity (fraction cTnT+) after 2, 4, 6, or 7 days of exposure 
to Lactic acid (LA) media. Significance bars: p < 0.05.  
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Figure 4.6: Histological Comparison of Unpurified (top, EB2) and Purified 
(Bottom, LA media) Cardiomyocytes.  
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Figure 4.7: Cross-Sectional Views of 50 uL hemispheres constructed with 
purified hiPSC-CMs and varying numbers of PCs. (A-C). hiPSC-CMs in all 
conditions spread out along the top (media) surface of the hemispheres and 
displayed visible sarcomeric striations based on whole-mount staining of 
hemispheres  
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Figure 4.8: Contraction Force Generation of human pluripotent stem cell 
derived CM (hPSC-CMs) patches, state of the field. Bursac25, Murry10 
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Chapter 5: Functional Effects of a Tissue-Engineered Cardiac Patch from 
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in a Rat 
Infarct Model  
5.1  Introduction 
Human pluripotent stem cell derived CMs have been used for myocardial 
repair by direct myocardial injection, but engraftment rats are very low a few 
weeks after transplantation,109, 110 which makes engineered tissues an attractive 
method to deliver CMs to the myocardium. There are only a few reports of an 
ECT prepared from hiPSC-CMs,entrapped in collagen-matrigel10, 111  or fibrin-
matrigel112 scaffolds, and these were not implanted into infarcted myocardium.  
Thus, it is as yet unknown whether ECTs made from clinically-relevant hiPSC-
CMs yield similar effects as ECTs made from hESC-CMs in an infarct model.   
This study reports ECTs made from hiPSC-CMs entrapped in a fibrin gel 
and uses pericytes (PCs) as a non-CM cell population. PCs are vascular support 
cells that in the context of microvascular tissue engineering have been shown to 
regulate capillary stability and diameter.48, 108, 113 PCs were chosen in this study 
to induce compaction of the fibrin gel, which is essential to concentrate and align 
CMs37, and also to support the ingrowth of host microvessels into the ECT.107 In 
addition, future strategies that include preformed microvessels in fibrin gel 
together with CMs may utilize a mixture of hiPSC-CMs, PCs, and endothelial 
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cells. This study demonstrates that PCs can be co-entrapped with hiPSC-CMs as 
a support cell type, eliminating the need for additional cell types in future studies.  
Expanding upon a previous study in Chapter 3 reporting ECTs fabricated 
with neonatal rat cardiac cells, this study investigates the use of an aligned ECT, 
referred to as a patch, consisting of lactate-purified hiPSC-CMs and human PCs 
entrapped in a sacrificial fibrin gel to engraft into a nude rat acute infarct model 
and limit left-ventricular remodeling in vivo. Efficacy of the patch was assessed 4 
weeks post-transplantation via echocardiography and histological 
characterization of scar size and patch engraftment, and compared to the effects 
of an engineered cardiac tissue created using only PCs.  
5.2  Methods 
 5.2.1  Culture and purification of human iPSC-derived 
cardiomyocytes and human brain pericytes 
Cells were purified, as detailed in Chapter 4, by using a media comprised 
of glucose-free DMEM supplemented with 4 mM lactic acid, NEAA, β-
mercaptoethanol, penicillin/streptomycin, and 2 mM L-Glutamine (Sigma-
Aldrich)102 Cells were treated with lactate media for 4 days, changing lactate 
media twice, on days 4 and 6, before being returned to EB2  on day 8 for an 
additional 2 days prior to being harvested for construct preparation on day 10 of 
culture. The final cardiomyocyte purity was 94.2±2.9% cTnT+ cells.  
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 5.2.2  Construction and Culture of Patches 
 Aligned patches containing both purified cardiomyocytes and 
pericytes (CM +PC) were constructed by mixing 2.2x106 purified CMs and 
3.4x105 PCs with a fibrin-forming solution and injecting it into a 8mm-ID, 1.25 mL 
tubular mold as previously described37  to create a final fibrin concentration of 3.3 
mg/mL. The cell-containing, fibrin-forming solutions were incubated at 37°C for 
15 min to allow formation of a fibrin gel. Gels were then removed from their 
casings and placed in EB20 culture medium supplemented with 2mg/mL 
aminocaproic acid (to limit fibrinolysis, Acros Organics) for the first 48 hours of 
culture, followed by culture in 2% serum medium for the remaining 12 days 
culture, 14 days total static culture.  
Pericyte-only (PC) patches were constructed identical to CM + PC 
patches, containing 3.4x105 PCs in a 1.25 mL, 3.3 mg/mL fibrin gel. hiPSC-CM 
only patches were not possible to construct because the cell induced fibrin gel 
compaction required to convert soft isotropic fibrin gel into a patch with functional 
CMs that can be sutured does not occur without the presence of non-CMs, as 
also reported by others. 11, 104 
 5.2.3  Implantation of Patches into an Acute Nude Rat Infarct Model 
Procedures used in this study were reviewed and approved by the 
Institutional Animal Care and Use Committee (IACUC) and Research Animal 
Resources (RAR) at the University of Minnesota.  
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Female Foxn1rnu nude rats (Harlan Sprague-Dawley) weighing 135-190 g 
were used in these studies. Rats were anesthetized using isoflurane, intubated, 
and received a left lateral thoracotamy to expose the heart. The pericardium was 
opened and MI was achieved by permanently ligating the left anterior descending 
(LAD) coronary artery with a 7-0 polypropylene suture. After a MI was 
established, a single patch was applied by removing one ring from its mandrel 
(Figure 5.1a) and cutting it into 3-8 mm long strips and suturing them parallel to 
each other over the epicardial surface of the left ventricle below the ligation 
suture, approximately parallel to the alignment of the surface myocardium (Figure 
5.1b). After patch placement, the chest was closed and the animal was allowed 
to recover. Rats were administered 2.5 mg/kg ketoprofen and 15 mg/kg 
enrofloxacin (Baytril, Bayer) immediately post-operatively and daily for 3 and 5 
days, respectively.  
 5.2.4  Cardiac Functional Analyis 
Cardiac function was evaluated via echocardiograph assessments (Visual 
Sonics Vevo2100) of left ventricular ejection fraction and fractional shortening 
prior to ligation (baseline) and both 1 week and 4 weeks post-implantation. 
Hearts were harvested after 4 weeks in vivo for histological assessment.   
 5.2.5  Contraction Force Assessment of Patches 
A subset of patches from the same batches were not implanted and 
instead subjected to twitch force assessment to evaluate their contractile force 
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generation. Twitch force measurements were recorded as previously described5 
on a custom-built testing system both spontaneously (when applicable) and in 
response to pacing. Briefly, CM-containing patches were placed in a media bath 
containing DMEM/F12 basal medium supplemented with 2mM CaCl2, pre-
tensioned between two posts, and subjected to field stimulation from two carbon 
electrodes. Data were recorded using LabVIEW and analyzed using a Matlab 
script.  
5.2.6  Histology and Immunohistochemistry 
Non-implanted patches and explanted hearts were fixed in 4% 
paraformaldehyde and frozen in embedding medium (Tissue-Tek OCT), and 
cryosectioned into 5 μm sections for immunohistochemistry and histological 
characterization. For immunofluorescence staining, sections were permeabilized 
with 0.01% Triton-X-100 (Sigma), blocked in 5% Normal Donkey Serum (Jackson 
Immunoresearch), incubated overnight at 4°C in primary antibody followed by a 
60 minute incubation in secondary antibody at room temperature and a 10 
minute incubation in Hoescht 3332 (LifeTech). Slides were mounted in 
fluorescent mounting medium (Dako) and imaged within 24 hours. Sections 
labeled for Isolectin B4 (IB4) were incubated for 10 minutes at room temperature. 
Information on immunofluorescence antibodies can be found in Appendix 4.  
Infarct size was measured from Masson’s Trichrome stained sections as 
the percentage of the surface area of the left ventricular anterior wall occupied by 
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scar. For each heart the infarct size was averaged from three areas of the heart: 
just below the ligation suture, mid-way between the ligation suture and the apex, 
and a section close to the apex. Left ventricular anterior wall thickness was 
measured across the infarcted region of the heart wall.  
5.2.7  Protein Extraction and Western Blotting 
Cells in each well of the 24-well plates used to compare unpurified and 
purified hiPSc-CMs were lysed at 4°C in a NP-40 lysis buffer consisting of 0.5% 
Nonidet P-40, 5% glycerol, 25 mM Tris (pH 7.4), 25 mM NaF, 225 mM NaCl, 
0.025% sodium deoxycholate, 1 mM EDTA, 2 mM NaVO4, and 1 mg/mL each of 
aprotinin, pepstatin, and leupeptin (Sigma-Aldrich). Total protein was assessed 
using a BCA protein assay (Pierce Biotechnology). 10 μg of protein from 
unpurified (n=4) and purified (n=5) hiPSC-CMs were loaded into the lanes of a 4-
20% Mini-Protean TGX 10-well gel (BioRad) for protein separation and transfer. 
Western blot was conducted by assessing using primary antibodies for the α and 
β isoforms of myosin heavy chain and GAPDH (Santa Cruz Biotech), blocked in 
5% blocking grade buffer (BioRad) with 0.1% Tween (Sigma-Aldrich), 
horseradish-peroxidase conjugated secondary antibodies (GE Healthcare Life 
Science) and chemiluminescence agent (Millipore). Expression intensity was 
analyzed using ImageJ software, and is outlined in Figure 5.11. 
5.2.8  Statistical Analysis and Experimental Design 
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Three groups were investigated for this study: 1.) MI only (n=5): ligation 
only, no treatment; 2.) CM + PC patch (n=6): ligation + patch constructed with 
cardiomyocytes and pericytes; 3.) PC patch (n=4): ligation + patch constructed 
with PCs only.  
Data are presented as means ± standard deviations. All results were 
analyzed using MiniTab statistical software. Student’s t-tests and one-way 
analysis of variance (ANOVA) in conjunction with Tukey HSD post hoc testing 
was used to compare all groups. p-values <0.05 were considered significant.  
5.3  Results 
 5.3.1  In vitro characterization of Patches 
To establish that hiPSC-CMs can be co-entrapped with PCs to create an 
aligned, beating patch, patches were created and characterized in vitro prior to 
implantation. Both CM + PC and PC patches compacted into short tubes of 
comparable length from an initial length of 13 mm to less than 3 mm (Figure 
5.1a).  CM + PC patches had compacted down from an initial thickness of 2.83 
mm to less than 0.5 mm (406±98.2 μm), and PC patches had a thickness of 
403.8±87.6 μm, CMs (cTnT+ cells) made up 79.2±12.3% of the total cell number 
at implantation, with 8.8±6.3% of the cells being PCs (GFP+) and the remaining 
12.0±6% of cells non-cardiomyocytes not purified from the CM cell culture, for a 
total cross-sectional cell density of 495±193.7 cells/mm2 (Table 5.1, Figure 5.2a).  
The CM cross-sectional density was thus 405.7±63.1 CMs/mm2.  PC patches had 
  101 
a final cell density of 63.3±9.9 cells/mm2 compared to 40.4±43.9 cells/mm2 for 
PCs in the CM + PC patches. Both CMs and PCs in both patches were well 
distributed across the patch thickness (Figure 5.2 a, d), elongated and aligned in 
the circumferential direction (Figure 5.2 b, c), and elongated CMs displayed 
organized sarcomeres (Figure 5.2c).  
  CM + PC patches generated measurable forces in response to multiple 
pacing frequencies (Figure 5.2 e, f).  Average twitch force generation ranged 
from 0.35 to 0.46 mN (0.15-0.20 nN/input CM) over 0.5-1.5 Hz stimulation 
frequency. The maximum frequency in which a patch beat synchronously with 
pacing ranged between 1.5-2.0 Hz for each patch.   
Cells within both CM + PC and PC patches had begun to deposit ECM 
throughout the scaffold during in vitro culture (Figure 5.3), despite the overall 
ECM remaining primarily fibrin at the time of implant (Figure 5.3 g, h). Collagen I 
(Figure 5.3 a, d) and basement membrane proteins Collagen IV and Laminin 
were present in both patches in the pericellular space and in the surrounding 
ECM (Figure 5.3 b, c, e, f).  Cell-deposited fibronectin was not distinguishable 
histologically due to the presence of fibronectin from serum in the fibrin ECM (not 
shown). There was an increase in the amount of non-CM deposited Collagen IV 
in CM+ PC patches compared to PC only patches (Figure 5.3 i). 
 5.3.2  Functional Consequences of Patch Implantation  
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Echocardiography was conducted prior to infarction / patch implantation, 
and both 1 and 4 weeks post-operatively. 1 week post-op, all groups displayed a 
reduction in both left ventricular ejection fraction (LVEF) and fractional shortening 
(LVFS) relative to baseline (Figure 5.4a, Figure 5.5).  However, animals that 
received CM + PC patches had higher LVEF and LVFS compared to both MI only 
controls and animals that received a PC patch (Figure 5.4 b, c). After 4 weeks 
post-op, LVEF and LVFS remained lower than baseline values, but the CM + PC 
patch group had higher LVFS than both MI only controls and PC patch animals, 
and higher LVEF than MI only controls. No improvements over MI only were 
seen with the administration of a PC patch at any time point. Additional ECHO 
data can be found in Table 5.2. 
 5.3.3  Left Ventricular Remodeling 
Animals that received no patch (MI only) had infarct scars that covered 
47.9±14.7% (range 30.7- 71.5%, median 45.4%) of the left ventricular free wall 
(Table 5.3, Figure 5.6).  CM + PC patch animals had infarct sizes of 30.7±14.6% 
(range 15.9-50.0%, median 27.9%), smaller than MI only controls; PC patch 
animals had infarct sizes of 35.8±7.8% (range 27.3-46.1%, median 34.9%), not 
different than MI only or CM + PC patch animals. Wall thinning of the infarct area 
was seen in all groups compared to non-infarcted animals, with no reduction in 
wall thinning seen with the application of either CM +PC or PC patches. Patches 
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are not easily visualized in Figure 5.6. Additional measurements can be found in 
Table 5.4.  
 5.4.4  Patch Engraftment 
 After 4 weeks post-op, hearts that received CM + PC patches were 
observed to have a pale, thin tissue layer covering much of the left ventricular 
epicardial surface. This layer was found to be comprised of both scar tissue from 
the initial surgery and a thin, 81.3±33.5 μm layer of densely packed CMs located 
on the left ventricular epicardial surface (Figure 5.7a-c).  The patch contained 
interspersed PCs (Figure 5.7b, e, f) and covered both infarcted and intact 
myocardium, separated from the host myocardium by a 103.3±33.1 μm non-
myocyte interface zone (Figure 5.7a-d). Imaging of trichrome-stained sections 
revealed the extracellular matrix (ECM) of the engrafted patch to be primarily 
collagenous (Figure 5.7a). Elongation and circumferential alignment was 
observed in the majority of engrafted CMs (Figure 5.7c, e, f), but the cells were 
very small in size, indicating immaturity of the CMs. Gap junction protein 
connexin 43 was found between adjacent CMs within the engrafted patches 
(Figure 5.7e), which was only sparse after in vitro culture (Figure 5.8), although 
not concentrated at cell-cell junctions as observed in adult myocardium. These 
CMs were verified to be transplanted cells through Human Nuclear Antigen 
(HNA) staining 10.9±1.4% of imaged donor CMs stained positive for Ki67 (Figure 
5.7d) at the 4 week time point, consistent with some level of CM proliferation over 
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4 weeks in vivo. Assuming no lateral contraction of the patches, after 4 weeks in 
vivo the number of cTnT+ nuclei in the engrafted patches increased 2-fold 
(102.9% increase). Little to no Ki67 positive cells were found in the patches at 
the end of in vitro culture (Figure 5.8).  
Pericytes entrapped in PC patches did not survive 4 weeks in vivo, with 
few to none GFP+ and HNA+ cells being found within the host myocardium or 
along the epicardial surface of the heart. The ECM of patches was converted 
from being primarily fibrin at implant to collagenous after 4 weeks in vivo, similar 
to that of the infarct scar or adhesions from the chest wall, making it difficult to 
confidently identify the presence of a patch at this time point without the 
presence of HNA+ donor cells. 
 Two animals that received CM + PC patches died at the 1 week time 
point due to anesthesia. The patch on these animals was visible in trichrome, 
and contained somewhat sparsely distributed CMs and PCs with a few CMs 
Ki67+ (Figure 5.9). All other animals that survived the initial surgery lived to the 4 
week time point.   
CM + PC patches became vascularized via angiogenesis from the host 
based on isolectin B4 (IB4) staining, with small diameter vessels present in the 
patch 4 weeks post-op (Figure 5.10a). Active perfusion of the vessels was 
verified by the presence of red blood cells in H&E stained images of the 
  105 
engrafted patches (Figure 5.10b).  In the host myocardium, there were no 
differences in the density of IB4+ microvessels in infarcted myocardium among 
the groups after 4 weeks, but an increased density occurred in the area of 
myocardium bordering the infarct zone with the administration of a CM + PC 
patch (Figure 5.10c, d). 
5.5 Discussion 
This study demonstrated that the co-entrapment of hiPSC-CMs and 
human PCs in a fibrin gel results in a compacted, aligned, and beating cardiac 
patch (engineered cardiac tissue), and after 4 weeks in vivo the patch remained 
viable and resulted in a reduced infarct size (Table 1) and improved cardiac 
function compared to infarct-only controls (Figure 5). In contrast, a patch 
containing only PCs did not survive 4 weeks in vivo and resulted in no 
improvements in contractile function or reduction in infarct size. These results 
suggest that similar to our recent report of an ECT similarly made from a 
neonatal rat heart isolate and also implanted acutely,37 the improvements seen 
with patch administration originate from cardiomyocytes.  To our knowledge, this 
is the first demonstration of a cardiac patch utilizing hiPSC-CMs that not only 
remains viable, with CM proliferation, after 4 weeks in vivo, but also covers large 
portions of the left ventricular epicardial surface and contributes to the limitation 
of left ventricular remodeling post-infarction. 
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The creation of an ECT in vitro is a subject that has received increasing 
interest as a method to deliver cells to the injured myocardium, supplement the 
contractility of the left ventricular wall, and ultimately contribute to and facilitate 
cardiac regeneration. This study focused on limiting the loss of left ventricular 
contraction and infarct expansion by acute placement of the patch on the 
infarcted myocardium (rather than replacing infarct scar tissue with the patch in a 
second surgery), and to compare the use of hiPSC-CMs in a patch to a previous 
study utilizing neonatal rat cardiomyocytes and non-cardiomyocytes37. The same 
gel formulation was used in both studies, 1.25 mL of a 3.3 mg/mL fibrin gel in a 
tubular mold, and cultured for a total of 14 days. The concentration of 
cardiomyocytes was kept the same, with the neonatal rat study containing ~60% 
(3x106) of a heterogeneous population of non-cardiomyocytes, and the current 
study containing 15% (3.4x105) human PCs and 5% (1.13x105) non-
cardiomyocytes that survived the purification process. However, the neonatal rat 
CM patches were stretch-conditioned prior to implantation, while these CM+PC 
patches were cultured statically for the entirety of culture. Early stage 
differentiated hiPSC-CMs have shown a relatively high proliferation ability 
compared to late stage mature hiPSC-CMs,17 and we used the day 15-
differentiated hiPSC-CMs in this study in an effort to maintain the hiPSC-CM 
proliferation after patch transplantation. Furthermore, immature CMs are more 
tolerant of perturbation and are more likely to survive transplantation than more 
mature CMs.61  Both patches exhibited measurable twitch forces, although lower 
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for the hiPSC-CM patches (0.2 nN/input CM) compared to the neonatal rat cell 
patches (1.2 nN/input CM).37 
 In both the study utilizing neonatal rat CMs and the current study using 
hiPSC-CMs, a reduction in infarct size and improvements in cardiac function 
occurred with the implantation of a patch that contains both CMs and non-CMs 
while the implantation of patches containing non-CMs resulted in minimal 
(neonatal rat) or no (hiPSC-CM) improvement. However, near complete rescue 
of the myocardium resulted from the implantation of a neonatal rat cell patch37, 
while moderate infarct sizes of 30.7±14.6% (p<0.05, Table 2) resulted from the 
implantation of a CM+PC patch in this study. These larger infarct sizes were 
associated with reduced improvements in cardiac function and thinning of the left 
ventricular wall, which were not observed with the application of the neonatal rat 
CM patch. Additionally, invasion of non-cardiomyocyte cells into the host was 
seen with the neonatal rat CM patch, but was not observed in this study. The 
reduced improvement found with the administration of a CM + PC patch 
compared to our previous neonatal rat patch may be due to several reasons. 
Different strains of rats were used (Fisher rats vs. athymic nude rats), a species 
mismatch of the transplanted cells (rat-rat vs human-rat), and a different initial 
maturation state of the transplanted cardiomyocytes (neonatal vs. 
embryonic/fetal). Additionally, there were fewer non-CM cells transplanted in the 
CM + PC patches in this study (0.45x106 cells vs 2.75x106 cells) and the 
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population of non-CM cells in the neonatal rat cell patches was a heterogeneous 
population consisting of cardiac fibroblasts as well as other non-characterized 
cells from the myocardial interstitium, including PCs. Pericytes are normally 
found in the myocardium as microvascular support cells, but the results from this 
study indicate that pericytes are likely not the migratory cell type seen in our 
neonatal rat patch study. Pericytes have been shown to minimally improve 
cardiac function and suppress fibrosis when transplanted into mouse 
myocardium114, but these effects did not occur in this study, either due to the 
different source tissue, method of delivery or culture differences prior to 
implantation. Interestingly, while the PCs did not survive 4 weeks in vivo when 
transplanted as a PC only patch, they did survive when transplanted in the CM + 
PC patches, suggesting that not only are PCs required for the compaction and 
alignment of fibrin gels for patches containing CMs, but also that CMs are 
required for PC survival in vivo.  In contrast, the hiPSC-CMs not only survived but 
appeared to proliferate based on co-localization of cTnT and Ki67 staining, which 
is a common marker for proliferation of stem cell-derived CMs32, 115 but may also 
indicate multinucleation of CMs.116, 117 It can be additionally noted that even 
though the non-cardiomoycytes that survived purification comprised only 5% of 
the total cell number at the time of ECT fabrication, they expanded over the 14 
days of in vitro culture to comprise 12% of the final cell population at implant, 
higher numbers than PCs. These results indicate that future studies will have to 
further optimize the CM purification process and further characterize these non-
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CM cell types to elucidate any potential contribution these cells contribute to 
myocardial protection post-infarction. 
 In both studies, the ECM of the patch was converted from fibrin to 
primarily collagen, and a collagenous interface zone developed, separating the 
host myocardium from the patch, suggesting the beneficial effects of the patches 
were not due to electrical integration of the CMs. The thin size of the engrafted 
patches in both studies makes any patch beating, if it occurred, an unlikely 
mechanism of functional improvement. In all, the mechanism by which the 
benefits afforded by CM + PC patch administration occurred are not clear, but the 
increase in microvessel density in the myocardium bordering the infarct could 
implicate paracrine mechanisms that stabilize the infarct scar and prevent further 
expansion. Although cell migration from the CM + PC patch into the host was not 
seen in this study, the increase in collagen IV deposition in vitro in the CM + PC 
patch compared to PC only patches following in vitro culture indicate altered 
behavior of pericytes in the presence of cardiomyocytes. Some of the ECM 
deposition could also be attributed to the entrapped non-CM cells remaining after 
the CM purification process.  
There are no other reports thus far of ECTs made from hiPSC-CMs that 
have been implanted for comparison with this study. Improvement in cardiac 
function of nude rats was recently reported with the delayed administration of a 
scaffold-free cell sheet consisting of hiPSC-CMs co-cultured with endothelial and 
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vascular support cells,104 but the cell sheets engrafted with limited success and 
did not substantially limit infarct expansion or left ventricular thinning104. In 
combination, this cell sheet and current study indicates a definite benefit from 
hiPSC-CMs administered to nude rat infarcts. However, optimization of this 
hiPSC-CM patch will be needed to achieve the near complete rescue of the 
myocardium we achieved with the neonatal rat patch. 
This study provides preliminary data demonstrating not only the ability of 
an ECT containing hiPSC-CMs to remain viable after transplantation, but also 
with the potential for cell expansion. However, this study is limited by the acute 
infarct model used, limited sample size, and 4 week endpoint. For clinical 
applicability, an alternative, potentially autologous source of pericytes will need to 
be used, such as dermal pericytes,118 and longer term studies in larger animals 
with delayed implantation will also be needed to assess the long term fate of the 
graft and any potential for teratoma formation of these hiPSC-CMs. Larger 
animal models will be additionally required to fully characterize the engraftment 
of immature, donor hiPSC-CMs with the adult, recipient myocardium, as rodent 
and human hearts have different intrinsic heart rates, which may hamper 
accurate assessment of electrophysiological integration  
 In conclusion, we created an aligned, force-generating engineered cardiac 
patch using hiPSC-CMs and PCs entrapped in a sacrificial fibrin gel and found 
that when transplanted onto acutely infarcted rat myocardium, the patch 
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remained viable and the CMs proliferated.  This patch resulted in improved 
cardiac function and a reduced infarct size 4 weeks after transplantation, along 
with increased microvessel density in the host border zone myocardium, 
implicating potential paracrine-based, infarct-stabilizing mechanisms originating 
from the transplanted CMs.   
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5.7 Figures and Tables 
Table 5.1: Cell composition of patches pre-implantation 
 
Patch Cell Density (cells/mm2) %CM %PC Other Cell Types 
CM + PC 495±193.7 79.2±12.3 8.8±6.3 12.0±6 
PC 63.3±9.9 0 100 0 
 
CM + PC: hiPSC-CM + pericyte patch, PC: Pericyte only patch. Data are mean ± 
standard deviation. 
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 CM + PC PC MI only 
Baseline Heart Rate 
(BPM) 383 ± 43.9 406±31.1 419±18.5 
 Diameter;s 
(mm) 1.71±0.4 *, # 2.21±0.41 *, # 
1.68±0.3 *, 
# 
 Diameter;d 
(mm) 4.95±0.5 # 5.46±0.33 # 5.3±0.4 * # 
 Volume;s (μL) 10.2±6.7 18.7±6.6 9.44±3.7 
 Volume;d (μL) 118±28 147±20 137±21.5 
 Stroke Volume 
(μL) 108±28.3 # 128±22.9 
127±21.1 *, 
# 
 Cardiac 
Output 
(mL/min) 42±14.2 52.6±12.5 53.7±10.5 # 
 Ejection 
Fraction (%) 90.7±6.7 87.2±5.9 93.1±2.9 
 Fractional 
Shortening 
(%) 65.1±9.7 59.6±8.8 68.4±5.0 
 
1 week Heart Rate 
(BPM) 388±58.2 362±47.6 397±27.4 
 Diameter;s 
(mm) 2.97±0.4  #, + 4.08±0.8 4.16±0.6 # 
 Diameter;d 
(mm) 5.54±0.6  # 5.91±1.0 5.77±0.4 
 Volume;s (μL) 36.2±10.5 81±35.4 79.9±27.1 
 Volume;d (μL) 154±38.5 182±66.2 167±23.2 
 Stroke Volume 
(μL) 118±30.6 101±33.8 87.1±13.5 
 Cardiac 
Output 
(mL/min) 46.7±16.3 35.6±11.1 34.7±6.7 
 Ejection 
Fraction (%) 75.6±3.5 57.1±7.2 52.6±10.6 
 Fractional 
Shortening 
(%) 46±4.0 31.6±4.6 28±7.0 
 
4 week Heart Rate 
(BPM) 394±14.6 362±70.3 375±35.4 
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Table 5.2: Additional ECHO data. All data are represented as mean ± standard 
deviation.  *p,0.05  vs. 1 week   # p<0.05 v.s 4 week  +p<0.05 vs. MI only. BPM = 
beats per minute, s= systole, d= diastole. CM + PC = hiPSC-CM + Pericyte 
patch, PC = pericyte only patch, MI = infarction only, no treatment.  
Table 5.3: Infarct Size and Left Ventricular Anterior Wall Thickness of 4-Week 
Implants. 
Group Infarct Size (%) LV anterior wall 
thickness (mm) 
MI only (n=5) 47.9±14.7 1.04±0.3  
CM+PC patch (n=6) 30.7±14.6* 1.17±0.37  
PC patch (n=4) 35.8±7.8 1.13±0.21  
Non-Infarcted Heart (n=4) - 2.47±0.21 * # $ 
 
 Diameter;s 
(mm) 4.19±0.65  + 5.24±1.0 5.5±0.4 
 Diameter;d 
(mm) 6.58±0.33 7.06±1.0 6.91±0.3 
 Volume;s (μL) 83.8±32.4 142±63.2 152±25.3 
 Volume;d (μL) 227±24.3 269±83.6 252±27.6 
 Stroke Volume 
(μL) 143±23.6  + 127±31.4 100±13.6 
 Cardiac 
Output 
(mL/min) 56.7±10.8 + 44.7±10.5 37.3±6.1 
 Ejection 
Fraction (%) 63±10.2 48.9±11.3 40±5.4 
 Fractional 
Shortening 
(%) 36.1±7.5 26.3±7.7 20.6±3.2 
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All groups displayed a significant thinning of the LV anterior wall 4 weeks post-
transplantation, but at the 4 week time point CM + PC patch recipient hearts had 
significantly smaller infarct sizes than MI only control animals. *p<0.05 vs. MI 
only, # p<0.05 vs. CM + PC patch, $ p<0.05 vs. PC patch  
 
 
 
 
Table 5.4: Thickness Measurements of the Interventricular Septum (IVS), Right 
Ventricular Wall (RV), and the Non-Infarcted Remote Zone of the Left Ventricular 
Anterior Wall (LV RZ). Data are represented as mean± standard deviation.  No 
significant differences were found between groups. 
 
 
Thickness (mm) IVS RV LV RZ 
CM+PC patch 2.42±0.33 1.26±0.27 2.79±0.23 
PC patch 2.68±0.24 1.35±0.33 2.69±0.38 
MI only 2.37±0.27 1.20±0.16 3.09±0.29 
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Figure 5.1: CM + PC patch at Implantation. (A) CM + PC patch in its 
mandrel prior to implantation. (B) Oblique view of the patch on heart after being 
cut into 3 strips and sutured onto the left ventricular epicardial surface. The 
ligation suture is marked by the white arrow.  
  116 
 
Figure 5.2: CM+ PC and PC patches prior to implantation: Cross-sectional 
(A) and longitudinal (B-D) sections of CM+ PC  and PC patches showing uniform 
distribution (A), circumferential alignment (B), and striation  (C) of entrapped 
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CMs. (D) Longitudinal section of PC patch showing uniform PC distribution and 
alignment. Scale = 200 μm (E-F) Twitch force generation of CM + PC patches 
prior to implantation. (E) Total force generation of patches, (F) Force generated 
normalized to number of cardiomyocytes seeded into gels at the beginning of 
culture.  
 
Figure 5.3: Cell-deposited ECM in CM + PC and PC patches. Collagen I 
deposition in CM + PC (A) and PC (D) patches in vitro. Basement membrane 
proteins Collagen IV (B, E) and Laminin (C, F) were also present in both CM + 
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PC and PC patches. Overall ECM of patches remained primarily fibrin at implant 
as seen in Masson’s trichrome stained sections (G, H). More collagen IV was 
produced by non-cardiomyocytes in the CM + PC patch compared to the PC 
patch (I).  Red: Matrix Protein; Blue: nuclei. Scale = 100 μm. 
 
Figure 5.4: Echocardiography results 1 and 4 weeks post-infarction and 
transplantation. (A) Representative M-mode ECHO images of CM + PC patch 
recipient, PC patch recipient, and MI only hearts at each study time point. At the 
1 week time point, animals receiving a CM + PC patch had improved LVEF and 
LVFS compared to both MI only controls and animals receiving PC patches (B, 
C). At 4 weeks post-infarction, animals receiving CM + PC patches had improved 
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LVFS over both groups and improved LVEF compared to infarct only controls (B, 
C). p < 0.05 is considered significant.  
 
Figure 5.5: Additional echocardiography results both 1 week and 4 weeks 
post-transplantation. A significant reduction from baseline in both left ventricular 
ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) was 
seen in all treatment groups both 1 week (A) and 4 weeks (B) post-infarction. A 
significant reduction in both LVEF and LVFS was also seen from week 1 to week 
4 in the CM+PC patch group.  
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Figure 5.6: Masson’s trichrome images of MI only, CM +PC, and PC patch 
hearts, showing representative infarct sizes (blue) and left ventricular anterior 
wall thicknesses. CM + PC patch recipient hearts had smaller infarct sizes than 
infarct only control animals, and no reduction in infarct size was seen in PC patch 
recipient hearts. Patch not easily visualized in sections.  
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Figure 5.7: CM +PC patch engrafted onto heart 4 weeks post-
transplantation. Top row: Masson’s Trichrome image (A) showing engrafted 
patch on the epicardial surface of the heart surrounded by collagenous ECM, 
separated from the host myocardium by a collagenous non-cardiomyocyte 
interface zone. High (B) and low (C) magnification views of an engrafted patch on 
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top of infarcted myocardium. The patch was also present on top of intact 
myocardium far from the infarct zone. Bottom row: Inset of engrafted patch 
showing HNA+ cells within the patch (D), dispersal of pericytes (E, F) in the patch 
and CMs coupled via gap junctions (E). Some of the CMs (F, white arrows) in the 
patch were positive for Ki67 at the 4 week time point in vivo, indicating some 
level of CM proliferation in vivo. Green arrow = Ki67+ pericyte. 
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Figure 5.8: In vitro labeling of Ki67 and CX43. Cross-sectional (A) and 
longitudinal (B) images of in vitro CM + PC patches, indicating little to no 
presence of proliferating CMs (A) and gap junctions (B) in patches prior to 
transplantation.   
 
Figure 5.9: CM + PC patch engraftment 1 week post-op.  Low 
magnification (A) and higher magnification (B) images of patches after 1 week in 
vivo. (C) Trichrome-stained section of a CM + PC patch recipient heart after 1 
week in vivo, patch is indicated by black arrows. (D) Some transplanted CMs 
(white arrows were Ki67+ after 1 week in vivo.  N= 2.  
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Figure 5.10: Host vascularization of CM + PC patch in vivo. (A) Isolectin 
B4 (IB4) + small diameter host vessels were found in the patch 4 weeks post-
transplantation, and perfusion was indicated by the presence of red blood cells 
(blue arrows) in H&E stained slides (B). (C) Microvessel density in the host 
myocardium. An increase in microvessel density was seen in the areas of 
myocardium bordering the infarct zone with the administration of the CM + PC 
patch. 
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Chapter 6: The Effect of Cyclical Mechanical Stretch on the Maturation of 
Human Induced Pluripotent Stem Cell derived Cardiomyocytes 
6.1  Introduction 
 Although it was shown in Chapters 4 and 5 that hiPSC-CMs are a 
promising cell source for cardiac repair post-infarction, concerns remain about 
the ability of these cells to successfully and safely engraft into the adult, human 
myocardium. A primary concerns stems from the relative maturation level of 
these cells. There is no definitive assessment of CM maturation, but human 
pluripotent stem cell –derived CMs (hPSC-CMs)are frequently described as 
resembling embryonic or fetal CMs, an immature phenotype. Yang, et al105 
reviewed the primary discrepancies between immature and mature CMs featured 
in Table 6.1. As evident from this work, immature CMs differ greatly from adult 
CMs in nearly all aspects, from cell morphology and intracellular organization to 
metabolism, force generation and electrophysiological properties. How these 
disparities affect cell engraftment, integration, and therapeutic efficacy of these 
cells in vivo has yet to be determined, largely due to the relative lack of success 
seen thus far in inducing maturation in pluripotent stem cell derived 
cardiomyocytes for comparative studies. Extended culture times and biochemical 
agents have been used to try and induce maturation in hPSC-CMs with limited 
success. Based on the results outline in chapter 2 showing that cyclic stretching 
increases the contractile force generation of neonatal rat CMs in a 3D 
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environment, in this study we seek to investigate whether or not stretch-
conditioning can be used to induce maturation in hiPSC-CMs, and if so, to what 
degree in a smaller scale, 2D environment. Through protein analysis, we assess 
the relative quantities of α-sarcomeric actinin (αSA), and both the α and β 
isoforms of myosin heavy chan (α, β MHC) as a measure of the myofibril 
presence and assembly inside the cell, and also the ratio of the α to β isoforms of 
MHC, as the slow-twitch β isoform predominates as CMs progress towards the 
adult phenotype. In addition to these proteins, we assess the relative presence of 
Connexin 43 (CX43), a protein involved in cell-cell propagation of action 
potentials, and sarcoplasmic endoplasmic reticulum calcium (Ca2+) ATPase 
(SERCA2A), a calcium reuptake pump located on the sarcomplasmic 
reticulum involved in CM relaxation post-stimulation. Extended relaxation 
time prevents re-initiation of contraction, leading to a reduction in the 
maximum stimulation frequency at which CMs can be paced.  
6.2  Methods 
6.2.1  Cyclic Mechanical Stretch Using the Flexcell System  
 Cells were exposed to cyclic mechanical stretch through the use of the 
Flexcell® Tension System. In this system, cells are cultured on distensible 
silicone membranes in a 6 well plate or 24 well plate format. Plates are placed 
over loading posts and vacuum is applied to the back side of the membrane, 
stretching it over the loading post (Figure 6.1). The pressure waveform the 
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membranes are exposed to is regulated on an external software system119. The 
24 well plate system is capable of stretching cells at 1.2 – 8.0% biaxial strain, 
while the 6 well plate system can generate 0.8-21.8% uniaxial or biaxial strain 
(Flexcell, Int). Preliminary experiments in this study were conducted with a 5% 
amplitude square wave pulse at 1 Hz frequency with biaxial loading posts to 
compare the effects of using the 6 well or 24 well systems. Cells were exposed to 
cyclic stretch for 7 days prior to being harvested for protein and histological 
analysis.  
 6.2.2 Cell Culture 
  6.2.2.1  24-Well Plates 
 hiPSC-CMs were either seeded directly from thaw into Pronectin-
conjugated 24 well Flexcell plates (Flexcell, Inc) (Figure 6.1a) at a seeding 
density of 100-120 x105 cells/cm2, or thawed into T75 flasks coated with 2.5 
μg/cm2 fibronectin for 72 hours, per the standard culture protocol outlined in 
chapter 4, prior to harvesting and re-seeding into the Flexcell plate at a density of 
100 x105 cells/cm2. Once in the Flexcell plates, cells were cultured in EB20 for 48 
hours post-seeding and EB2 for an additional 24 hours before initiation of stretch.  
  6.2.2.2  6-Well Plates 
 For use with a 6 well plate, hiPSC-CMs were seeded only into the center 
regions of the wells using a custom 17 mm diameter silicone seeding ring to 
conserve the number of cells required for experiments (Figure 6.2b). CMs were 
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seeded into plates directly from thaw, suspended in 800 μL of EB20 and placed 
into the center of the seeding ring. Cells were allowed to adhere for 24 hours 
inside the seeding ring before the ring was removed and the media replaced with 
3 mL EB20/ well. The next day, media was changed to EB2 and cells were 
allowed to culture statically for an additional 24 hours prior to the initiation of 
stretch.  
 6.2.3  Protein Extraction and Western Blotting 
 To assess the protein changed in hiPSC-CMs after exposure to stretch, 
protein was extracted for Western Blot analysis. Cells were rinsed twice in cold 
PBS before being lysed at 4°C in a NP-40 lysis buffer consisting of 0.5% Nonidet 
P-40, 5% glycerol, 25 mM Tris (pH 7.4), 25 mM NaF, 225 mM NaCl, 0.025% 
sodium deoxycholate, 1 mM EDTA, 2 mM NaVO4, and 1 mg/mL each of 
aprotinin, pepstatin, and leupeptin (Sigma-Aldrich). Cells were either lysed 
directly on the flexcell membranes in 100 μL lysis buffer  for 5 minutes on ice 
before removing the lysate and placing it in a 1.6 mL eppendorf tube, or removed 
from the silicone membranes with a cell scraper and spun down in a 1.6mL 
eppendorf tube before adding 100 μL lysis buffer to the tube. Once in lysis buffer, 
all tubes were incubated for 15 minutes on an end-over-end rocker at 4°C. 
Lysate was then centrifuged for 15 minutes at 13-14 x105 RPM at 4°C. At the end 
of centrifugation, the supernatant was removed from the tubes and stored at -
80°C until use for western blotting.  
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Total protein was assessed using a BCA protein assay (Pierce 
Biotechnology). 10 μg of protein was loaded into the lanes of a 4-20% Mini-
Protean TGX 10-well gel (BioRad) for protein separation and transfer. Western 
blot was conducted by assessing using primary antibodies for the proteins 
connexin-43 (CX43), alpha sarcomeric actinin (αSA), α and β myosin heavy 
chain (MHC), sarcoplasmic reticulum Ca2+ ATPase (SERCA2A), and GAPDH. 
Blots were blocked in 5% blocking grade buffer (BioRad) with 0.1% Tween 
(Sigma-Aldrich), and horseradish-peroxidase conjugated secondary antibodies 
(GE Healthcare Life Science) and a chemiluminescence agent (Millipore). 
Expression intensity was analyzed using ImageJ software and normalized to 
expression of GAPDH. 
6.2.4  Histology 
For histological analysis, wells that were not harvested for protein analysis 
were rinsed twice with PBS and fixed in 4% paraformaldehyde (PFA) for 10 
minutes at room temperature. Cell monolayers were permeabilized with 0.01% 
Triton-X-100 (Sigma), blocked in 5% Normal Donkey Serum (Jackson 
Immunoresearch), incubated for 60 minutes at room temperature in primary 
antibody followed by a 60 minute incubation in secondary antibody at room 
temperature and a 10 minute incubation in Hoescht 3332 (LifeTech). The silicone 
membranes were removed from the plates and inverted onto a glass slide with 
fluorescent mounting medium (Dako) for imaging on an inverted microscope.  
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 6.2.4  Statistics 
 All data are presented as mean +/- standard deviation when sufficient 
sample sizes were available. Comparisons between statically cultured and 
stretches samples were conducted using Student’s t-tests. P-values < 0.05 were 
considered significant.  
6.3  Results 
 6.3.1  Adhesion of hiPSC-CMs to Pronectin-Conjugated Silicone 
membranes 
  6.3.1.1  24-well plates 
 When seeded directly from thaw into 24-well Flexcell plates, enough cells 
were available to fill all 24 wells of two plates. However, hiPSC-CMs did not 
adhere uniformly, with super-confluent cells clustered towards the center of the 
well and sparse to no cell adherence found toward the edges of the wells. 
Enough protein was harvested from each well to allow for western blot analysis. 
 To combat the issue of non-uniform seeding, cell-seeding inserts made by 
Flexcell were used to enhance cell seeding uniformity (Figure 6.2a). Cell-seeding 
inserts were placed in the base plate in place of loading posts and a small 
amount of vacuum (1% strain) was applied to hold the membranes taut during 
cell adhesion. Based on the results of the pre-plating experiments in Chapter 4, 
cells were allowed to adhere for 1 hour with the inserts before vacuum was 
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released and the plates cultured statically for 3 days, per standard protocol. This 
was not successful, and cells either did not adhere at all or adhered to the 
silicone with the same distribution as cells seeded without the seeding insert.  
 As an alternative method to seed cells into the plates at uniform 
distribution, cells were thawed into T75 flasks, per the standard thawing protocol 
outlined in chapter 4, and cultured for 3 days before being passaged and 
replated into the 24 well Flexcell plates at 100 x 105 cells/cm2. There was a 
significant loss in cell number through this process, as ~20% of the CMs thawed 
into a flask can be recovered after 3 days in vitro, but CMs that did plate down 
did so in a relatively uniform manner. Thus, this approach was used for 
successive experiments with this setup.  
  6.3.1.2  6-well plates 
 Although the 24 well Flexcell plates allow for conservation of cells when 
running an experiment, a maximum of 8% stretch can be achieved with this 
system the only available loading posts are for biaxial stretch; there is no option 
for uniaxial stretch. Thus, 6 well plates were adapted to allow for the plating of 
cells in a confined region near the center of the well using silicone seeding rings 
as described in section 6.2.2.2. However, cell adhesion was very poor, with only 
1 experiment of 4 having the hiPSC-CMs remain confluently adhered to the 
membranes for the duration of the study (Figure 6.3). Toxicity of the silicone 
seeding rings was ruled out, and after a thorough search of the literature and 
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available resources regarding Flexcell membrane coatings, it was found that in 
the deficiency was in the plate coatings themselves.  
 To accommodate for inconsistencies in the pronectin coatings, plates 
were re-coated with fibronectin prior to seeding cells onto the membranes. A 
number of conditions were attempted, and ultimately wells were coated overnight 
with EB20 media at 37ºC, followed by a rinse with PBS and then incubated again 
with 2.5 μg/cm2 of fibronectin overnight on a shaker prior to seeding with cells. 
After the overnight coating, the fibronectin solution was removed and the wells 
were allowed to dry before placing the seeding rings in the wells and adding 
cells. The additional fibronectin coating interfered with the ability of the silicone 
seeding rings to form a tight seal with the underlying silicone membrane and 
nearly all wells had media leakage from the seeding rings in the first 24 hours of 
culture. However, this did not appear to affect the cell adhesion to the 
membranes, as all adherent cells were found within the bounds of the seeding 
rings, and cells adhered at confluence in these regions.   
 6.3.2  Changes in Protein Expression in Response to 7 days of 5% 
Biaxial Cyclic Stretching  
  6.3.2.1  24-Well Plates  
 When seeded directly from thaw into 24 well pronectin coated Flexcell 
plates (stretch initiated at day 3 of culture), an increase in the amount of αSA and 
near-significant increase in SERCA2A was found in samples that had been 
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exposed to 5% biaxial stretch. No difference was found in the presence of CX43, 
and insufficient sample size prevented any comparisons of MHCα, MHCβ, or the 
ratio of MHC α/β (Figure 6.4). Cells that were plated for 3 days prior to seeding 
into the flexcell plates (stretch initiated at day 6 of culture) did not generate 
enough replicates to draw conclusions, but data can be found in Figure 6.5.Cells 
that were cultured in flasks for 10 days prior to being replated into the Flexcell 
plates (stretch at day 13 post-thaw) resulted in decreases in the presence of 
αSA, MHCβ, SERCA2A, and an increase in the ratio of MHC α/β (Figure 6.6), 
contradicting both the results obtained when cells were plated directly from thaw 
and stretching was initiated at day 3 of culture, and any results that would be 
indicative of CM maturation.  
6.3.2.1  6-Well Plates 
Only one experiment was run with the 6-well plate setup, and this 
experiment was conducted without the additional fibronectin coating of the wells. 
These cells, plated from thaw into the flexcell plates (stretch initiation at day 3 
post-thaw), showed an increase in the amount of αSA and SERCA2A in these 
cells, but a decrease in the amount of MHCβ (Figure 6.7).  
6.4  Discussion and Future Work 
 No conclusions can be drawn from the data obtained to date investigating 
the use of stretch conditioning to induce maturation of hiPSC-CMs. Each 
experimental condition was run only once and thus it cannot be determined at 
  134 
this time if the high degree of variability observed in these studies was an effect 
of the method of cell plating, time of stretch initiation, or inherent inter-
experimental variability.  It is evident from these preliminary trials that further 
optimization of cell seeding conditions, repeat experiments and higher sample 
numbers are required to elucidate the exact effect cyclic stretching has on 
hiPSC-CMs in a 2D environment.  
 Future work will utilize fibronectin-coated 6 well plates with cells thawed 
directly into the flexcell membranes. Not only will a comparison of statically 
cultured cells to those exposed to 5% biaxial stretch be investigated, but also the 
comparison of 5% and 10% biaxial stretch and 5% and 10% uniaxial stretch run 
side-by-side in the same experiment. Additional proteins will investigated, notably 
the isotype switch of cardiac troponin I (cTnI) from a slow skeletal isoform (ssTnI) 
to an adult phenotype (TnI), as it has recently been shown that this isotype 
switch can be used as a quantitative marker of cardiomyocyte maturation.120 
Relative presence of Kir2.1, an inward rectifier potassium channel, and Cav 1.2, 
one of the subunits of the L-type calcium channel, will also be assesses.  
 Through collaboration with the lab of Alena Talkachova (UMN Biomedical 
Engineering), optical mapping will be performed on these monolayers after the 
conclusions of the stretching regimen as a functional, electrophysiological 
measurement of cell maturation to complement the acquired protein data.  
 The only histological investigation conducted of thus far had been the 
assessment of the level of cell adherence. Future studies will label fixed cells for 
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αSA, CX43, and prelabeled with mitotracker to assess sarcomere size, CX43 
organization, and the relative number of mitochondria in stretched and static 
cells. Sarcomere spacing should increase with cell maturation, CX43 expression 
should shift from being diffuse over the cell membrane to organized at cell-cell 
junctions, and the number of mitochondria should increase as CMs mature as a 
side effect of cellular hypertrophy and increased reliance on oxidative 
phosphorylation for energy production.  
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6.5 Figures 
 
Figure 6.1: 24-well (A) and 6-well (B) Flexcell base plates with biaxial (A) and 
uniaxial (B) loading posts. Vacuum is applied through the inlet and outlet ports 
(A, B right side) to the back side of the silicone membranes, stretching them over 
the loading posts.  
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Figure 6.2: Cell Seeding Inserts for the 24-well system (A) and silicone seeding 
rings for the 6-well system (B). Cell suspension is placed inside the ring and 
incubated 24 hours before removing the ring and adding media to the entire well.  
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Figure 6.3: Representative images of successful (A) and unsuccessful (B) 
adhesion of hiPSC-CMs to the silicone membranes.  
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Figure 6. 4: Western blot protein analysis of hiPSC-CMs exposed to 5% biaxial 
stretch 3 days post-thaw and compared to statically cultured hiPSC-CMs. An 
increase in αSA was found in stretched samples compared to static. N=2-3. 
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Figure 6. 5: Western blot protein analysis of hiPSC-CMs exposed to 5% biaxial 
stretch 6 days post-thaw and compared to statically cultured hiPSC-CMs. 
Insufficient sample sizes were available to make comparisons. N=2 
 
Figure 6.6: Western blot protein analysis of hiPSC-CMs exposed to 5% biaxial 
stretch 6 days post-thaw and compared to statically cultured hiPSC-CMs. A 
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decrease in the amount of αSA, MHCβ, SERCA2A, along with an increase in the 
ratio of MHC α/β was found in this study. N=3 
 
Figure 6.7: Western blot protein analysis of hiPSC-CMs exposed to 5% biaxial 
stretch 3 days post-thaw in 6-well plates and compared to statically cultured 
hiPSC-CMs. An increase in αSA and SERCA2A was observed in this study, 
along with a decrease in MHCβ. N=3-4 
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Chapter 7: Conclusions and Future Directions 
7.1 Major Contributions  
The work presented in this dissertation has had a sizeable contribution to 
the field of myocardial tissue engineering. Two manuscripts substantial 
manuscripts have been published, with one more in preparation, and this work 
has been presented at numerous oral and poster presentations at both internal 
and national conferences and meetings. The major conclusions from this work 
and its contribution to the literature are summarized here.  
7.1.1  Contractile Force Generation of Neonatal Rat Cardiac Cell Patches 
Can be Increased Over 2-Fold through Cyclic Mechanical Stretch 
 This topic, included as supplemental material in a related publication37 
rather than a free-standing report, builds upon previous work establishing the 
ability to create aligned cardiac patches containing neonatal rat cardiac cells5 
and uses cyclic mechanical stimulation to increase the force generation of the 
cardiac patches (Chapter 2). Though similar techniques had been used 
elsewhere44 and shown to induce some level of CM hypertrophy, this work 
verifies that cyclic stretching can be applied to fibrin-based engineered cardiac 
tissues and results in a increase in contractile force generation much larger than 
previous reports. This research also determined that the observed increase in 
force generation was sensitive to the amplitude of stretching and likely a stimulus 
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response rather than a sustained one, as the duration of stretching had no effect 
on the degree of force increase.  
7.1.2  The Acute Implantation of a Cardiac Patch Containing Both Neonatal 
Rat Cardiomyocytes and Non-Cardiomyocytes Limits Left Ventricular 
Remodeling Post-Infarction 
 Following the work  optimizing the neonatal rat cardiac cell patches 
detailed in chapter 2, this work assessed the capacity of a cardiac patch to not 
only survive in vivo after transplantation, but also to engraft and assist the injured 
myocardium post-infarction. It was found that not only do cells delivered to the 
myocardium via an engineered tissue engraft with high cell retention (36% 
survival at 4 weeks post-transplantation), but also have beneficial effects post-
infarction, resulting in a limited infarct scar and preserved cardiac function with 
patch treatment.  
The major finding and contribution of this work was that cardiomyocytes 
are required for the observed myocardial benefits, as a patch consisting of only 
non-cardiomyocytes resulted in reduced improvements. However, donor CMs 
were not coupled to the host myocardium, indicating a paracrine factor- mediated 
benefit of the patch originating from the co-culture of CMs and non-CMs.  
7.1.3  A Fibrin-Based Cardiac Patch can be Constructed Using hiPSC-CMs 
 With the advent of iPSCs and the ability to differentiate them into beating 
cardiomyocytes, hiPSC-CMs became an attractive candidate for the creation of a 
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human cell-based cardiac patch. These cells had previously been entrapped in a 
collagen-matrigel scaffold with minimal elongation and contractile force 
generation. In the basic research covered in Chapter 4, we show that hiPSC-
CMs can be entrapped in a fibrin gel without the support of additional growth 
factors, align, and generate forces higher than previously reported, albeit still 
substantially lower than the contractile forces generated by patches constructed 
with neonatal rat cardiomyocytes.  
7.1.4 A Cardiac Patch Containing Both Purified hiPSC-CMs and PCs 
Engrafts Post-Transplantation with the Potential to Expand and Results in 
Improved Cardiac Function and Smaller Infarct Sizes  
 This work was the first publication in the literature that assessed the 
capacity of an engineered cardiac patch containing hiPSC-CMs to engraft and 
assist the injured myocardium post-infarction. As detailed in Chapter 5, we first 
demonstrated that hiPSC-CMs purified via lactate treatment can be co-entrapped 
with a defined non-CM cell population consisting of human PCs in a fibrin 
scaffold and over time can develop into a beating engineered tissue with static 
culture. When transplanted into a nude rat infarct model, patches containing both 
hiPSC-CMs and PCs resulted in improved cardiac function and smaller infarct 
sizes after 4 weeks in vivo compared to infarct-only controls. PC patches did not 
survive 4 weeks in vivo and provided no benefits to the host myocardium.  
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 The major finding from this work was that transplanted hiPSC-CMs in CM+ 
PC patch recipient hearts successfully engrafted and  10.9% of imaged hiPSC-
CMs were positive for Ki67, indicating some level of cell proliferation and/or cell 
maturation in vivo.  
7.2 Future Directions 
 Although significant, much of the work detailed in this dissertation utilizing 
hiPSC-CMs remains preliminary and much work and further development is 
needed to bring hiPSC-CM based engineered tissues towards clinical trials and 
relevance.  
7.2.1  Optimization of hiPSC-CM Patches 
 Although patches utilizing hiPSC-CMs were successfully created and 
transplanted in the work covered in this dissertation, the quality of these patches 
was far from optimal. Entrapped CMs remained small, with limited elongation and 
force generation. These insufficiencies may be due to a number of factors, 
including, but not limited to matrix properties, cell densities and culture 
conditions. The same basic gel formulation and CM seeding density as the 
neonatal rat cell patches was used in this work to enable side-by-side 
comparisons of the two cell types when entrapped in a fibrin scaffold. However, 
these conditions may not be optimal for hiPSC-CMs. Also, the culture media 
used in this work was the basic culture media used to culture cells when in 2D 
culture. No additional growth factors or media supplementation was used when 
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culturing these cells in a 3-dimensional environment, save the addition of ACA to 
limit fibronolysis. Additional media supplementation may be required to increase 
force generation For example, neonatal rat cardiac cell patches were 
supplemented with insulin and ascorbic acid to promote matrix deposition.  
 It can also be noted that the neonatal rat cardiac cell patches were 
stretch-conditioned prior to implantation while the hiPSC-CM patches were 
statically cultured. Future work will expand upon the preliminary 2D studies 
outlined in Chapter 6 to investigate the effect of cyclic stretching not only on 
hiPSC-CM maturation, but also on force generation when entrapped in a 3D 
matrix. Physiological hypertrophy is a component of CM maturation and leads to 
an increase in cell size and contractile force generation. Utilizing the methods 
available, hiPSC-CMs can be either pre-conditioned (stretch in 2D prior to 
entrapment in fibrin), exposed to stretch post-entrapment as in Chapter 2, or a 
combination of the two methods. Optimal stretching regimens will also need to be 
established to obtain the desired results.  
7.2.2  Combination of a hiPSC-CM Patch with a Microvascular Patch to 
Enable the Creation of Large-Scale Engineered Cardiac Tissues 
 In order for the cardiac patches outlined in this dissertation to become 
clinically relevant, patches must be able to be created in larger sizes and 
thicknesses. Current patches rely on diffusion for oxygen and nutrient supply, 
limiting the thickness of the patch to > 1mm. In order to create larger scale 
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patches, a functional, perfusable microvasculature must be established within the 
patch to provide CMs throughout the thickness with oxygen and avoid a central 
necrotic region of the patch. Much work has already been completed in the 
creation of a microvessel network in fibrin gels48, and the next steps will be to 
merge this patch with the patches created in this body of work. This will likely be 
no easy task, as both patches either have or will require significant optimization 
to obtain the optimal results from each individual cell type and finding optimal 
conditions to maintain both hiPSC-CMs and a microvessel network in vitro will be 
a significant undertaking.  
7.2.3  Long Term and Large Animal Preclinical Models 
 The translational, animal studies covered in this dissertation are 
preliminary studies only and limited by the choice of animal model and the 4 
week time scale. The rat model was chosen as a preliminary animal model due 
to its small size, limiting the number of cells required to complete these initial 
proof-of-concept studies. However, transplanting human cardiomyocytes into a 
rat model is not ideal, as human CMs, especially immature CMs, have lower 
native beating frequencies (<100 bpm) than rodent hearts (>400 bpm), potentially 
providing a basis for arrhythmic events and making it difficult to assess events 
originating from the patch. In order to fully assess patch engraftment, 
electrophysiological integration and long term effects of patch transplantation on 
donor myocardium.  
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 Appendix 1: Supplemental Studies 
 
A1.1 Grooved Molds for the Creation of Aligned Patches With Uniform CM 
Distribution 
 A1.1.1 Motivation 
 As seen in Chapters 2 and 3, although cells from neonatal rat cardiac 
isolates were seeded homogenously within the fibrin biomaterial scaffold at 
casting, after 2 weeks in vitro culture, CMs were not uniformly distributed 
throughout the gel. CMs were sparsely distributed throughout most of the patch 
and concentrated at very high densities in small regions located close to the ends 
of the ring near the ablumenal surface of the ring (Figure 3.2). This ‘edge effect’ 
occurs for yet unknown reasons, but may be partially due to a number of factors, 
among them minute changes in regional patch mechanics or microstructure at 
some stage of gel compaction. As the gel compaction process in the presence of 
multiple cell types is very complex and difficult to assess on the scales 
mentioned, an alternate solution was proposed. Rather than attempt to elucidate 
and subsequently control the dynamic mechanical and microstructural 
environments of the compacting gels, a new mold design sought to capitalize on 
this ‘edge effect’ and create a patch that consisted of entirely ‘edges.’  
 A1.1.2 Mold Design 
 The new molds were designed in the style of rectangular slab gels with a 
series of parallel grooves. The design of the molds was intended to match size 
  159 
as close as possible to the 1.25 mL, 13 mm wide, 2.83 mm thick cylindrical gels 
created with ring patches. As a result, the inner chamber was 38 mm long with 
the center 24 mm containing the grooves and 7 mm on each end being open, 
without grooves to allow for the placement of foam or glass rods for patch 
anchorage. The groove features do not extend the full thickness of the mold, with 
the top 2 mm remaining open, to enable the gel forms and compacts as a single 
piece of tissue rather than individual strips. Grooved molds were constructed as 
an assembly of 45 pieces consisting of end pieces, grooves, and spacers, all 
either custom machined or laser cut out of thin materials. Glass rods and silicone 
o-rings were used to thread the pieces together and hold them taut. End pieces 
were machined out of Ultem, spacers were laser cut out of 0.8 mm thick Teflon 
and the grooves were laser cut out of 250 μm thick poly ether ether ketone 
(PEEK) or 127 μm thick polycarbonate to create 800 μm wide grooves separated 
by 127 μm. Pieces were cleaned and sterilized unassembled and then 
assembled by stacking pieces together on glass rods and held in place by 
silicone o-rings (Figure A1.1). Schematics of individual pieces can be found in 
(Figure A1.2). Due to the millimeter-scale height of some of the features, it was 
not feasible to create a grooved mold using microfabrication, and 3D printing was 
not available during the design process. Additionally, the modular design enables 
patches of different volume to be created by simply altering the number of 
grooves, creating either a narrower or wider slab. Additionally, for optimization 
purposes the laser-cut slats and spacers can be rapidly and relatively 
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inexpensively redesigned and constructed to allow for changes in the overall 
design.  
 A1.1.3 Preliminary Results with Neonatal Rat Cardiac Cells and 
hiPSC-CMs 
 Once assembled, gels were cast with the same gel formulation and cell 
composition as the ring-mold patches. Gels were cast by placing the assembled 
mold upside down on a slab of silicone rubber and pipetting the cell-containing, 
gel-forming solution into the underside (now upward facing) of the mold, filling it 
to the tops of the grooves. Gels were allowed to polymerize for 6 minutes at room 
temperature before being moved to a 37ºC incubator for the remaining 10 
minutes of polymerization. After polymerization, the molds were picked up using 
sterile tweezers and placed upright into a dish containing the appropriate culture 
media for the cell type (See chapter 2, chapter 4). Gels were cultured statically 
for 14 days prior to being harvested for histological analysis.  
 The resultant, compacted patch was approximately 1.5 cm in length after 
being removed from the mold, retained its ridge-like features (Figure A1.3), and 
beat both spontaneously and in response to pacing. However, optimization of the 
casting and culture process for these grooved molds was conducted concurrently 
with preliminary studies creating ring-shaped patches with unpurified hiPSC-
CMs. As found in Chapter 4 (Chapter 4.3, Figure 4.2), hiPSC-CMs are 
substantially uniformly distributed after 14 days static culture, making the use of a 
grooved mold to enhance CM distribution in patches unnecessary.  
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A1.2 Implantation of Decellularized Neonatal Rat Cardiac Cell Patches 
The material discussed in the following appendix was adapted from the following:  
Wendel et al, Functional Consequences of a Tissue-Engineered Myocardial 
Patch for Cardiac Repair in a Rat Infarct Model. Poster Presented at: AHA 2013. 
American Heart Association Scientific Sessions. Dallas, TX. November 2013.  
A1.2.1 Motivation 
 In chapter 3, it was found that animals that received a CM+ patch had 
improved cardiac function and smaller infarct sizes than animals that received no 
treatment or a CM- patch. Additionally, animals that received CM- patches also 
resulted in some benefits, although to a lesser extent than CM+ recipient 
patches. One aspect of the patches that was not investigated in Chapter 3 as a 
potential source of the benefits seen was that of the transplanted matrix itself. 
Here we decellularized a subset of CM+ patches created for implantation in 
Chapter 3 and transplanted them onto the LV epicardial surface of Fisher rats 
acutely post-infarction 
A1.2.2 Methods 
Stretch-conditioned CM+ patches were created in Chapter 2. CM+ 
patches were chosen to be decellularized, as it was shown in Figure 3.3 that 
CM+ patches contain more cell-deposited matrix than CM- patches and thus any 
effects of cell-deposited matrix will be more prevalent with decellularized CM+ 
patches. Following a pre-established protocol121, patches were kept on their latex 
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mandrels, rinsed in PBS, and exposed to a solution of 1% Sodium Dodecyl 
Sulfate (SDS) for 2 hours on a shaker. Patches were then removed from their 
mandrels and exposed to SDS for an additional 2 hours floating freely in solution. 
Patches were then rinsed in deionized H2O (DIH2O) and the SDS was removed 
by exposing the patch to a solution of 1% Triton-X-100 in DIH2O for 30 minutes. 
Patches were then moved back onto their latex mandrels and rinsed in PBS 
containing 1% Penicillin/Streptomycin for 36 hours, with 6 changes of PBS over 
the time frame. Patches were then incubated in culture medium containing 
DNAse at a dilution of 1:1000 for 4 hours at 37ºC, followed by a 24 incubation in 
culture medium at 37ºC. Lastly, decellularized patches were rinsed in PBS and 
stored at 4ºC until needed for transplantation.  
Decell patches were sutured into the LV epicardium of n = 5 Fisher rats as 
three 8 mm strips identical to patches implanted in Chapter 3. ECHO was 
conducted 1 week and 4 weeks post-op, and hearts were explanted at 4 weeks 
for histological analysis.  
A1.2.3 Results 
CM+ patches were successfully decellularized with no evidence of cells 
present in the patches observed through H&E or DAPI staining. There was a 
qualitative increase of matrix porosity and decrease in the presence of deposited 
matrix proteins (Figure A1.4, A1.5). If validated these results would potentially be 
indicative of protein degradation and loss through the decellularization process 
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and would lead to a subsequent decrease in mechanical properties, though this 
was not investigated in this study and no conclusions can be made.  
No improvements in infarct size and cardiac function were seen with the 
administration of the decell patch, as shown in Figures A1.6-A1.7 and Table 
A1.1. Due to the absence of cells and that the ECM of the patches is remodeled 
to a collagenous ECM over 4 weeks in vivo, it was difficult to differentiate any 
potential residual patch from scar tissue or adhesions from the chest wall. As a 
result, the fate of these patches in vivo is unknown. The combination of this 
inability to characterize the patch in vivo, the lack of improvement seen with the 
administration of a decell patch, and the potential loss of protein through 
decellularization, this treatment was neither further characterized nor pursued 
further.  
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A1.3 Figures and Tables 
Table A1.1: Infarct Size and LV Thickness Measurements, Adapted From Table 
3.2  
Group Infarct Size LV free wall thickness 
Sham (no 
ligation) 
- 2563.9± 306μm * # $ 
MI only 68.8 ±9.7 % 637.2 ± 28.9μm 
MI + DC patch 53.5 ±5.2% 680.5±88.2µm 
MI + CM-  patch 34.0 ±5.6% * 932.7±345.6μm * 
MI + CM+ patch 16.32±13.5%*# 1905.0±514.5μm * # $ 
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Figure A1.1: Assembled Grooved Mold With Patch After 2 Weeks Static Culture. 
This is an image of an early phase design. Later versions featured spacers and 
grooves open on the top side rather than closed as pictured. Foam was used to 
anchor the tissues at the edges of the slabs.  
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Figure A1.2: Schematics of Grooved Mold Pieces  
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Figure A1.3: Grooved Patch After Removal From the Mold  
 
Figure A1.4: H&E –stained section of a decellularized  CM+ patch. No 
observable nuclei were found in the patch, but a qualitative increase in porosity 
of the patch was observed.  
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Figure A1.5:  Adapted From Figure 3.3. ECM labeling of decellularized CM+ 
patch and a CM+ patch.  
 
Figure A1. 6: Masson’s Trichrome- Stained section  of a DC patch recipient heart 
4 weeks- post infarction and transplantation  
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Figure A1.8: Echocardiography results 1 week and 4 weeks post-
implantation. Adapted from Figure 3.4.  
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Appendix 2: Cell Count Matlab Code 
 
Contained in this appendix is the User’s Manual written to run the cell count matlab 
script. The code itself can be obtained from the lab server.  
Matlab Cell Count Code: User’s Manual 
(I) Running the Code: 
a. Hit Run on the .m file window 
b. Select the directory to the folder containing the files to import 
c. Sequentially select the grayscale image files corresponding to Blue, Red, 
Green and Far Red channels to import. The directory window title will 
show which file to import at a given time (i.e. File Selector: Green = pick 
the image corresponding to the Green/FITC/GFP channel) 
d. Scale and Objective  
i. User Prompt: Have the scale and objective changed? 
ii. If the scale and objective are the same as the defaults, select ‘no’ 
iii. If they are different, select ‘yes’ and enter the scale (1 pixel = X 
um) in the command window and hit enter. Then enter the 
objective (5, 10, 20 or 40) and hit enter. 
iv. If you selected ‘yes,’ the command prompt will reappear. Select 
‘no’ the second time. 
e. Thresholding Images: Composite and Component image examples are 
shown in Figures A2.1 and A2.2 
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i.  An intensity histogram will appear for the ‘Blue’ channel. Select 
the level to threshold the DAPI image (Figure A2.3a). 
ii. A second image will then appear with the original grayscale image 
on the left and the thresholded (binary) image on the right (Figure 
A2.3b). 
iii.  A prompt will appear asking ‘Try another initial guess?’ If the 
binary image is an adequate representation of the image, select 
‘no’. If it does not, select ‘yes’ and pick a new threshold on the 
histogram.  
iv. Repeat this process until a representative binary image is 
obtained 
f. Repeat this process for the ‘Red’, ‘Green’, and ‘Far Red’ images. (Figure 
X.4) 
g. A figure will appear with the title ‘area’ (Figure A2.5) The white region 
represents the calculated area of the tissue section in the image.  
i. Select an Area: User Prompt: ‘Select a Region?’ If you wish to 
calculate the cell distribution in both the total tissue section and a 
sub-region, select ‘yes’ (select ‘no’ if you do not).  
ii. A binary image of the DAPI channel will appear. Select points to 
outline a sub-region of the tissue section (Figure A2.6) 
iii. A second user prompt will appear, select ‘no’. At this time the 
program is not set up to record multiple sub-regions.  
h. Done! Some representative intersection images will appear (Figure A2.7-
A2.9), along with a data table with cell numbers, densities and 
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percentages (Figure A2.10). Copy and paste this into an excel sheet 
because that’s what you ran this whole code to get.  
 
(II) Optimization 
a. Scale and Objective: Obviously, you have to know the pixel/um 
conversions for every objective for whatever microscope the slides were 
imaged on. The conversions provided in the command window are for the 
Tranquillo lab microscope 
b.  Thresholding: Thresholding parameters must be optimized for the 
proteins you are staining for.  
i. Change the ordering, number of uses and parameter size of the 
bwmorph operations.  
c. Size of the Structuring Elements (Lines 124, 128, 132, 136). Changing 
this size will affect the time it takes to run the code but also effect the 
accuracy of background removal 
(III) Limitations 
a. This code fails at higher magnifications of tissue sections and most 
magnifications of plated cell monolayers due to the minimal overlap of 
cytosolic proteins with nuclei. 
b. This code was developed to detect cytosolic proteins for cell counting. 
The use of cell-membrane proteins has not been investigates and is not 
recommended for use with this code.  
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(IV) Figures: 
 
 
Figure A2.1: Color Composite Image of Sample Image run in this code  
 
 
Figure A2.2: Grayscale component images of the four channels analyzed in this code. 
Note: The composite image in Figure X.1  only features labels in the Cy3, GFP/FITC, 
and DAPI channels. For example purposes, Far red/Cy5 is a duplicate of the Cy3 
channel.  
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Figure A2.3: Thresholding of the Blue/DAPI channel. (A) shows the intensity histogram 
where a threshold is selected and (B) shows the resultant original and thresholded 
binary images.  
 
 
 
 
Figure A2.4: Thresholding for the Cy3 (top) and GFP/FITC channel images.  
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Figure A2.5: Section area (white) and region of interest selector  
 
 
 
Figure A2.6: Selecting a Region of Interest 
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Figure A2.7: Sample output: overlay of DAPI+ nuclei with Cy3 and Cy5. Note the 
imperfect separation of nuclei, and the presence of particles smaller than nuclei, 
 indicating some processing optimization is needed for the component image processing 
and thresholding.  
 
 
 
Figure A2.8: Sample output: Overlay of DAPI+ nuclei with FITC/GPF + structures  
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Figure A2.9: Sample Output: DAPI+ nuclei. Note the incomplete singling out of individual 
nuclei, indicating optimization is needed in the processing and thresholding of the DAPI 
image.  
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0 # 
density 
(cells/mm^2) 
% of cells 
in section 
% of total 
cells 
Blue 1081 4.0656e+03 0 0 
Green 409 1.5382e+03 0 0 
Red 259 974.0852 0 0 
Far Red 334 1.2562e+03 0 0 
B/G 206 774.7551 0.1906 0 
B/R 265 996.6509 0.2451 0 
B/FR 100 376.0947 0.0925 0 
B/G/R 163 613.0343 0.1508 0 
B/G/FR 81 304.6367 0.0749 0 
B/R/FR 100 376.0947 0.0925 0 
B/G/R/FR 81 304.6367 0.0749 0 
Select Area Blue 105 1.5846e+04 0 0.0971 
Select Area 
Green 
27 4.0748e+03 0 0.0660 
Select Area Red 14 2.1128e+03 0 0.0541 
Select Area Far 
Red 
41 6.1876e+03 0 0.1228 
Select Area B/G 88 1.3281e+04 0.8381 0.4272 
Select Area B/R 61 9.2060e+03 0.5810 0.2302 
Select Area B/FR 61 9.2060e+03 0.5810 0.6100 
Select Area B/G/R 59 84.8012 0.5619 0.3620 
Select Area 
B/G/FR 
54 77.6147 0.5143 0.6667 
Select Area 
B/R/FR 
54 77.6147 0.5143 0.5400 
Select Area 
B/G/R/FR 
54 77.6147 0.5143 0.6667 
 
 
Table A2.1: Data Table Output from code 
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Appendix 3: Protocols 
 
MOLD CLEANING AND PREPARATION PROTOCOL 
1.) Disassemble Molds 
2.) Put mold parts into a beaker with ~10% (enough to make the solution look pink-
ish) Formulated Cleaning Concentrate in DIH20. 
3.) Sonicate for 1h 
4.) Rinse beaker and mold parts well with tap H20 
5.) Return mold parts to beaker and fill with DIH20 
6.) Sonicate for 1h 
7.) Drain and dry mold parts on the benchtop on a clean blue chuck.  
8.) Autoclave: 10-20min exposure, 10min exhaust. Don’t let the mold parts sit in the 
autoclave after the cycle is complete. The extra heat exposure will cause the 
casings to break during assembly.  
9.) Coat in 5% pluronic (sterile) for 1-3h in a sterile beaker in the hood.  
10.) Remove pluronic and refilter. It can be used 3x. Let the mold parts dry on 
a sterile drape in the hood 
11.) Once dry, assemble the molds on the drape using sterile gloves to 
maintain sterility. When done, place assembled molds into a cleaned and 
autoclaved jar. 
 Molds can be cleaned and assembled ahead of time and stored at RT 
Product Info: 
Detergent: Branson GP Formulated Cleaning Concentrate 
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NEONATAL RAT CARDIAC CELL ISOLATION 
Checklist 
4 litters Sprague-Dawley rats, supposedly 48 hrs old: order by 4pm Friday for 
Wednesday delivery (Thursday isolation) or by 4pm Wednesday for Monday delivery 
(Tuesday isolation) 
Solutions: 
MyoMedia:  5 mL FBS- frozen in aliquots in our freezer 
  5 mL Pen/Strep - frozen in aliquots in west side freezer 
  50 mL Horse Serum – frozen in 45 and 5 mL aliquots in our freezer 
  5 mL 100x ACA – in our fridge 
  435 mL DMEM- in our fridge and/or cold room 
  -combine and sterile filter 
PBS Glucose: 1.98g D-glucose 
  500mL sterile PBS 
  5 mL P/S 
  -Combine, dissolve and sterile filter 
Stop Solution: 25mL FBS 
  5mL P/S 
  470mL DMEM 
  -combine and sterile filter 
Insulin:  In aliquots in Main fridge if not in our fridge, 2mg/mL (1000x) 
AA:  In 0.5 and 1 mL aliquots in west side fridge (1000x) 
If not already made for the day, 50 mg/mL in DD H20 and filter sterilized. AA is 
kept by the scale. Filter sterilizers are in the cabinet with the bottles.  
  181 
5% Pluronic Solution:  50g Pluronic +800mL water 
- Stir until dissolved, then bring up to 1L and sterile filter 
Equipment Needed: 
Sterile Tool Packet containing: Hemostat 
    Fine tweezers 
    Large scissors 
    Microscissors 
    Scalpel handle (#4) 
Mold casings (syringe parts): autoclaved and coated in 5% Pluronic for 1.5h+. Make 
sure you have ejectors (smaller syringe parts) too.  
Mold Parts:  cleaned and autoclaved, enough for 15/litter to be on the safe side 
Plastic jars for culturing finished constructs:  cleaned and autoclaved, have 6 small and 6 
large on hand minimum 
4-across 50mL conical tube rack 
12mL and 6mL syringes 
18 and 30 GA needled:  at least 10 of each on hand 
Sterile Drapes:  At least 6 on hand 
Sterile gloves:  at least 6 on hand 
3 ice buckets:  1 large, 2 small 
Carcass bucket:  with small black trash bag in it 
2 x100mm Petri dishes/litter 
Scalpel Blades, #20: 1/litter on hand 
Sterile gauze:  2 sheets 
50mL conical 
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Sterile dropper pipet 
Shaker in incubator 
Collagenase, type 2 
Notes:  
Day before: - Assemble mold parts, make stop solution and PBS glucose if needed 
Day of:  -thaw serums and make media as late as possible. Thaw FBS aliquot in 
cold water. Make AA before starting if not already made.  
 - Place shaker in incubator 
 
 
Neonatal Rat Cardiac Cell Isolation (for 4 litters of rats, scale down for fewer litters) 
Start warming 1 bottle PBS glucose. The other stays cold. 
Weigh out collagenase: want 200mL of 300U/mL. current lot is 200U/mg. Dump into 
250mL bottle 
Fill and label 8 petri dishes (2/litter) with cold PBS. Place 4 open on ice, reserve other 4 
(all in hood) 
Label 4 50mL conicals and place in hood 
Place two petri dishes (or small beakers) in hood and fill with 20-40mL betadine each 
Place mold casings in pluronics (in hood) if not already coated 
Lay down sterile drape on each side and dump tool packets onto them. Don’t touch 
without sterile gloves on. Also open and dump scalpel blades onto drape 
Weigh pups, then put on ice and into the hood.  
Glove up (sterile), assemble scalpel + blade and hemostat + gauze (gauze not 
completely sterile- don’t touch!) and place in betadine dish 
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Swap pup torsos with betadine, euthanize and remove hearts. Place hearts in PBS 
glucose dishes on ice. 
Once finished with rats, trim upper 1/3 off of each heart with micro scissors. Place 
remaining 2/3 (supposedly the ventricles only) in the other PBS glucose dish.  
Mince heart pieces with micro scissors into as small of chunks as you can get (without 
taking too much time) and when done remove heart pieces and PBS glucose and place 
in 50mL conical. Rinse the dish a few times with the excess PBS glucose. Place tubes 
on ice.  
Make up collagenase solution: 200mL warm PBS glucose into bottle with collagenase. 
Filter sterilize into another bottle. 
Start warming up stop solution 
Draw off most of the PBS glucose from the tubes and add 7mL collagenase solution 
apiece. Incubate 7 min on shaker in bottom incubator.  
Place 8 50mL conicals in the hood. 
After the first collagenase digestion, titrate gently on slow 4 times and aspirate off liquid 
(mostly crap and dead cells). Replace collagenase solution and incubate 7 min. 
Titrate 5 times on slow. Remove supernatant and place in 50mL conical. Add 7mL 
collagenase to tubes with chunks and 10 mL stop solution to tubes with cells.  
For remaining titrations (7 total) titrate 10 times on fast.  
Filter cells through 70um cell sieves into new tubes, fill with warm DMEM and spin down 
for 5 min at 1.6 
Resuspend cells in 50mL DMEM each and spin again, then resuspend into 20mL total 
and count.  
Resuspend cells to 23.5mil cells/mL and put on ice 
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During the digestions and while the cells are spinning,  dry off mold casings, thaw 
serums to make fresh media and start assembling mold parts and make fibrinogen and 
thrombin solutions: 
Aligned molds: Fill with agarose first then place in fridge until cold 
Fibrinogen aliquots are in freezer with horse serum, make sure the right lot #, 
Thrombin aliquots are in the -80. 20 mM HEPES in saline is in the west fridge 
door. CaCl is in one of the fridges. 
1.25 mL/ME total solution. 4:1:1 Fibrinogen: cells: thrombin. Add fibrinogen and cells 
first, then add thrombin and inject. Draw up into syringe with larger gauge needle (green) 
then switch to pink for injecting into molds. Keep needle upright as much as possible and 
watch out for bubbles.  
Place molds in small jar and incubate upright for (15-20: 20 for 2mg/mL) min. Then eject 
into DMEM and place in labeled jars with fresh, supplemented media.  
 *pre-aliquot the media (enough for 1-2 jars apiece) and heat only until warm 
before adding MEs 
(Optional) Fix extra cells for FACS analysis in 4% PFA for 15 min. then spin, resuspend, 
spin, resuspend and place in fridge 
Replace media ~12h later (next morning) and gently nudge constructs with Pasteur 
pipette to make sure they are not sticking to the endcaps. 
Change media  and pick constructs every MWF. Harvest at d14.  
 
Percoll: 
If making constructs enriched for myocytes, extra step after spinning cells down and 
counting.  
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Percoll gradients: 9mL percoll stock solution in HBSS (in our fridge) + 11mL HBSS 
(usually by microscope) 
10mL each into two 15mL tubes. Gently place cells for separation on top of gradients 
then spin at 2200rpm for 20 min.  
Reserve top layer, aspirate off middle, and collect bottom cells. 
Spin down cells in DMEM and count.  
 
Preplating: (A more reliable method to enrich for CMs) 
45min in PP media (15%FBS, 1%P/S in DMEM).  
Non-myocytes adhere to the TCP in this time, CMs remain in suspension.  
1 step = ~60-70% CMs, 2 steps~90-95% CMS. 
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PATCH CONSTRUCTION PROTOCOL: GENERIC 
Checklist 
Solutions: 
Culture Media  for final product 
 
Basal media 
 
Trypsin, FBS, whatever is needed to harvest cells 
 
20mM HEPES buffer in saline:  
10mL HEPES 
490 mL saline 
-combine and sterile filter 
 
Fibrinogen Solution (for 1 mL total solution): 
   
Final fibrinogen 
conc. -> 
2 mg/mL 3.3 mg/mL 4 mg/mL 
Fibrinogen stock 
(36mg/mL) 
0.037mL 0.0614mL 0.0744 mL 
20mM HEPES in 
saline 
0..633mL 0.6053 mL 0.592 mL 
 
Thrombin Solution: 
 
Final fibrinogen 
conc. -> 
2 mg/mL 3.3 mg/mL 4 mg/mL 
Thrombin stock  
(80U/mL) 
4.2 uL 5.2 uL 9.3 uL 
2M CaCl 1.9uL 1.9uL 1.9uL 
Basal Media 0.161 mL 0.161 mL 0.156 mL 
(the ratio of fibrinogen/thrombin remains the same for all concentrations in this 
formulation) 
 
5% Pluronic Solution:  50g Pluronic +800mL water 
- Stir until dissolved, then bring up to 1L and sterile filter 
 
Equipment Needed: 
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Mold casings (syringe parts or tubing): autoclaved and coated in 5% Pluronic for 
1.h+. Make sure you have ejectors (smaller syringe 
parts) too.  
 
Mold Parts:  cleaned and autoclaved, coated in 5% Pluronic if using small molds 
 
Plastic jars for culturing finished constructs:  cleaned and autoclaved, have 6 small and 6 
large on hand minimum 
 
12mL and 6mL syringes 
 
18 and 20 GA needled:  at least 10 of each on hand 
 
Sterile Drapes:  At least 6 on hand 
 
Sterile gloves:  at least 6 on hand 
 
50mL conicals 
 
Ice Bucket with Ice in it 
 
Prep (day of, but prior to casting) 
-assemble molds 
Large molds:  - Pluronic coat mold casings for 1.0h+ and let dry on a sterile 
drape in hood.  Pour pluronic back into bottle. It can be used 3x. 
   - agarose-fill mandrels 
   - assemble molds (sterilely) 
 Small molds:  - Pluronic coat everything for 1h+ and let dry on a sterile drape in 
hood 
   - assemble molds 
- make sure enough media is made 
 
Harvest Cells 
Per optimized protocol for each cell type, harvest CMs last since they are the most 
sensitive cell type 
 
Casting: 
 
Large Molds: 1.25 mL/gel total solution.  
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4:1:1 Fibrinogen: cells: thrombin.  
Important: Keep all cells, fibrinogen, and thrombin solutions on ice until mixing. Warm 
cells will die quicker and the fibrin polymerization is accelerated at higher temperatures. 
Keeping it cold gives you more working time.  
Also, If there are particles in the fibrinogen solution, that’s not good. It means the 
fibrinogen has started to fall out of solution. Warm it up to 37C until the solution is clear 
again and then put it back on ice to chill.  
- Add fibrinogen and cells first to a 50mL conical, then add thrombin and mix. 
Quickly (it’s already started polymerizing) draw up into syringe with larger gauge needle 
(18GA/green) then switch to pink/20GA and inject the solution into molds. Keep needle 
upright as much as possible and watch out for bubbles.  
- Place molds in small jar and incubate upright for (15-20: 20 for 2mg/mL) min. 
Then eject into a 100mm petri dish with warm basal media in it. Pick mold up by the 
endcaps  with a pair of sterile tweezers and place in labeled jars with fresh, warm media. 
*pre-aliquot the media (enough for 1-2 jars apiece) and heat only until 
warm before adding the gels 
- Replace media ~12h later (next morning) and gently pick constructs 
- To pick gels: use a sterile Pasteur pipet and gently nudge 
edge of gel along mandrel to ensure it is not adherent to the 
Teflon.  
- Culture and exchange media every other day (or MWF) until 
harvest.  
Analysis: 
Uniaxial tensile testing 
Alignment mapping 
Contraction force testing 
Histology  
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PATCH CONSTRUCTION PROTOCOL: HEMISPHERES 
Supplies Needed 
- Tissue Punch of desired size 
- Well plate of appropriate size (large enough to fit the tissue punch), sterile 
- Heating source, either a bunson burner or a tissue culture hood sterilizer 
- Tissue Culture Hood 
- Cells and Reagents to cast fibrin gels (see fibrin casting protocol) 
- Dental pick 
 
Procedure: 
 
Stamping of Tissue Culture Plate 
1.) Bring sterile well plate, tissue punch, and heating source into the tissue culture 
hood 
2.) Heat the tissue punch for 10-30s until hot 
3.) Use the heater tissue punch to create a stamp in a single well of the well plate, 
evenly applying pressure to create a circular region of melted plastic, rotating as 
needed. 
*This may take some practice, too little pressure or too cool of a tissue 
punch may result in an incomplete ring while too much pressure could 
cause the plate to crack or create a hole in the well.  
4.) Correct defects in the ring, if they appear, with a heated dental pick 
5.) Repeat steps 2-4 for each well you wish to place a hemisphere into.  
*This process can be done ahead of time, as long as the plate is stored 
such that it remains sterile.  
Casting of Hemispheres 
1.) Prepare fibrinogen and thrombin solutions and cells as per standard protocol 
2.) To cast a hemisphere, mix the component solutions in a batch of appropriate 
volume (per standard casting protocol) and then gently add the desired volume 
of cell-laden gel forming solution into the center of one of the stamped rings. The 
gel solution should be bounded by the melted plastic and look like a rounded 
droplet on the plastic (i.e. hemisphere) 
3.) Continue this process for the remaining hemispheres. Be careful not to bump the 
plate or they will spill.  
4.) Let hemispheres sit in the tissue culture hood for 6 minutes before carefully 
transferring them to a 37C incubator for 15 additional minutes. 
5.) At the end of polymerization, remove well plate form the incubator and return to 
the tissue culture hood. Add an appropriate amount of media for the number and 
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type of cells entrapped, with a minimum enough to cover the hemisphere 
entirely.  
6.) Change media 24h (the next day) after casting to remove any excess thrombin 
and dead cells. After that, media can be changed 3x weekly, or whatever is 
deemed optimal for the entrapped cell types. Supplement media with ACA to 
reduce fibrinolysis.  
 
 
Sample of Stamp Diameters and the Hemisphere Sizes That Can Be Made With 
Them: 
 
Diameter of Stamp (mm) Volume of Hemisphere (uL) 
4.5 25 
6 50 
7.25 75 
10 150 
11 225 
13.25 400 
17 750 
20 1000 
22 1200 
23 1400 
 
Use this information as a starting point to calculate the volumes for different 
diameter stamps 
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Example of stamped rings in a tissue culture well plate 
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CONTRACTION FORCE (AKA TWITCH FORCE) TESTING 
Equipment: 
The Biggies: 
Contraction Force Tester (force transducer + movable media bath on optical board): 
Located on shelf next to incubators #8 and 9 
Stimulator (S88X GRASS, Astromed, Inc): also on shelf next to the incubators.  
Filter (900 Tunable Active Filter, Freq Devices Inc): also on shelf next to incubators 
Laptop (crappy little Acer): usually found on the shelf next to the incubators, on my 
bench or put away in the bottom drawer next to Krissy’s desk.  
Small 37C Incubator: the one on Pat’s bench. It will not fit onto one of the shelves 
where the rest of the equipment is, put it on a cart and roll it up next to the shelves. 
DAQ card: good luck finding it. Most frequent locations: on the same shelves as the 
above equipment, on the cart with the pressure transducer (which also moves around a 
lot).  
 
Other Miscellaneous things you will need: 
Foam: the black blocks of it located either on the shelves or on top of the fridge in 
Tranquillo East 
Contraction Force Media: 2uM CaCl + 1000x AA in DMEM, warm. 10mL for each 
sample you plan on testing 
Tweezers 
Pipet-aid 
Waste Container for used contraction force media 
24well plate to store tested samples 
 
Setting up the System: 
1. Place the Contraction force tester into the small incubator. Put foam underneath 
it to limit noise in your data. Let warm up for ~5min before doing anything.  
2. There is a cable coming from the filter that ends in 2 wires. Red goes into A/1 + 
and Black to A/1 – on the DAQ card. There should also be a black ground wire 
connected to the A/1 – wire. That goes into the ground slot. Screw all wires into 
their ports tightly.  
3. Plug the USB port of the DAQ card into the laptop 
4. Plug in the force transducer output display box. Make sure it is set to 5g rather 
than 0.5g.  
5. Plug in and start up the computer. This may take a while.  
6. Turn on the filter. The switch is on the backside. Don’t mess with the settings, 
they are fine as is. 
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7. Turn on the stimulator. The switch is on the front panel (pictured). It will start up 
and ask you to change settings or hit enter. Hit enter.  
8. Connect the alligator clips from S1 output on the stimulator (they should be the 
ones without covers) to the electrode wires on the contraction force tester.  
9. Once the computer is setup, go into the contraction force testing folder on the 
desktop, copy the template folder and file and rename it with today’s date.  
10. Add 10mL contraction force media to the bath on the contraction force tester. 
 
LABVIEW: 
There are two programs on the desktop, each calibrated to a specific force transducer. 
Use the Old Pacing Test 
 
1. Select file to write to from your template folder 
2. Set to 5g 
3. Run program 
4. Hit record when you want to record data. It will continually display output, but 
only records when you want it to. 
 
Loading a Sample: 
1. Once everything is set up and warmed up, remove a sample from its mandrel (I 
usually measure a representative width with calipers first).  
2. Place sample over the fixed post.  
3. Wait about 30s and see if you can observe any spontaneous contractions. 
4. If yes, continue to step 7 
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5. If no, turn the S1 output on to 1 Hz and see again if you can see any 
contractions. If you do, continue to step 7 
6. If not, ramp up the stimulator to a high frequency until you see hydrolysis 
(bubbles) from the electrodes near where the silver wire comes out of the bath.  
a. If you do not see bubbles, you hooked up something wrong. Troubleshoot 
and try again.  
b. If you do, the sample is probably a dud. Congratulations. Continue onto 
step 7 anyways because sometimes once you tension them they start to 
respond. 
7. Make sure S1 is OFF and slide ring over force transducer probe, such that it 
goes around both the probe and the fixed post.  
8. Adjust the stage until the sample is tensioned to 1g force (0.4V on this 
transducer) 
9. Hit record! Be careful not to bump the incubator now…. 
10. Give it ~30s to 1 min for the stress relaxation to level off a bit. Then turn S1 back 
onto 0.5 or 1Hz. 
11. Ramp up the output to ~15Hz and then quickly back down again 
a. We do this to try and get all the cells somewhat synchronized… 
sometimes they aren’t and you will see secondary beats in the output 
12. Wait about 5 beats or so and then record the max and min values of the twitch 
response 
13. Repeat for increasing frequencies until the sample stops beating at the paced 
frequency (I call this the ‘maximum capture rate’ per Radisic et al.) 
14. Turn the output off and observe for 1-2min to see if spontaneous beating returns. 
15. Stop recording, return the sample to no tension and remove it from the bath.  
16. Replace the contraction force media after each sample with fresh solution to 
avoid excess acidification of the media.   
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Picture Cheat Sheet: 
 Filter 
 
Stimulator 
 
 Force Transducer Display 
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Contraction Force Tester 
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NEONATAL RAT CARDIAC CELL CULTURE (2D AND 3D) 
Insulin: In aliquots in West side fridge if not in our fridge, 2mg/mL (1000x) 
AA: In 0.5 and 1 mL aliquots in west side fridge (1000x) 
If not already made for the day, 50 mg/mL in DD H20 and filter sterilized. AA is 
kept by the scale. Filter sterilizers are in the cabinet with the bottles.  
MyoMedia:  5 mL FBS- frozen in aliquots in our freezer 
  5 mL Pen/Strep.- frozen in aliquots in west side freezer 
  50 mL Horse Serum – frozen in 45 and 5 mL aliquots in our freezer 
  5 mL 100x ACA – in our fridge 
  435 mL DMEM- in our fridge and/or cold room 
 Filter sterilize into 500 mL bottle 
*keep all ingredients cold until feeding. Make media with cold DMEM, thaw 
serums –especially the FBS- in cold water then use immediately 
Cardiac Fibroblast (CF) media:  
  75 mL FBS – frozen in 45 and 30mL aliquots 
  5 mL penn/strep 
  420 mL DMEM 
 Filter sterilize into 500 mL bottle 
Feeding Patchess: 
Aspirate off old media with a Pasteur pipet that has been heated in the bead sterilizer for 
> 10s 
Remove pipette from vacuum line and gently pick aligned constructs, nudging them 
along the mandrel, making sure they are not sticking to the ends.  
Replace media: 42 mL for small jars, 126 for large jars (21 mL/construct) 
Supplement with insulin and AA (1000x = 1 ul for each mL media) 
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* Pre-aliquot media to be used for feeding and heat only as long as absolutely 
necessary.  For the first feeding or two after an isolation, the media must be freshly 
made as well 
 
 
Feeding plated non-CMs:  
30 mL CF media for T175s, 10-15mL for T75s 
Aspirate off old, replace with new media. Check for confluence first.  
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Thawing and Culture of hiPSC-CMs (From the Kamp Lab) 
Culture Medias 
EB20 (500mL): 
910 μL β-mercaptoethanol (55mM stock) 
5 mL non-essential amino acids 
5mL Pennicillin/Streptomycin 
100 mL FBS 
389 mL DMEM/F12 
 
EB2 (500mL): 
 
910 μL β-mercaptoethanol (55mM stock) 
5 mL non-essential amino acids 
5mL Pennicillin/Streptomycin 
10 mL FBS 
479 mL DMEM/F12 
 
Combine and sterile filter 
 
 
Thawing iPSC-CMs (Jianhua Zhang/Kamp Lab) 
1. Remove vial from liquid nitrogen and quickly place to 37oC water bath for 
1 minute. Using long forceps or floating rack to hold the vials, avoid 
submerging the cap. 
2. Immediately remove vial from water bath, spray with 70% ethanol and 
wipe with Kimwipes. Place the vials in the cell culture hood.  
3. Gently transfer thawed cells to a 15 ml conical tube using 1ml or 5ml 
pipette. If multiple vials of the same lot cells to thaw, use a 50 ml conical 
tube to combine cells. 
4. Slowly, add 11 ml/vial room temperature EB20 medium drop-wise to 
cells in the 15 ml or 50 ml tube. While adding the medium, gently move 
the tube back and forth to mix the cells. This reduces osmotic shock to the 
cells. After adding the medium, cap the tube tightly and gently invert tube 
2-3 times to mix the contents. 
5. Centrifuge at 200x g for 5 minutes. 
6. Aspirate the supernatant and resuspend in 4ml/vial EB20 medium. 
7. Count the cells with Trypan Blue to determine the total viable cells and the 
viability. 
8. Add 11 ml EB20 medium to fibronectin coated (2.5 μg/cm2) T75 flask. 
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9. Add 4 ml cell solution to flask (total of 15 ml medium). 
10. Change to the EB2 maintenance media 48 hours after the cells attached. 
11. Harvest after 4 days. 
 
Edits: Change EB20 media the day after thaw, harvest at or after 4 days.  
 
Harvest of iPSC-CMs  
1. Rinse 2x with 10 ml PBS. 
2. Add 10 ml 0.25% Trypsin/EDTA with 200 μl chicken serum. 
3. Put in incubator for 5 min.  If cells are still attached, gentle tapping, or additional 
time in the incubator can be used (no more than 15 min total exposure to 
Trypsin). 
4. Quench with 10 ml EB-20.  
5. Spin at 200g for 5 min. 
6. Resuspend in EB-20. 
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LACTATE PURIFICATION OF HIPSC-CM 
 
Reagents Needed: 
T75 flask 
Fibronectin (Sigma F1141-5mg) 
EB20 media 
EB2 media 
PBS 
 
Lactate Media: 
  Stock Conc.  Volume   Final Conc. Cat# 
L-Glutamine  200mM 2mL 50x 0.584g/L 
Sigma 
G7513 
Pennicillin/ 
Streptomycin 
10k U/10k 
µg/mL 1mL 100x     
MEM NEAA   1mL 100x 0.1mM 
Gibco 
11140-050 
Lactic Acid 1M 400uL 250x 4mM 
Sigma 
25476-100g 
β-
mercaptoethanol 55mM 182uL   0.1mM 
Gibco 
21985-023 
DMEM no 
Glucose - 96mL - - 
Gibco 
11966-025 
    100mL       
 
 
Protocol: 
 
Day 0: Thaw cells as per normal protocol into 1 T75 flask/vial coated with 
2.5ug/cm2 fibronectin. Media: EB20, 15mL 
Day 1: Media change: EB20, 15mL 
Day 2: Media Change: EB2, 15mL 
Day 3: Rinse flask twice with PBS then add 15mL Lactate Media 
Day 4: - 
Day 5: Rinse flask twice with PBS, add 15mL Lactate Media 
Day 6: - 
Day 7: Rinse flask twice with PBS, add 15mL EB2 
Day 8: - 
Day 9: - 
Day 10: Harvest 
 
 
  202 
Notes: 
 
 - Cells should start beating on day 4-6 of culture. Lactate media does not affect 
this timeline, you should see cell start to beat while in lactate media. If they aren’t 
beating by day 10 of culture, you have a problem…. 
- 1M lactic acid: Dilute from stock into HEPES, aliquot and freeze immediately. For 
some reason, the lactic acid we use is stable indefinitely at high concentration in water, 
but when diluted into saline or HEPES, that lifetime gets cut to maybe a week 
- Upon returning the cells to EB2, the CMs will expand to fill the empty space. Or 
maybe divide some too. We have not looked into it thoroughly, but a lot of the cell counts 
post-purification come close to the average yield (both overall and compared to side-by-
side cultured unpurified cells) and ~95% CM. It could be that CMs like the lactate media 
and fewer of them die. Either way, if you see that, nothing went wrong. Stem cells are 
just weird.  
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HISTOLOGY: IMMUNOSTAINING OF SECTIONS AND CELL MONOLAYERS 
Immunostaining: Sections/Cell Monolayers 
Rinse 3x in PBS, 1st rinse incubate 5 min 
- After 1st rinse, outline sections with water pen 
Permeabilize in 0.1%TX100 (on shelf above Sonja’s bench) in PBS at RT for 10 min 
Rinse 3x, 5 min incubations in PBS 
Block in 5% NDS in PBS for >30min at RT NDS in Ab freezer in 500ul aliquots (500ul 
NDS + 9.5mL PBS) 
Add primary Ab at optimal dilution in NDS 
Incubate overnight in coldroom or for 1h at RT (1h only for monolayers) 
Rinse 3x in PBS with 5 min incubations 
Add secondary Ab. RTT secondaries are diluted 1:200 in NDS (secondaries are diluted 
1:1 in glycerol upon receipt and stored at -20) 
*shield from light from this point on 
Incubate at RT 1h or in cold room overnight 
Rinse 3x PBS with 5min incubations 
Incubate 10min in a 1:10000 dilution of DAPI @ RT 
Rinse 3x5min in PBS 
Coverslip when applicable with Dako mounting media (in fridge). Coverslips are in the 
long drawer on Sonja’s bench or in the drawer at the end of Sandy’s bench marked 
‘Cover Slips.’ 
Image 
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Whole Mount Immunostaining 
Fix tissues as normal, leave them in PBS. No need to embed and freeze them.  
Permeabilize in 0.1%TX100 (on shelf above bench) in PBS at RT on shaker for 1h 
Rinse 3x by 3x, 5 min incubations in PBS 
Block in 5% NDS in PBS for >1h at RT on shaker- NDS in Ab freezer 
Add primary antibody, diluted in NDS 
Incubate overnight in coldroom on shaker 
Rinse 3x by 3x in PBS with 10 min-1h incubations 
Add secondary antibody, diluted in NDS 
Incubate a few hours-overnight in coldroom, shielded from light 
Rinse 3x by 3x in PBS with 10min-1h incubations 
Image. You can image on a typical upright microscope, but be aware only small parts of 
the surface may be in the focal plane at any given time. If the inverted scope doesn’t 
work out and you want to image large areas at higher magnifications, use the confocal.  
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WESTERN BLOTTING: PROTEIN HARVEST FROM A CELL MONOLAYER (I.E. 
FLEXCELL PLATES) 
Purpose: To harvest protein from the 24 well HTS Flexcell plates for Western Blotting 
1. Put the plate on ice, all steps should be done @ 4C 
2. Rinse the monolayer 2x with PBS to remove media.  
3. Add 80-100uL Lysis Buffer to each well. Make sure the buffer covers the entire 
well.  
1x Lysis Buffer (for 10mL): 
5mL of 2x NP-40 lysis buffer 
50uL of NaVO3, 200mM stock (sodium orthovanadate) 
5uL each of Aprotinin, Pepstatin, and Leupeptin, 1 mg/mL stock 
10uL of PMSF, 200mM stock in DMSO 
250uL Sodium Deoxycholate, 10% stock 
Fill to 10mL with ddH2O 
4. Gently scrape the bottom of the wells with a spatula, rinsing the spatula between 
each well, to loosen adherent cells 
5. Let sit for ~2-3min 
6. Remove lysate from each well and place into 1.5mL eppendorf tubes.  
7. Incubate lysate end-over-end in the cold room for 15min 
8. Centrifuge lysate for 15min at top speed (13-14K RPM) at 4C in the Alford lab 
refrigerated centrifuge.  
9. Move supernatant into new eppendorf tubes, label, and store at -80. 
 
Notes and Future Protocol Development: 
- Try switching to RIPA buffer and bought protease inhibitor cocktail in the future. It 
will make things a lot easier 
- Sodium orthovanidate doesn’t like to stay in solution, re- make frequently…  
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Western Blotting: Gel Running and Blotting Procedure 
 
Cells (an example used for this protocol): Lactate Purified (LA) iPS-CMs and unpurified 
(UN) iPS-CMs cultured statically for 10 days in a 24 well plate. Harvested on XX/XX/XX 
with the following protocol: 
 
Cell Lysis: 
  1mL Lysis Buffer:  -     500uL of NP40 lysis buffer 
- 25uL of 40x Sodium Deoxycholate 
- 10uL 100x Sodium Orthovanadate (NaOV3) 
- 1ul each of Aprotinin, Pepstatin, and Leupeptin 
- Fill to 1mL with ddH2O 
Place plate on ice, rinse cells in well with PBS 
Add 100ul Lysis Buffer/well 
Let sit 3min, scrape bottom of well to loosen cells from bottom of wells 
Collect buffer from each well and place into a 1.6mL Eppendorf tube 
Incubate 30min on the end over end incubator in the cold room 
Spin down in refrigerated centrifuge (Alford lab) at 4C for 15min at 13k 
rpm 
Remove supernatant and place in a new 1.6mL tube 
Store in -80 
BCA assay: 
  Follow the protocol on the box, all samples must be done in triplicate.  
   
SDS-PAGE:  
Running Buffer: Make 750 mL. 10x SDS/Tris/Glycine running buffer 
diluted in DI H2O.  
 
Samples (for the 10 well/50uL gels): Protein diluted in ddH2O to 23 uL + 
23 uL 2x Lamelli Sample Buffer with 100mM DTT (stock is 2M) in a 
labeled 1.6 mL eppendorf tube. An example is shown below: 
 
Sample UN1 UN2 UN3 UN4 LA1 LA2 LA3 LA4 LA5 
uL protein 
for 10ug 
16.89 18.9 21.23 16.25 14.5 14.18 15.6 16.77 18.19 
uL ddH2O 6.11 4.1 1.77 6.75 8.5 8.82 7.4 6.23 4.81 
uL 2x 
sample 
buffer + 
100mM 
DTT 
23 23 23 23 23 23 23 23 23 
total 46 46 46 46 46 46 46 46 46 
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‘Boil’ samples for 5 min via a 95C heating block. Hold onto the caps when 
removing the tubes from the heating block.  
 
Sample Gel Layout: 
 
Gel Lane 
1 
2 3 4 5 6 7 8 9 10 
A UN1 UN2 UN3 UN4 LA1 LA2 LA3 LA4 LA5 Ladder 
   
Gently remove the comb form the gel and put gel into the cassette. If only 
running one gel, use the plastic plate for the other side of the cassette to 
create a seal. Remember to take the tape off of the bottom of the gel! Put 
the cassette in the gel running chamber.  
 
Fill the inner part of the chamber with running buffer up to the top of the 
gels. Check for leaks. Then fill the outer part of the chamber with running 
buffer about halfway full, past the bottom of the gels at the very least.  
 
Run gel at 200V for 1 hour. Keep track of the dye front, once it reaches 
the bottom you can stop the power supply or it will keep running off the 
gel.  
 
 
Western Transfer: 
 
1x CAPS buffer (80mL MeOH + 80mL 10X CAPS buffer + 640mL ddH2O).  
 
Pre-wet sponges, filter paper, and nitrocellulose in CAPS buffer 
 
For one gel, made a sandwich in the transfer cassette in the following order: 
Black side of cassette, sponge, filter paper, gel, nitrocellulose , filter paper, 
sponge, white side of cassette. The protein travels from (-) to (+) To remove the 
gel, use the crow bars at the arrows to crack open the casing.  
 
Place transfer cassette in transfer box, black side facing black. Place transfer box 
and ice block in reservoir and fill with CAPS buffer. You won’t need all of the 
CAPS buffer.  
 
Run at 75V for 1h on stir plate with a stir bar in the bottom of the reservoir.  
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Remove the nitrocellulose (gently with the flat tweezers) and place protein side 
up in a blotting dish with 5% milk + 0.1% Tween. Label with pencil along the edge 
OR, if you’re not going to start blotting right away, rinse blot in TBS, wrap in 
saran wrap and store in the fridge until ready.  
 
Transfer buffer has a waste container.  
The gel, once done with it can go in the trash.  
Running buffer can be poured down the sink.  
 
 
Blotting 
 
Milk solution: 
5g milk (blocking powder) 
100mL PBS 
1 mL 10% Tween 
 
 
Block in the cold room O/N on the shaker OR for >30min @ RT on shaker 
Primary Ab: 1h @ RT on shaker or O/N in cold room on shaker 
Rinse: 3x3x5min in TBS-T 
Secondary Ab: 1h @ RT on shaker or O/N in cold room on shaker 
Rinse 3x3x5min in TBS-T, last rinse being TBS (no T) 
 
ECL: (shield from light at this time) 2mL Luminata Classico (in fridge) on 
benchtop (no shaker) @ RT for 3min 
 
Developing: 
Placed blot on plastic wrap, protein side (the side with pencil on it) down. 
Wrapped in plastic wrap and taped in place (protein side up) in the developer 
case.  
Exposed in developer room (while locked) for 10s, 30s, 1min, 5min. Notched film 
in one corner to mark orientation. Each film labeled with blot name, date, stain, 
exposure, initials, ladder markings.  
 
 
Stripping: 
1 rinse in TBS, 5 min on shaker @ RT 
5min in Restore PLUS stripping buffer on shaker @RT 
4x3x5min Rinses in TBS-T 
Block >30min @ RT on shaker before adding next primary.  
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Appendix 4: Antibody Dilutions and Supply Information 
 
Antibodies and Labels used for Immunohistochemistry  
Primary 
antibody Mfr. Catalog # Dilution 
Dilution 
Conc. 
Incub. 
Time 
Incub. 
Temp 
Cardiac 
Troponin T 
(cTnT) 
Thermo 
Fisher 
Scientific MS-295-P1 1:100 2 μg /mL O/N 4C 
Collagen I 
Novus 
Biologics NB 600-408 1:1000 1 μg /mL O/N 4C 
Collagen IV Abcam ab6586 1: 200 5 μg /mL O/N 4C 
Laminin Abcam ab11575 1:100 5 μg /mL O/N 4C 
Connexin 43 
(CX43) Santa Cruz sc-9059 1:100 2 μg /mL O/N 4C 
HNA* Millipore MAB1281 1:200 - O/N 4C 
Ki67 Abcam ab15580 1:400 2.5 μg /mL O/N 4C 
Cardiac 
Troponin I 
(cTnI) Abcam ab47003 1:100 O/N 4C 
Myosin Heavy 
Chain  α Santa Cruz Sc-32732 1:100  2  μg /mL O/N 4C 
Fibronectin Abcam Ab6584 1:200  5  μg /mL O/N 4C 
Secondary 
Antibodies             
Alexa Fluor® 
594 AffiniPure 
Donkey Anti-
Mouse IgG 
(H+L) 
Jackson 
Immunorese
arch 715-585-150 1:400 3.75 μg /mL 1h RT 
Alexa Fluor® 
488 AffiniPure 
Donkey Anti-
Mouse IgG 
(H+L) 
Jackson 
Immunorese
arch 715-545-150 1:400 3.75 μg /mL 1h RT 
Alexa Fluor® 
647 AffiniPure 
Donkey Anti-
Mouse IgG 
(H+L) 
Jackson 
Immunorese
arch 715-605-150 1:400 3.75 μg /mL 1h RT 
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Alexa Fluor® 
594 AffiniPure 
Donkey Anti-
Rabbit IgG 
(H+L) 
Jackson 
Immunorese
arch 711-585-152 1:400 3.75 μg /mL 1h RT 
Alexa Fluor® 
488 AffiniPure 
Donkey Anti-
Rabbit IgG 
(H+L) 
Jackson 
Immunorese
arch 711-545-152 1:400 3.75 μg /mL 1h RT 
Alexa Fluor® 
647 AffiniPure 
Donkey Anti-
Rabbit IgG 
(H+L) 
Jackson 
Immunorese
arch 715-605-152 1:400 3.75 μg /mL 1h RT 
Other Labels 
and Reagents             
IB4 (Griffonia 
(Bandeiraea) 
Simplicifolia 
Lectin I, 
Isolectin B4 
(fluorescein 
labeled)) Vector FC-1201 1:50 20 μg /mL 10 min RT 
DAPI 
(Hoechst 
33342) LifeTech H3570 1:10000 1 μg /mL 10min RT 
F-Actin 
(Phalloidin) 
Alexa Fluor 
488 LifeTech A12379 1:500 0.6 U/mL 1h RT 
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Antibodies and Labels used for Western Blotting 
Primary 
antibody Mfr Catalog # Dilution 
Dilution 
Conc. 
Incub. 
Time 
Incub. 
Temp 
Myosin Heavy 
Chain α Santa Cruz sc-32732 1:1000 0.2 μg /mL 1h RT 
Myosin Heavy 
Chain β Santa Cruz sc-53089 1:1000 0.2 μg /mL 1h RT 
GAPDH Santa Cruz Sc-48167 1:2000 0.1 μg /mL 1h RT 
α-Sarcomeric 
Actinin 
Sigma-
Aldrich A7811 1:2000 1h RT 
SERCA2A 
ATPase Abcam Ab2861 1:1000 1h RT 
Connexin 43 
(CX43) Santa Cruz sc-9059 1:1000 0.2 μg /mL 1h RT 
Secondary 
Antibodies 
Amersham ECL 
Prime Mouse 
IgG, HRP-linked 
whole Ab 
GE 
LifeScience
s 715-585-150 1:2500 
0.4  μg 
/mL 1h RT 
Peroxidase 
AffiniPure 
Donkey Anti-
Goat IgG (H+L) 
Jackson 
Immunorese
arch 705-035-003 1:2500 
0.32  μg 
/mL 1h RT 
Amersham ECL 
HRP Conjugated 
Antibody, Anti-
Rabbit 
GE 
LifeScience
s NA934-1mL 1:2500 1h RT 
Other Reagents 
Luminata 
Classico 
Western HRP 
substrate Millipore WBLUC0100 - - 3 min RT 
Luminata 
Crescendo 
Western HRP 
Substrate Millipore WBLUR0100 - - 3 min RT 
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Non-Standard Cell Culture Supplies: 
Item Mfr Catalog # 
2-mercaptoethanol, 50mL 
55mM Gibco 21985-023 
Nonessential amino acids 
(100x) Life Tech 11140-050 
ε- aminocaproic acid 
Acros 
Organics 103305000 
Fibronectin 
Sigma-
Aldrich F1141-5mg 
Horse Serum Hyclone 26050088 
Lactic Acid 
Sigma-
Aldrich 
252476-
100g 
Glucose-Free DMEM Invitrogen 11966025 
 
 
Other Supplies 
Blue Basic 
Autorad Film 
5x7” Bio-Rad F-9023 
4-20% Mini 
Protean TGX 
Gel, 10 well, 
50uL Bio-Rad 456-1094 
BCA Protein 
Assay Kit 
Thermo 
Fisher PI23227 
Blotting Grade 
Blocker Bio-Rad 170-6404 
Tris/Glycine/SDS 
running Buffer 
10x Bio-Rad 161-0732 
